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Abstract 
Mitochondrial Myopathies and Muscle Stem Cells 
Mitochondrial myopathies are a group of progressive muscle disorders caused by 
mutations in the mitochondrial genome (mtDNA) for which there is no effective 
treatment. Culturing of myoblasts from patients with sporadically occurring 
mitochondrial diseases has suggested that mtDNA mutations may be lower or absent 
in muscle stem cells (satellite cells). The activation of muscle satellite cells and 
subsequent repair of muscle fibres may favourably shift the balance of delete to wild-
type (WT) mtDNA, thereby decreasing mtDNA mutation load in affected muscle. This 
research has investigated muscle precursor cells from patients with mitochondrial 
myopathy due to sporadically occurring mtDNA deletions. This was to determine if 
they will benefit from attempts to “gene shift” the balance of WT and mutated mtDNA 
in their muscles using high intensity resistance training. 
Fluorescently Activated Cell Sorting (FACS) on the basis of CD56 (NCam) was used to 
isolate satellite cells and real time PCR to analyse them. In all eight patients 
investigated mtDNA deletions were detected in satellite cells at levels similar to 
mature muscle. In most of these patients the mtDNA deletions were lost during the 
culturing of their myoblasts. In some patients, however, the mutation was maintained, 
although there was a gradual decline in mutation load as the myoblasts headed 
towards differentiation. It was hypothesised that this difference between patients in 
the maintenance or loss of mutations in their myoblasts was attributable to an mtDNA 
bottleneck effect at the point of satellite cell activation. A second selection point 
occurred during the process of myoblast proliferation, possibly mediated by 
segregation of WT and delete mtDNA after cell division. Daughter cells that inherit 
large amounts of delete mtDNA will be unable to continue to proliferate. 
If efforts to “gene shift” in these patients will involve the activation of satellite cells to 
repair damaged muscle, it is paramount that this process does not exhaust the muscle 
stem cell pool. Satellite cell numbers have been determined in patients harbouring 
sporadically occurring mtDNA deletions, who will be considered potential beneficiaries 
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of exercise based interventions. No significant difference was observed in satellite cell 
numbers when patients were compared to controls. In addition, a single patient was 
examined for satellite cell numbers over eleven years and no reduction in numbers 
was found. 
Given that the large majority of single deletion patients will lose their mtDNA mutation 
during the process of muscle regeneration and that they will not suffer from an 
exhaustion of the satellite cell pool, “gene shifting” remains a viable therapy in these 
patients. However, the mechanisms behind the process are somewhat different to 
what was originally hypothesised. 
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Chapter 1 Introduction 
1.1 Mitochondria 
The more that is learned about the mitochondrion and its DNA (mtDNA), the more its 
importance is realised. Whether it is the vital role this organelle plays in generating 
energy and buffering cells or the devastating effects of mutations within its DNA. This 
review aims to give general background information on mitochondrial biology and 
DNA, and then focus in on the problems that can be caused when it goes wrong. In 
addition, a possible source of therapy for some conditions, muscle stem cells, will be 
introduced. 
1.1.1  Mitochondrial Origins 
“Cells without nuclei were the first to evolve. Cells with nuclei, however, are not merely 
mutant descendants of the older kind of cell. They are the product of a different 
evolutionary process: a symbiotic union of several cells without nuclei”  
(Margulis, 1971). 
Mitochondria evolved through one such relationship, they descended from eubacteria 
which underwent an endosymbiosis with a nucleus containing host. When Lynn 
Margulis proposed the endosymbiotic theory of mitochondrial origins, she highlighted 
the fact they contain their own DNA, messenger RNA, ribosomes, and are capable of 
protein synthesis, as evidence they were once able to live independently. 
This endosymbiotic event is believed to have occurred between 1.5-2 billion years ago. 
It is still debated whether it happened in a nucleus containing, amitochondrial cell, or 
the bacterial endosymbiont entered a prokaryotic host which later developed 
eukaryotic characteristics (Embley and Martin, 2006). 
Sequencing the genome of the intracellular parasite Rickettsia prowazekii, an α-
proteobacteia, revealed many similarities to mitochondria, including genes encoding 
components of the tricarboxylic acid (TCA) cycle and the respiratory chain complexes 
(Andersson et al., 1998). Coupled with phylogenetic reconstructions (Gray et al., 1999), 
the evidence would point towards this early mitochondrion being a member of the α 
division of the proteobacteria. Other members of this group include Ehrichia which 
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cause the tick borne disease Ehrlichiosis, and Rickettsi which have been implicated in 
the spread of typhus. 
Prior to the symbiosis, early mitochondria contained the entire DNA required for 
independence. As the symbiosis developed there was a gradual loss of mtDNA to the 
host genome leaving behind a compact molecule consisting of 16,569 base pairs (bp). 
1.1.2 Structure 
Mitochondria are present in the cytoplasm of eukaryotes; their numbers, size, and 
shape fluctuate depending on the energy requirements of the cell. Investigations into 
the structure of mitochondria have relied a great deal upon electron microscopy (EM), 
and have progressed as the technology and tissue preparation methods have 
improved. 
While sizes vary, mitochondria are usually between 1-4µm long and 0.3-0.7µm in 
diameter. Early investigations reported cylindrical or rod shaped organelles, with 
smooth outlines, a mitochondrial matrix, and an outer membrane. Images also 
revealed an internal system of lamellae lying perpendicular to the long axis of the 
mitochondria. These lamellae were described as “ridges” or “folds” protruding from 
the inside surface of the mitochondrial membrane that failed to reach the other side 
(Palade, 1952). Palade named these lamellae cristae mitochondriales. Later EM studies 
identified a double plasma membrane, consisting of an inner membrane (IM) and an 
outer membrane (OM). The lamellae were hypothesised to be cristae continuous with 
the IM (Palade, 1953), which has since been shown to occur through dynamic tubules 
termed cristae junctions (Frey and Mannella, 2000, Frey et al., 2002). 
These early EM studies resulted in the “Baffles” model of mitochondrial structure 
(Figure 1.1A). An alternative model has been suggested in which the lamellae, termed 
septa, crossed the matrix and divided the mitochondria into compartments (Figure 
1.1B) (Sjostrand, 1956). 
The OM contains large amounts of the transmembrane channel porin, also known as 
voltage dependant anion channel (VDAC), which is freely permeable to ions less than 
10KDa in size. In order for proteins to enter the organelle the OM contains 
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translocases of the outer membrane (TOMS) and the IM has translocases of the inner 
membrane (TIMS). 
The IM is folded into many cristae and houses the protein components responsible for 
energy generation; the electron transport chain (ETC) and ATP synthase. In addition it 
provides a barrier across which the respiratory chain complexes can generate a 
chemiosmotic gradient in order to generate energy. The folding of the IM increases its 
surface area approximately five times, allowing for a greater area across which 
oxidative phosphorylation (OXPHOS) can occur. 
1.1.2.1 Mitochondrial Structure in Muscle 
Mitochondrial morphology and numbers differ according to the energy demand of 
their host tissue. In skeletal muscle they sit underneath the sarcolemma and penetrate 
the myofibrils. The greater energy demand of muscle is satisfied by an increase in 
cristae packing and organisation. This gives around a threefold increase in cristae 
surface area, thus allowing for greater amounts of energy to be generated. 
In his original EM investigations Palade (1953) observed tightly packed cristae and a 
smaller matrix in skeletal muscle mitochondria when compared to liver cells. But even 
within muscle, human studies have revealed differences in mitochondrial morphology 
and positioning (Ogata and Yamasaki, 1997). Using scanning EM, Ogata and colleagues 
investigated three types of skeletal muscle fibres from the triceps brachii and vastus 
lateralis, that they termed red, white, and intermediate. The diameter of the 
mitochondria differed, with white fibres containing the smallest at 0.3µm, the red 
fibres the largest 0.9µm, and the intermediate fibres in the middle at 0.6µm. 
Striated muscle contains a reticulum of mitochondria penetrating the myofibrils and 
tethered to the cytoskeleton. All three fibre types contain paired mitochondria at the 
I-band; in the white fibres these mitochondria circle the myofibril at this position. 
While the red and intermediate fibres contain a stalk of mitochondria crossing the A-
band (Figure 1.18B) to the next row of mitochondria (Ogata and Yamasaki, 1997). 
In terms of mitochondrial numbers, the greatest densities are observed in the highly 
oxidative muscle types; for example cardiac muscle has 30-50% muscle volume, while 
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Figure 1.1. Mitochondrial structure. A. The “Baffles” model of mitochondrial structure. 
EM investigations revealed mitochondria to consist of a double membrane, with the 
inner membrane folding inwards to create cristae. Within the confines of the inner 
membrane is the matrix, which houses the mtDNA and RNA, along with various enzymes 
required for the TCA cycle. B. An alternative interpretation of the early EM images was 
the “Septa” model, whereby the cristae or septa crossed the width of the mitochondria 
dividing it into compartments. 
animal studies have shown skeletal muscle to have between 1-10% (Moyes and Hood, 
2003). 
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1.1.2.2 Dynamic Organelles 
While the singular oval shaped “Baffles” model of mitochondria are still presented in 
many images, these organelles are in reality, extremely lively structures. The dynamic 
nature of mitochondria was hinted at by Palade (1952), when he reported their “true 
branching”. This “branching” is the process of fission and fusion. Fission results in the 
division of mitochondria into separate structures, while fusion is their unification via 
inner and outer membranes (Figure 1.2). This process results in changes to 
morphology, size, and numbers of mitochondria, and also allows for the exchanging of 
contents. The trading of mitochondrial contents is important for the health of the 
mitochondria. Many of the proteins involved in the process of fission and fusion were 
first identified in yeast, though their mammalian homologues are now being 
elucidated. 
1.1.2.2.1 Mitochondrial Fission 
In order for fission to occur in yeast, a dynamin-related protein (Dnm1) is recruited 
from the cytosol, it assembles itself into punctate spots around the mitochondria. This 
forms a ring like structure around the mitochondrial tubule, encircling and constricting 
it (Bleazard et al., 1999). In human cells this function is performed by the mammalian 
homologue Drp1, which localises to evenly spaced areas on the mitochondria which 
coincide with sites of constriction and division (Smirnova et al., 2001). 
In yeast, the process of fission also requires an outer mitochondrial membrane protein 
termed Fis1, this protein binds to Dnm1 through an adaptor protein, Mdv1, and allows 
for the proper distribution and function of Dnm1 (Mozdy et al., 2000). The human 
protein hFis1 has been suggested as a possible homologue to Fis1, and its binding to 
Drp1 has been demonstrated (Yoon et al., 2003). However, discussions are ongoing as 
the loss of hFIS1 does not decrease Drp1 binding to mitochondria (Lee et al., 2004). 
The exact mechanism of IM fission is still being debated, although this could occur 
through the force generated by the OM components (Scott et al., 2003). Alternatively 
it could be via an IM protein for example transmembrane protein 11 (TMEM11), 
although the exact mechanism of action of TMEM11 is unknown (Rival et al., 2011). 
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1.1.2.2.2 Mitochondrial Fusion 
Mitochondrial fusion requires the joining of both the IM and OM, with the resultant 
mixing of the matrix contents. One of the first components identified in the process of 
fusion was the fuzzy onion protein (Fzo1) found in Drosophila. 
The fusion of the OM in mammalian mitochondria requires two large GTPases of the 
dynamin family, mitofusins 1 and 2 (Mfn1, Mfn2), which are both encoded by the 
nuclear genome (Santel and Fuller, 2001). These are required to act on adjacent 
mitochondria. Both Mf1 and Mf2 contain two hydrophobic heptad repeats, termed 
HR1 and HR2 which sit on either side of two hydrophobic transmembrane (TM) 
segments. In addition they contain a GTPase domain. HR2 is involved in the tethering 
of adjacent mitochondria through coiled-coil interactions, while the GTPase domain is 
required for the full fusion of the membranes (Koshiba et al., 2004). 
IM fusion also requires a GTPase, in the form of optic atrophy 1 (Opa1), the deletion of 
which does not affect fusion of the OM. Opa1 is a member of the dynamin related 
protein family and is localised to the intermembrane space. Unlike the mitofusins, 
Opa1 is only required in one of the two mitochondria that will undergo fusion. As well 
as requiring the homologue of Opa1, which is Mgm1, fusion in yeast also needs an 
adaptor protein, Ugo1. This binds to both Fzo1 and Mgm1 and coordinates the fusion 
of the two membranes. As yet, no mammalian homologue of Ugo1 has been 
determined (Song et al., 2009). 
The importance of the proteins involved in mitochondrial fusion can be seen through 
the disorders witnessed when their genes are mutated. In 50-60% of cases of 
autosomal dominant optic atrophy (ADOA), the disease is caused by a mutation in the 
Opa1 gene. This results in the destruction of the optic nerve, via degeneration of the 
retinal ganglion cells that constitute the nerve. Consequently, there is a loss of the 
central field and a sparing of the peripheral vision. Many pathogenic mutations 
causing ADOA have been identified in the GTPase domain and the central dynamin 
regions (Detmer and Chan, 2007, Yu-Wai-Man et al., 2011). 
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Mutations in Mfn2 have been implicated in Charcot-Marie-Tooth 2A disease, one of 
the commonest hereditary neuropathies. Symptoms include distal limb weakness and 
sensory loss, atrophy, and compromised mobility. It is caused by the degeneration of 
the long peripheral nerves, and as a result symptoms often start in the hands and feet 
(Detmer and Chan, 2007). The exact reasons why Mfn2 mutations disrupt the 
peripheral nerves are not known. One theory suggests that the disrupted fusion 
affects the transport and distribution of mitochondria in the long nerves, where 
energy is often required a long way from the soma (Cartoni and Martinou, 2009). 
 
 
 
Figure 1.2 Fission and fusion. Mitochondria are continuously undergoing the process of fission and 
fusion, allowing them to regulate their size, morphology, number, and matrix content. Fusion requires 
the joining of both inner and outer membranes, involving the mitofusins (Mfn) and optic atrophy 1 
(Opa1) respectively. Fission is the budding of mitochondria from the mitochondrial network. It 
requires Drp1 being recruited to the membrane, where it surrounds and constricts the organelle. 
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1.1.3 Mitochondrial Functions 
Mitochondria perform a number of functions in the cell. While they are popularly 
referred to as “batteries of the cell”, a reference to their energy generating 
capabilities, they also have roles in calcium regulation, reactive oxygen species 
generation, apoptosis, and the production of iron-sulphur clusters. 
1.1.3.1 Oxidative Phosphorylation 
A major function of mitochondria is to generate energy in the form of ATP via the 
process of oxidative phosphorylation (OXPHOS). The ninety or so protein components 
of OXPHOS, are embedded in the mitochondrial inner membrane. It consists of five 
protein complexes; I-IV comprising the electron transport chain (ETC), and complex V 
the ATP synthase. In addition there are a further two electron carriers (Figure 1.3). In 
the OXPHOS system electrons are transported through the ETC; this flow of electrons 
gives a free energy change which is used to create a proton (H+ ) gradient. This 
gradient is generated by complexes I, III, and IV, pumping H+ across the inner 
membrane into the intermembrane space. The gradient is then used by the last 
complex, the ATP synthase to generate ATP from ADP. The use of an electrochemical 
gradient across the inner membrane to generate energy is termed the chemi-osmotic 
hypothesis (Mitchell, 1961). 
While some of the ATP is utilised by the mitochondria themselves for their own needs, 
the majority of it is transported out of the organelles by the adenine nucleotide 
translocator (ANT) for use by the cell. 
 
 
 
 
 
  
 
Figure 1.3 Oxidative phosphorylation. Energy is generated for the cell by mitochondria via the process of oxidative phosphorylation. This involves the transport of 
electrons through a series of protein complexes by redox groups. As the electrons pass through the redox groups free energy is generated; this is used to pump protons 
across the membrane. The resultant proton gradient is used by complex V to generate ATP from ADP. 
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1.1.3.1.1 Complex I (NADH Ubiquinone Oxidoreductase) 
Complex I catalyses the first step in the ETC, utilising NADH, the products of the TCA cycle, 
and the β–oxidation of fatty acids. It transfers two electrons from NADH to ubiquinone 
and couples this with the translocation of four H+ across the inner mitochondrial 
membrane. 
Many of the experiments performed to determine the structure of complex I have been 
carried out using bovine enzyme as a model for the human enzyme. Complex I is the 
largest of the respiratory chain enzymes at almost 1000kDa. It is often depicted in an L 
shape and consists of a hydrophobic membrane domain, containing a number of 
transmembrane helices, and a hydrophilic peripheral arm lying perpendicular to the 
membrane component. In total there are forty five subunits (Carroll et al., 2006), of which 
seven are encoded by the mtDNA, and the rest by the nuclear genome (nDNA). 
Fourteen of these subunits are termed “core” subunits as they are conserved between 
eukaryotes and prokaryotes. Seven of these “core” subunits are hydrophilic, in the 
peripheral arm, and encoded by the nDNA; NDUFS1, NDUFS2, NDUFS3, NDUFS7, NDUFS8, 
NDUFV1 and NDUFV2. The remaining seven “core” subunits are encoded by the mtDNA, 
ND1-6, and ND4L and sit in the hydrophobic membrane arm (Lazarou et al., 2009, 
Zickermann et al., 2009). 
The exact mechanism of complex I assembly has caused many discussions, mainly due to 
its large nature and bigenomic control. But its importance is paramount, as many defects 
in complex I that cause diseases occur as a result of impaired assembly. The subunits 
encoded by the nDNA must be imported into the mitochondria and then assembled 
alongside mtDNA encoded subunits. Rather than a linear assembly, it has been suggested 
that nDNA encoded subunits are continuously imported into the mitochondria where 
they assemble into existing subunits in the complex (Lazarou et al., 2007). In contrast, 
mtDNA encoded subunits need to assemble into intermediate complexes before being 
integrated. A recent study, using mouse L929 cells (adipose fibroblasts) with mutations in 
ND4, ND5, and ND6, concluded that there are five entry points for the mtDNA encoded 
subunits into complex I. ND1 joins the peripheral arm subunit complexes to form a 
~400kDa intermediate that then anchors itself to the inner mitochondrial membrane. This 
is followed by a second sub complex (~460kDa) containing ND2, ND3, and ND4L that joins 
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the ND1 assembly. A third entry point is for ND4, followed by incorporation of ND6, and 
finally ND5 (Perales-Clemente et al., 2010). 
Complex I catalyses the oxidation of NADH to NAD+, this releases  two electrons which are 
passed to a flavin mononucleotide (FMN) prosthetic group. This reduces FMN to FMNH2, 
the electrons are then passed through a series of eight iron-sulphur (Fe-S) clusters. This 
takes place in the peripheral arm of the complex. The two electrons are then passed to a 
ubiquinone (Q) molecule reducing it to ubiquinol (QH2). This reaction is coupled with the 
pumping of 4H+ from the matrix into the intermembrane space (Figure 1.4). The proton 
translocation takes place in the membrane arm of the enzyme and utilises the energy 
generated in the peripheral arm via the redox reactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Complex I. Complex I is also known as NADH-ubiquinone oxidoreductase or 
NADH dehydrogenase. It consists of a hydrophobic and hydrophilic domain, often 
depicted in an L shape. It catalyses the reaction: NADH +Q+5H
+
>NAD
+
+QH2+4H
+
. The 
complex contains a number of redox groups that carry electrons, the first of which is the 
flavin mononucleotide (FMN). The electrons then pass through eight iron-sulphur 
clusters to reduce ubiquinone (Q) to ubiquinol (QH2). This reaction results in four 
protons being translocated. 
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1.1.3.1.2 Complex II (Succinate Dehydrogenase) 
Complex II is the smallest component of the ETC, comprising four polypeptides (Capaldi et 
al., 1977), termed A (73kDa), B (27kDa), C (15kDa), and D (12.5kDa). In humans these four 
subunits are encoded by the nDNA. A and B are hydrophilic and present on the matrix 
side of the membrane, while C and D are hydrophobic and integral membrane proteins. 
Within the hydrophilic component of the complex, subunit A contains a flavin adenine 
dinucleotide (FAD) prosthetic group, and B houses three Fe-S clusters (2Fe-2S, 4Fe-4S, 
3Fe-4S). The hydrophobic subunits C and D contain a haem group sandwiched between α-
helices (Figure 1.5). 
Complex II catalyses the oxidation of succinate to fumarate, a step in the TCA cycle. This 
allows a second entry point of two electrons to enter the ETC. These two electrons reduce 
FAD to FADH2 and are then passed through three Fe-S clusters before reducing 
ubiquinone to ubiquinol. Complex II is thought to contain two ubiquinone binding sites, 
one on the matrix side of the complex, and the other close to the intermembrane space 
(Sun et al., 2005). The enzyme is unusual in that it is the only component of the ETC 
where the transfer of electrons is not coupled to the translocation of H+, probably 
because the free energy change from succinate to ubiquinone is too small. 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Complex II. Complex II is also known as succinate: ubiquinone 
oxidoreductase. It consists of two hydrophilic polypeptides, A and B, and two 
membrane hydrophobic polypeptides, C and D. It catalyses the reaction: 
succinate+Q> fumarate+QH2. The movement of electrons through the redox 
groups does not result in enough free energy for the movement of protons across 
the membrane, but the complex is a source of further electrons for the ETC. 
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1.1.3.1.3 Complex III (Cytochrome bc1, Ubiquinol-cytochrome c oxidoreductase) 
Complex III (248kDa) is an integral membrane protein catalysing the electron transfer 
from ubiquinol to cytochrome c. It is a dimer, with each monomer consisting of eleven 
subunits, three of which contain prosthetic groups (Figure 1.6). Subunit III has two haem 
containing groups: cytochrome bL and bH. Subunit IV contains one haem group: 
cytochrome c1, and subunit V contains a 2Fe-2S containing Rieske protein (Xia et al., 
1997). These three subunits constitute the essential subunits, with the other eight termed 
supernumerary subunits. 
The two monomers of complex III form cavities through which substrate pockets can be 
accessed. The complex can be divided into three regions: intermembrane space, 
transmembrane helix, and matrix. The intermembrane space domain contains the 
functional part of cytochrome c1 and Fe-S, along with subunit VIII. Each transmembrane 
monomer contains eight helices from cytochrome b, and five from cytochrome c1, Fe-S, 
and subunits VII, X, XI. More than half the mass of the enzyme is contained in the matrix 
region and consists of subunits I, II, VI, and IX, as well as parts of subunit VII, Fe-S, and 
cytochrome c1 (Yu et al., 1999). Except for cytochrome b which is encoded by the mtDNA, 
complex III is nuclear encoded. 
Complex III catalyses the transfer of electrons from ubiquinol to cytochrome c and 
couples this transfer with the translocation of four H+. This electron transfer is thought to 
occur via the Q cycle, involving a bifurcation of electron flow and two active sites 
(Mitchell, 1976). The first step in this cycle is the oxidation of ubiquinol at Qo which 
generates two electrons. One of the electrons is then passed via the Rieske Fe-S centre to 
cytochrome c1 and is used to reduce the soluble electron acceptor cytochrome c. The 
second electron is recycled through cytochrome bL and then bH, and is used to reduce 
ubiquinone to ubisemiquinone at the Qi site. A second Q cycle further reduces 
ubisemiquinone to ubiquinol. Two protons are translocated for every quinol oxidised and 
in a complete cycle two ubiquinols are oxidised with the resultant two electrons being 
transferred to the Qi site and one ubiquinone being reduced, resulting in a total of four H+ 
being translocated (Gao et al., 2003, Yu et al., 1999). 
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Figure 1.6 Complex III. Complex III may also be named ubiquinone-cytochrome c 
oxidoreductase and bc1 complex. It is a dimer composed of two monomers, each 
consisting of eleven subunits. The complex catalyses the reaction: 
QH2+2cytc+2H
+
>Q+2cytc+4H
+
, which results in four protons being pumped into the 
intermembrane space. 
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1.1.3.1.4 Cytochrome c 
Cytochrome c is a 13kDa, water soluble, haem containing protein, consisting of one 
hundred and four amino acids. It is mobile within the plane of the mitochondrial inner 
membrane and is reduced by complex III. It then donates these electrons to complex IV. It 
is entirely nuclear encoded and evolutionary conserved (Huttemann et al., 2011). 
1.1.3.1.5 Complex IV (Cytochrome c Oxidase) 
Complex IV is the last component of the ETC and houses the terminal electron acceptor. It 
catalyses the transfer of two electrons to molecular oxygen (O2) to generate water (H2O) 
and results in two H+ being pumped into the intermembrane space. 
Complex IV (204kDa) is composed of two monomers each containing thirteen subunits. 
The largest subunits, I-III, are encoded by the mtDNA and form the functional core of the 
protein, while IV-XIII are encoded by the nDNA. The active site for the enzyme is located 
in the transmembrane region on subunit I. The complex contains two cytochrome 
containing haems (haem a, haem a3) and two copper centres (CuA, CuB), as well as 
additional metal centres of Zn and Mg. The haem a and haem a3 prosthetic groups along 
with the CuB group are bound to subunit I in the transmembrane region, which also 
contains twelve transmembrane helices. The CuA centre is located in subunit II on the 
cytosolic side of the complex. The Zn centre is in the nuclear encoded subunit V on the 
matrix side of the complex, while the Mg centre sits between subunits I and II (Tsukihara 
et al., 1995, Tsukihara et al., 1996). 
Cytochrome c binds to complex IV and donates electrons to the primary electron 
acceptor, CuA. The electron is then transferred to haem a and then on to the catalytic site 
which contains haem a3 and CuB. The reduction of molecular O2 to H2O requires four 
electrons, and cytochrome c can only donate one at a time. As a result cytochrome c 
cycles through four states, with each state being coupled to H+ uptake and translocation 
across the membrane (Faxen et al., 2005). 
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1.1.3.1.6 Complex V (ATP synthase) 
Complex V is the last component of the OXPHOS system. It is a large protein complex of 
approximately 500kDa and is responsible for the synthesis of ATP from ADP and inorganic 
phosphate (Pi) on the matrix side of the membrane. It utilises the flow of protons across 
the membrane and down the electrochemical gradient to do this. 
The complex contains sixteen subunits, two of which are encoded by the mtDNA, ATPase 
6 and 8. It consists of two domains, the transmembrane Fo part and the water soluble F1 
segment which is on the matrix side of the membrane (Figure 1.7). Fo contains a proton 
channel and is composed of a subunit c ring and an ab complex. F1 is composed of four 
subunits α3, β3, δ, and ε in a cylindrical shape surrounding a fifth, γ component. Three 
catalytic sites are present on the β subunit in F1 (Yoshida et al., 2001). In addition the 
complex contains two stalks (b), one connecting the Fo and F1 regions and another 
extending from the bottom of Fo to the top of F1 (Bottcher et al., 1998). 
H+ translocation through the Fo proton channel drives the rotation of the γ subunit within 
the F1 segment, with each 120
0 turn driving the release of one ATP molecule. The side 
stalks prevent unwanted rotation of the stationary parts of the protein. The catalytic sites 
for ATP hydrolysis are on the β subunit, and exists in one of three states, open (O), loose 
(L), and tight (T). When ADP and Pi are bound to a site it is “loose”, ATP is “trapped/tight” 
in the second site, and the third site will be empty (O). A rotation of F1 allows the ATP to 
be released, and ADP + Pi becomes ATP. 
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Figure 1.7 ATP synthase. The ATP synthase consists of a membrane component (F0), and a 
hydrophilic catalytic portion (F1). F0 is composed of a c ring, an ab complex and a proton 
channel. The c ring along with the ƴ and ε domains make up the rotating segment of the 
enzyme. The b stalk connects the F0 and F1 regions. The catalytic domain consists of α3, β3, δ, 
ε, and ƴ. 
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1.1.3.1.7 Adenine Nucleotide Transporter (ANT) 
ANT catalyses the exchange of ATP for ADP across the inner membrane in a 1:1 
stoichiometry. It is an integral membrane protein of approximately 32kDa and is encoded 
by the nDNA. Its role in OXPHOS is to exchange ATP out of the mitochondria for ADP in, 
but is able to work in reverse during times of stress (Chinopoulos et al., 2009). 
1.1.3.1.8 Mitochondrial Supercomplexes 
The OXPHOS system is often depicted as a sequence of proteins embedded in the 
membrane where they are able to move freely by lateral diffusion with electrons flowing 
between them connected by the mobile carriers ubiquinone and cytochrome c. This is 
referred to as the “Random Diffusion Model”. However, recent research has shown that 
the individual complexes form aggregates with each other which are termed 
supercomplexes. Investigations into supercomplex structures have been greatly helped 
with the development of Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE). This 
has revealed that the exact compositions of these supercomplexes appears to vary 
depending on the organism being investigated and the detergents used to solubilise the 
mitochondrial membrane (Lenaz and Genova, 2007). 
A recent paper demonstrated that supercomplexes can also contain ubiquinone and 
cytochrome c. In addition they were shown to respire, thus demonstrating their 
functional capabilities and earning them the name “respirasomes” (Acin-Perez et al., 
2008). Complex I has been found to associate with complex III in a I1III2 ratio, as well as in 
supercomplexes containing both III and IV. Only small amounts of complex I have been 
found in the free form. While initially not thought to form supercomplexes, complex II has 
now been demonstrated in these associations (Acin-Perez et al., 2008, Lenaz et al., 2010). 
It is thought that this organisation allows the close proximity of enzymes catalysing 
consecutive reactions, thus preventing OXPHOS intermediates being lost from the chain 
into the surrounding area. It can also aid the structural stabilisation of the complexes 
(Lenaz and Genova, 2007). 
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1.1.3.2 Apoptosis 
Apoptosis is the programmed cell death that occurs in many eukaryotes. It confers an 
advantage to the organism as it allows for control of cell numbers, tissue size, and the 
disposal of old or rogue cells. It differs from necrosis, which occurs in response to external 
factors outside the cell, for example injury, infection, or toxins. 
There are two main pathways of apoptosis, both of which result in the activation of 
caspases. Caspase activation leads to cell death through the modification of regulatory 
and structural proteins. The extracellular route is initiated by cell surface receptors and 
produces caspase-8 activation, while the intracellular route is mediated by mitochondria 
(Figure 1.8). 
The extracellular pathway is initiated by the ligation of “death-receptors”, which are 
members of the tumour necrosis factor (TNF) receptor family, for example FAS, or TNF 
receptor-1 (TNFR1). These receptors contain an intracellular domain which is able to 
activate caspase-8. This causes downstream activation of effector caspases, for example 3 
or 6 (Youle and Strasser, 2008). 
The intracellular route is mediated by mitochondrial release of cytochrome c from the 
cristae. This is controlled upstream by the Bcl-2 family of proteins, which in turn is 
controlled by BH3-only proteins. Upon the initiation of apoptosis, BH3-only proteins 
inhibit the anti-apoptotic Bcl-2 proteins, which allow the pro-apoptotic BAK and BAX 
proteins to permeabilise the outer mitochondrial membrane (Suen et al., 2008). This 
permeabilisation causes the release of cytochrome c, which leads to caspase activation. 
Cytochrome c binds to APAF1, which induces the assembly of an apoptosome which binds 
to caspase-9, causing caspase-3 initiation and cell death (Youle and Strasser, 2008). 
The release of cytochrome c happens close in time to BAX activation, which can then be 
observed to localise to the outer mitochondrial membrane at small focused areas; these 
foci become sites of mitochondrial splitting. This release occurs just after or 
simultaneously to mitochondrial fission, and is thought to be mediated by the protein 
Drp1, the binding of which to mitochondria increases during apoptosis (Landes and 
Martinou, 2011). Using short hairpin RNAs for RNA inhibition it has been shown that 
down regulation of Drp1 reduces cytochrome c release and eventual cell death. Inhibition 
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of hFIS1 decreases apoptosis to an even greater extent, possibly because it is required for 
BAX recruitment to the Drp-1 foci (Lee et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Apoptosis. Apoptosis may be initiated via an extrinsic or intrinsic route. The 
extrinsic pathway is activated by cell surface receptors FAS and TNFR1, and then through 
the activation of caspase-8 the caspase cascade is initiated. The intrinsic pathway relies on 
mitochondria. In response to a stress on the cell, BH3 is activated, it then stops the 
inhibition of BAX/BAK proteins, which causes the fission of mitochondria and cytochrome 
c release from the intermembrane space. This activates the apoptosome which again 
induces caspase activation. 
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1.1.3.3 Mitochondria and Calcium 
Calcium (Ca2+) serves many functions in the cell, including signalling, differentiation, 
apoptosis, and muscle fibre contraction. Its regulation is therefore very important. 
Mitochondria play a role in this regulation through the storage and buffering of Ca2+ 
(Contreras et al., 2010, Duchen, 2000). High cytoplasmic levels of Ca2+ are responded to 
by an uptake and storage of the ion by the mitochondria, thus protecting the cell from 
overload. The reverse is also witnessed when levels in the cell drop (Collins and Meyer, 
2010). Within mitochondria Ca2+ is able to stimulate ATP production through its activation 
of dehydrogenases coupled to the TCA cycle, and possibly via its interactions with the ETC 
(Hoppe, 2010). 
Mitochondria accumulate Ca2+ via the Ca2+ uniporter (MCU), in the inner mitochondrial 
membrane. This occurs against a concentration gradient and is driven by a negative 
potential rather than ATP-dependent pumping. Movement out of the mitochondria 
occurs via a Na+/Ca2+ exchanger. The outer membrane is permeable to Ca2+ through VDAC 
channels that allow the passage of molecules up to 10kDa. There is debate if VDAC is 
freely permeable to Ca2+ or provides some regulation (Hoppe, 2010). 
A recent study identified a regulator of the MCU through a series of focused genetic 
screens and knockdown experiments (Perocchi et al., 2010). The authors used a bank of 
mitochondrial proteins that they narrowed down to IM proteins that were present in the 
majority of mammalian tissues. They then ruled out all proteins that did not have 
homologues in vertebrates and kinetoplastids, but were present in yeast, as yeast does 
not demonstrate uniport activity. Eventually they were left with thirteen genes with 
which to perform RNA interference experiments. They identified one protein, the 
mitochondrial Ca2+ uptake 1 (MICU1), as a regulator of Ca2+ uptake. This 54kDa protein 
contains two EF-hands that are separated by a long helix, which are important for the 
Ca2+ uptake, as it is these sites the ion binds to. The channel is also sensitive to Ca2+ 
concentrations, suggesting it may additionally function as a Ca2+ regulator (Perocchi et al., 
2010). 
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1.1.3.4 Reactive Oxygen Species (ROS) Generation 
Reactive oxygen species (ROS) are termed reactive as they are able to react with 
reducible agents. ROS include hydrogen peroxide (H2O2), superoxide (O2
-) and the 
hydroxyl radical (·OH). The ETC produces O2
-, which is converted into H2O2 by superoxide 
dismutase (SOD), this can be further converted into ·OH (Camello-Almaraz et al., 2006). 
ROS is mainly generated at complexes I and III through the incomplete reduction of 
oxygen. Complexes I and II release ROS into the mitochondrial matrix while complex III 
produces it on both sides of the inner mitochondrial membrane (Muller et al., 2004). 
ROS generation may be considered a double-edged sword. While it has important roles to 
play in cellular signalling, especially pathways related to autophagy, it has also been 
implicated in the ageing process. 
When cells are exposed to hypoxia, adaptive signalling pathways are activated in order to 
decrease energy consumption and oxygen usage. The cellular responses to hypoxia 
require the activation of hypoxia inducible transcription factors (HIFs), an upstream 
regulator of which is thought to be H2O2 released from the mitochondria (Hamanaka and 
Chandel, 2009). In addition, mitochondrial ROS is thought to regulate tumour necrosis 
factor alpha (TNFα) mediated cell death, modulate inflammation, and play a role in Ca2+ 
signalling (Hamanaka and Chandel, 2010, Camello-Almaraz et al., 2006). However, 
mitochondrial ROS has also been suggested as one of the factors limiting lifespan 
(Balaban et al., 2005). 
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1.1.3.5 Iron – Sulphur (Fe-S) Cluster Biogenesis 
Iron enters the mitochondrial IM via mitoferrin, however it is not yet known how it 
crosses the OM. Once in the mitochondria it is used for haem and Fe-S cluster synthesis, 
or stored in mitochondrial ferritin. 
Mitochondria are a major site of Fe-S biogenesis formation, consisting of iron and 
sulphide anions (S2-), which assemble into clusters of 2Fe-2S, or 4Fe-4S. These clusters 
become protein cofactors, which can proceed to perform functions in electron transport, 
DNA repair, enzyme structural stability, ROS sensing, and iron homeostasis (Rouault and 
Tong, 2005, Richardson et al., 2010). 
The importance of Fe-S clusters can be observed in patients with Friedreich’s ataxia. This 
is a neurodegenerative disorder caused by a decrease in the frataxin gene due to a GAA 
repeat in its first intron. Frataxin is synthesised in the cytoplasm, targeted to the 
mitochondria and thought to participate in Fe-S biogenesis. Patients with Friedreich’s 
ataxia demonstrate a decrease in the activities of Fe-S proteins and have iron 
accumulation in their mitochondria, leading to oxidative damage and failure (Rouault and 
Tong, 2005, Stemmler et al., 2010). 
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1.1.4 The Mitochondrial Genome 
1.1.4.1 Structure and Organisation 
Mitochondria contain their own genome separate from the nDNA. It is present in multiple 
copies in each cell and is a covalently closed double stranded loop. The two strands are 
named heavy (H strand,) abundant in guanine, and light (L strand) which is rich in cytosine 
(Figure 1.9). The two strands were given their name because of their separate levels in a 
cesium chloride (cs-cl) separation gradient. In addition, the genome contains a short three 
stranded DNA region, termed the displacement loop (D-loop). The possibility of this 
structure being an intermediate in a repair mechanism, or a precursor of replication has 
been suggested, but its true function remains a mystery (Kasamatsu et al., 1971). 
While often depicted as a circular structure, mtDNA is in fact a supercoiled molecule. In 
addition, punctate staining of mtDNA in the cell suggests that it is packaged up with 
various proteins into nucleoids. These are thought to regulate the genetic content and 
intracellular distribution of mtDNA. Each nucleoid contains between two to ten copies of 
mtDNA and is located at discrete sites uniformly along the length of the organelle in the 
matrix. The mtDNA is tethered through the inner membrane to cytoskeleton proteins 
(Gilkerson and Schon, 2008, Iborra et al., 2004). 
An experiment solubilising mitochondria with detergent to release mitochondrial 
transcription factor A (TFAM) showed it was associated with mtDNA. In addition, it was 
not until the mtDNA was digested with DNAse I that the TFAM was released. It was 
further suggested that the ratio of TFAM to mtDNA was 900:1, enough to completely 
encapsulate the mtDNA (Alam et al., 2003). There is also evidence that TFAM is directly 
involved with regulating mtDNA copy number (Ekstrand et al., 2004). The above findings 
suggest TFAM is a nucleoid associated protein. 
Other proteins associated with the nucleoids include prohibitin, polymerase ƴ (POLG), 
mitochondrial single stranded binding protein (mtSSB) and TWINKLE (Gilkerson and 
Schon, 2008). 
 
 
Chapter 1  Introduction 
25 
  
 
 
 
 
 
 
 
Figure 1.9 MtDNA structure. MtDNA is a double stranded genome, consisting of a heavy and light 
component. It encodes thirty seven genes which are unevenly distributed between the two strands. 
It encodes seven genes of complex I (yellow), one of complex III (pink), three of complex IV (green) 
and two of complex V (dark blue). In addition it encodes twenty two tRNAs (blue), and two rRNAs 
(purple). The origins of light and heavy strand replication are also indicated. 
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1.1.4.2 Genetic Code 
Sequenced in its entirety back in 1981, mtDNA is extremely tightly packed, in that it 
contains very few non coding regions with no introns, and is highly conserved among 
mammals. It is 16569bp long and encodes thirty seven genes (Figure 1.9); these are 
thirteen structural proteins, twenty two tRNAs, and the 12S and 16S rRNAs (Anderson et 
al., 1981). The thirteen structural proteins are core subunits of the OXPHOS system, with 
the tRNAs and rRNAs that are required for their translation in the cell. These genes are 
distributed unevenly between the H and L strands of the DNA, with eight tRNAs and one 
structural protein on the L strand and everything else on the H strand. The remaining 
components required by the mitochondria are encoded by the nuclear genome and 
imported into the organelle. The genome is confined within the inner membrane (Tuppen 
et al., 2010, Smeitink et al., 2001). 
The genome sequenced in 1981 formed the Cambridge Reference Sequence, however the 
mtDNA was sourced from a single human, HeLa cells, and bovine cells. This has resulted in 
some discrepancies in the sequence. A more recent paper (Andrews et al., 1999) sought 
to correct these discrepancies and produced the Revised Cambridge Reference Sequence. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1  Introduction 
27 
  
1.1.4.3 MtDNA Replication 
Work in mouse L cells (fibroblasts) has demonstrated that mtDNA replication occurs 
independently of the cell cycle (Bogenhagen and Clayton, 1977). The genome also 
continually replicates in post mitotic tissues, for example muscle and brain. However, the 
exact mechanism of mtDNA replication is still under debate. Two models have emerged in 
this discussion, the strand asynchronous or displacement model (Robberson and Clayton, 
1972, Clayton, 1982), and the strand synchronous or coupled model (Holt et al., 2000). 
1.1.4.3.1 Strand Asynchronous Model 
In this model, replication initiates at the origin of heavy strand replication (OH), which 
causes displacement of the L strand from the H strand. Replication then proceeds in a 
clockwise direction until the origin of light strand replication (OL) is exposed, which occurs 
when about 67% of the H strand has been synthesised. At this point, L strand replication 
is initiated in the opposite direction, using the exposed L strand as a template (Figure 
1.10A). This order of replication has resulted in the heavy and light strands being termed 
“leading” and “lagging” respectively. When replication of the strands is complete they are 
covalently closed. When both daughter strands have been synthesised and dissociated 
from their templates super-helical turns are introduced. It has been suggested that this 
whole process is complete in two hours (Clayton, 1982). 
1.1.4.3.2 Strand Synchronous Model 
While earlier work investigating mtDNA replication involved the utilisation of Cs-Cl 
density gradients, later work involved the use of 2D-PAGE techniques, allowing for the 
separation of DNA molecules on the basis of both size and shape. Using this approach the 
strand synchronous model was proposed (Holt et al., 2000). 
As in the asynchronous model, H strand synthesis is thought to be instigated at OH and 
proceeds in a clockwise direction, again being termed the leading strand. Shortly 
afterwards this initiates replication of the “lagging” L strand in the opposite direction 
(Figure 1.10B). However, the L strand is generated in short segments (replication 
intermediates) that have been named Okazaki Fragments (Holt et al., 2000). The 
researchers did leave open the possibility that both mechanisms of replication could 
occur within the mitochondria. With the strand asynchronous model occurring when cells 
require large amounts of mtDNA for example during growth, and the synchronous model 
being used for cell maintenance. 
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In a development of the strand synchronous model it has been proposed that the lagging 
L strand is initially composed of RNA, before being converted to DNA in maturation steps. 
This “RNA incorporation throughout the lagging strand” (RITOLS) model would allow for 
the stabilization of the displaced DNA strand during replication (Yasukawa et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 MtDNA replication. A. Strand asynchronous model of mtDNA 
replication. Replication begins at the origin of heavy strand replication (OH), it then 
proceeds until the origin of light strand replication (OL) is exposed. Replication 
then commences in the opposite direction until both strands are complete. B. 
Strand synchronous model. Replication is also initiated from OH, but very quickly 
replication of the light strand begins. This occurs through the production of 
Okazaki Fragments. Both strands continue to be replicated until two genomes 
have been generated. Green arrow = heavy strand replication, blue arrow = light 
strand replication. 
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1.1.4.3.3 Protein Machinery for MtDNA Replication 
The proteins required for mtDNA replication are encoded by the nDNA, translated in the 
cytosol and then imported into the mitochondria. These enzymes include POLG, a 
replicative DNA helicase TWINKLE, the mitochondrial single stranded DNA-binding protein 
(mtSSB), and mitochondrial RNA polymerase (POLRMT) (Figure 1.11). 
The TWINKLE helicase moves in a 5’ to 3’ direction unwinding the double stranded 
mtDNA. MtSSB instigates TWINKLE activity, in addition to stabilising the single strands 
created and stimulating POLG activity. POLG has both 5’-3’ and 3’-5’ exonuclease activity, 
and is a heterotrimer consisting of one catalytic subunit (POLGα) with two accessory 
subunits (POLGβ). POLRMT is the OL specific primase and synthesises the RNA primer 
needed for lagging strand synthesis (Wanrooij and Falkenberg, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 Proteins involved in mtDNA replication. TWINKLE helicase (blue) unwinds 
the double stranded DNA into single strands which are then stabilized by 
mitochondrial single stranded binding protein (mtSSB) (red). The new strands are then 
synthesised by POLG (α&β) (grey & green), while POLRMT (orange) synthesises the 
RNA that is required for the laggings strand synthesis that is initiated at OL. 
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1.1.4.4 MtDNA Transcription 
MtDNA transcription is initiated in the D-loop, from one promoter on the light strand 
(LSP) and two promoters on the heavy strand (HSP1 & 2) (Figure 1.12). Transcription from 
LSP is initiated from the transcription initiation site L (ITL) at nucleotide 407 in the D-loop 
and proceeds to generate a polycsistronic molecule almost the entire length of the L 
strand. Transcription from HSP2 begins at transcription initiation site H (ITH2) and also 
results in long molecules corresponding to the entire length of the genome. Another 
transcription initiation site H (ITH1) is present in HSP1 and transcribes the two rRNAs (12S 
& 16S), mt- tRNAPhe and mt-tRNAVal (Chang and Clayton, 1984, Taanman, 1999, Ojala et 
al., 1981, Montoya et al., 1982). 
Transcription activator A (TFAM) is a 25kDa protein composed of two high mobility group 
(HMG) domains, separated by a twenty five amino acid residue. It binds upstream of HSPs 
and LSB, allowing for the protein to initiate structural alterations in the promoter region 
and is essential for transcriptional activation. While it strongly promotes L strand 
transcription, its effect on H strand transcription is somewhat weaker. Mitochondria have 
their own polymerase, POLRMT, initially identified in yeast and then in humans. This is a 
1230 amino acid protein that cannot initiate transcription on its own, but works in 
combination with TFAM and TFB2M. TFB2M forms a heterodimeric complex with 
POLRMT that is also required for transcription initiation (Falkenberg et al., 2007). 
The termination of transcription is mediated by mTERF, a 39kDa protein. It is thought to 
attenuate both L and H strand transcription through binding to the 3’ end of the mt-
tRNALeu(UUR) gene and providing a physical barrier (Taanman, 1999). The importance of 
this protein is seen with the m.3243A>G mutation, often causing the disease 
mitochondrial encephalopathy lactic-acidosis and stroke-like episodes (MELAS). The 
mutation reduces the binding affinity for mTERF and results in impaired transcription 
termination (Taanman, 1999). 
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Figure 1.12 MtDNA transcription. MtDNA transcription is initiated from the D-loop. It commences 
from one promoter on the light strand (LSP) and from two promoters on the heavy strand (HSP1 & 
2). Transcription from LSP and HSP2 creates long transcripts almost the length of the entire genome, 
while that initiated from HSP1 only transcribes two rRNAs and two tRNAs. TFAM works in 
combination with POLRMT and TFB to initiate transcription, while mTERF is required for its 
termination. 
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1.1.4.5 MtDNA Translation 
Many of the proteins required by the mitochondria are encoded by the nDNA and 
imported into the organelle through channels, for example through the outer membrane 
via TOMs (translocases outer membrane) or the inner membrane via TIMs (translocases 
inner membrane). However, the mtDNA still encodes a few of the proteins it requires 
using its own translation system, although this system is somewhat different to that of 
the cytoplasm. 
Mitochondria only use the codons UAA, and UAG for termination. While AGG and AGA 
were originally thought to be stop codons it has recently been shown that they simply 
cause a -1 frameshift allowing for the recognition by the termination factors (Temperley 
et al., 2009). In mitochondria, UGA codes for tryptophan rather than a stop codon, and 
AUA is a methionine rather than an isoleucine. In addition mRNAs have no or few 5’ un-
translated nucleotides, they are uncapped and have a poly (A) tail added after the last 
stop codon. 
MtDNA translation consists of three stages, initiation, elongation, and termination. During 
the initiation phase, initiation factor 3 (IF3) catalyses the separation of the mitoribosome 
into its components, the small (12S) and the large (16S) subunits. This allows for the 
binding of the mRNA start codon (AUG) in the peptidyl site (P-site) on 28S subunit. The 
fMet-tRNAMet also binds to the 12S subunit which requires initiation factor 2 (IF2). The 
12S and 16S subunits then recombine dissociating IF3 and IF2 in the process. 
The elongation phase requires elongation factors EFG1 and 2, EFTs and EFTu. ETFu forms 
a structure with the tRNA and carries it to the acceptor site (A-site), where the codon-
anticodon interaction can occur. Peptide bond formation occurs on the 16S subunit and 
an amino acid is added to the growing peptide (Smits et al., 2010). 
The termination phase requires a stop codon (UAA, UAG,) to pass through the acceptor 
site (A-site). This is recognised by a termination release factor mtRF1a causing the protein 
to be released (Soleimanpour-Lichaei et al., 2007). 
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1.1.4.6 MtDNA Inheritance 
MtDNA is inherited in a non-Mendelian manner. In many animals and plants mtDNA is 
inherited from one parent, in humans this is the mother. This maternal inheritance was 
first demonstrated by Giles et al. (1980). Through the isolation of mtDNA from blood 
platelets and examination of Hae II restriction enzyme patterns it was demonstrated that 
mtDNA is maternally inherited. An atypical Hae II cleavage pattern was observed for all 
three children as well as in the mother, while the father contained a typical set of cleaved 
fragments that was not detectable in the children (Giles et al., 1980). 
It is currently thought that in humans maternal inheritance occurs through the 
destruction of the male mitochondria in the sperm cell. This is performed by proteosomes 
and lysosomes in the egg cell. At the point of fertilisation, sperm mitochondria are able to 
enter the egg, but ubiquitination, which has occurred in both the male reproductive tract 
and inside the egg, marks these mitochondria out for destruction (Sutovsky et al., 1999). 
There has however been a finding of paternal mtDNA inheritance identified in humans. 
Schwartz and Vissing (2002) reported the case of a twenty eight year old male, who 
presented with a mitochondrial myopathy that included exercise intolerance. 
Histochemical investigations into a muscle biopsy revealed accumulation of abnormal 
mitochondria within the fibres, termed Ragged Red Fibres (RRFs). Genetic investigations 
revealed a 2bp mtDNA deletion present in 90% of his muscle DNA. The mutation occurred 
in the ND2 gene, causing a defect in complex I. In addition, the patient was shown to have 
two different mtDNA haplotypes. His blood haplotype matched his mother’s, while his 
muscle haplotype was that of his father. It was hypothesised that a breakdown had 
occurred in the male mtDNA elimination mechanisms (Schwartz and Vissing, 2002). 
While paternal leakage has currently only been reported in one human case, it would 
appear to occur more frequently in animals, including birds and lizards. This is 
hypothesised to occur in hybrid zones, where closely related species meet and breed. Due 
to the reproductive barriers not being fully developed, the mechanisms in place to 
eliminate male mitochondria may not be functioning, resulting in paternal leakage (Kvist 
et al., 2003, Ujvari et al., 2007). 
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Despite discussions regarding the clonality of mtDNA (Eyre-Walker et al., 1999, Elson et 
al., 2001a, Macaulay et al., 1999), its sequence and polymorphisms therein have been 
used extensively charting evolutionary history and population genetics. 
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1.1.5 Mitochondrial DNA in Disease 
1.1.5.1 Mitochondrial Mutations 
It was not until 1988 that mutations of mtDNA were linked with mitochondrial diseases. 
Holt et al. (1988) described patients with mitochondrial myopathies caused by large scale 
single mtDNA deletions (Holt et al., 1988). Then later that year Wallace et al. (1988) 
reported a point mutation that was necessary, though not sufficient, to cause Leber’s 
Hereditary Optic Neuropathy (LHON) (Wallace et al., 1988). Since then, advances in 
molecular biology and in particular genetics, have resulted in mtDNA mutations being 
recognised as a major cause of genetic diseases. 
MtDNA mutations can be grouped into point mutations, which are single base pair 
substitutions, and rearrangements, which include deletions and duplications. In addition 
mtDNA can become depleted. Mutations can affect mitochondrial protein synthesis genes 
for example tRNA genes, and protein coding genes, for example complex I mutations. 
However, linking mtDNA mutations with particular diseases is not straight forward, as a 
particular genetic mutation may cause many different phenotypes and a single phenotype 
may be caused by many different mutations. MtDNA behaviour demonstrates threshold 
effects, heteroplasmy, and segregation, with resulting difficulties trying to define a 
genotype-phenotype relationship. 
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1.1.5.2 Mutation Rate and Repair Mechanisms 
Due to its close proximity to the respiratory chain complexes, its exposure to reactive 
oxygen species, and a lack of protective histones, mtDNA has a very high mutation rate. In 
addition, the mtDNA POLG is substantially less accurate than the nDNA polymerase α 
(Kunkel and Loeb, 1981). All these factors result in a mtDNA error rate in higher primates 
of around ten times that of the nDNA (Brown et al., 1979). Adding to this mutation rate is 
the fact mtDNA is very efficient, which means any mutations are more likely to be present 
in coding regions and therefore pathogenic. 
While it was originally thought that mammalian mitochondria lacked a DNA repair 
mechanism (Clayton et al., 1974) it has now been shown that this is not the case. 
Mitochondria undergo base excision repair (BER). The first step of which, is the cleavage 
of the glycosydic bond between the base to be removed and the sugar. Lyase activity then 
breaks the phosphodiester bond 3’ to the site, and an endonuclease cleaves the 5’ bond. 
The space created is then filled by DNA POLG, and the repair site sealed by DNA ligase III 
(Mandavilli et al., 2002). In addition, human mitochondria have recently been shown to 
have mismatch-repair (MMR) activity, that is independent from the nuclear MMR system 
and involves the protein YB-1 (de Souza-Pinto et al., 2009). 
1.1.5.3 Point Mutations 
MtDNA point mutations involve the substitution of a single base pair, are often 
maternally inherited, and frequently affect tRNA genes. They may be transversions, when 
a purine (A & G) is substituted for a pyrimidine (C & T), or vice versa. Alternatively they 
may be transitions which involve the substitution of a purine for another purine, or a 
pyrimidine for a pyrimidine. Because they can drastically alter the shape of a molecule, 
transversions are often more severe than transitions. If the resultant amino acid remains 
the same then it is also known as synonymous, if the amino acid is changed then it is a 
nonsynonymous mutation. The first point mutation to be implicated in a mitochondrial 
disease, was the m.11778G>A transition, which results in a nonsynonymous change of an 
arginine amino acid for a histidine and is needed for the LHON phenotype (Wallace et al., 
1988). 
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1.1.5.4 Rearrangements 
MtDNA rearrangements can be duplications of the genome or deletions of portions of the 
molecule. 
1.1.5.4.1 Duplications 
MtDNA duplications can consist of two delete mitochondrial genomes joined together 
(deletion dimers), or a delete molecule inserted into a WT one. They have been linked 
with sporadically occurring myopathies (Poulton and Holt, 1994), Pearson’s syndrome 
(Rotig et al., 1995), and maternally inherited diabetes and deafness (MIDD) (Martin 
Negrier et al., 1998). 
MtDNA duplications were first identified as being causative agents in mitochondrial 
disease in the 1980’s, when restriction digest of blood mtDNA revealed linearised bands 
of 24.5kbp long, suggesting part of the mtDNA had been duplicated (Poulton et al., 1989). 
One study suggested they were primarily associated with Kearns-Sayre Syndrome (KSS). 
Investigations into eighteen patients with chronic progressive external ophthalmoplegia 
(CPEO) and KSS revealed all patients with KSS harboured both mtDNA deletions and 
duplications, while the CPEO patients contained only deletions. It was suggested that the 
relative proportion of these rearrangements present in the tissue accounts for the 
differing phenotypes of these two conditions (Poulton et al., 1994b). 
It has been hypothesised that duplications are recombination intermediate forms that will 
eventually become deletions. This requires the delete molecule to be excised from the 
enlarged genome. This hypothesis has been put forward after results showing that the 
amounts of duplicated genomes reduce over time, coinciding with an increase in delete 
molecules (Poulton et al., 1993). 
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1.1.5.4.2 Single Deletions 
MtDNA deletions have long been accepted as a major cause of mitochondrial disease 
(Holt et al., 1988), and are thought to represent around 18% of adults presenting with 
mitochondrial conditions (Schaefer et al., 2008). While original investigations often relied 
on restriction enzymes and Southern blots, there are now a whole host of methods to 
determine both the presence and levels of mtDNA deletions, including long range and 
real time PCRs. 
While mtDNA deletions could potentially arise anywhere in the molecule, they tend to 
occur in the major arc region of the genome, between the two origins of replication OH 
and OL (Figure 4.13). They vary in size, but can remove up to the majority of the genome. 
The “common deletion” is a 4977bp deletion that removes mtDNA between nt.8469 and 
nt.13447. It is the most frequently reported mtDNA deletion and has been associated 
with both KSS and CPEO (Zeviani et al., 1998, Moraes et al., 1989a, Samuels et al., 2004). 
The majority of deletions are flanked by short repeats, between 4-16bp long, one of 
which will be removed by the deletion. About 60% of deletions are flanked by perfect 
repeats and are termed class I deletions. Class II deletions are flanked by imperfect 
repeats and make up around 30% of deletions, while the remaining 10% are not flanked 
by repeats and are class III deletions (Samuels et al., 2004). 
While mtDNA deletions have long been linked with mitochondrial disease, they have 
more recently been associated with aging phenotypes. MtDNA deletions have been 
shown to accumulate in ageing muscle, potentially leading to fibre breakage and eventual 
fibre loss. This process could be instrumental in the age related muscle loss observed in 
humans termed sarcopenia (Bua et al., 2006). Other studies have demonstrated mtDNA 
deletions in the substantia nigra of older control subjects (Bender et al., 2006) and 
patients suffering from neurodegeneration (Reeve et al., 2008). 
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1.1.5.4.3 Causes of Deletions 
There is some debate regarding the exact cause of single mtDNA deletions. The finding 
that the majority of single deletions occur in the major arc and are flanked by repeats has 
led to the development of a “slip-strand” mechanism of formation. This suggests that the 
deletion occurs during the process of mtDNA replication via the asynchronous (or strand 
displacement) model. If during mtDNA replication the heavy strand is displaced, and its 3’ 
direct repeat then anneals to the 5’ direct repeat on the light strand, the excess DNA 
would loop out and eventually be degraded (Shoffner et al., 1989). 
Problems with this model have been raised by Krishnan et al. (2008). The model’s reliance 
on a strand displacement mode of replication does not fit with more recent evidence that 
mtDNA replication involves a strand asynchronous mechanism, with the incorporation of 
protective RNAs (Yasukawa et al., 2006, Holt et al., 2000). This prevents the regions of 
single stranded DNA that the slip-strand mechanism requires. In addition, not all mtDNA 
deletions are flanked by repeats, and some have been found which remove the 3’ repeat, 
which is required to bind with the 5’ repeat on the light strand (Reeve et al., 2008). 
Krishnan et al. propose a model based on double stranded breaks (DSBs). A DSB allows 3’ 
to 5’ exonuclease activity on the DNA, which results in single strands. The 3’ and 5’ 
repeats then ligate, with the degradation of the unbound single strands (Krishnan et al., 
2008). 
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1.1.5.5 Nuclear DNA Mutations 
MtDNA encodes thirteen polypeptides, two rRNAs, and twenty two tRNAs needed by the 
mitochondria. The remainder of the machinery is encoded by the nuclear genome. 
Nuclear DNA mutations are also an important cause of mitochondrial disease. They may 
induce secondary mutations in the mtDNA for example causing multiple deletions, or they 
may affect mitochondrial function directly. As a result many mitochondrial disorders have 
been linked to defects in the nDNA. 
TWINKLE is the 5’ to 3’ helicase which unwinds double stranded DNA during the process 
of mtDNA replication. Mutations in this gene have been linked to autosomal dominant 
progressive ophthalmoplegia (adPEO). These patients harbour multiple mtDNA deletions 
(Spelbrink et al., 2001). Another protein important for mtDNA replication is POLG, again 
with mutations causing multiple mtDNA deletions. Early reports of POLG mutations came 
from Van Goethem and colleagues, who mapped mutations to the POLG gene in patients 
with adPEO (Van Goethem et al., 2001). Since then numerous other mutations of POLG 
resulting in a wide variety of clinical conditions have been described (Horvath et al., 
2006). 
The adenine nucleotide translocator (ANT) is a homodimer gate responsible for the 
exchange of ATP for cytosolic ADP across the inner mitochondrial membrane, thus 
providing energy to the cytosol. Two mutations in the ANT1 isoform have been linked 
with adPEO in both a sporadic case, and in several families (Kaukonen et al., 2000). In the 
first report of a recessive case, a patient presented with myopathy, hypertrophic cardiac 
myopathy, lactic acidosis, and exercise intolerance, but no opthalmoplegia (Palmieri et al., 
2005). 
1.1.5.6 MtDNA Depletion  
Again caused by nuclear defects, genetic mutations have been linked with mtDNA 
depletion, which is a severe reduction in the amount of mtDNA. Many sufferers present in 
infancy with muscle weakness and liver problems, possibly due to the high amounts of 
mitochondrial biogenesis that occur in these tissues during the initial years of life. 
In 1991, Carlos Moraes reported the first case of mtDNA depletion syndrome in patients 
with autosomal recessive disorders. Southern blot analysis clearly showed the depletion 
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was segregated to the liver and muscle, and while they could not identify the responsible 
mutation, they did hypothesise it was nuclear in origin (Moraes et al., 1991). 
Since then many genes have been associated with depletion syndromes, including POLG 
(Naviaux et al., 1999), thymidine kinase 2 (Saada et al., 2001), h-mtTFA (Poulton et al., 
1994a), and deoxyguanosine kinase (DGUOK) (Freisinger et al., 2006). Interestingly, the 
depletion observed in myotubes with DGUOK mutations can be rescued with 
dAMP/dGMP supplementation (Bulst et al., 2009). 
1.1.5.7 MtDNA Behaviour in Disease 
The number of identified mutations in both the nDNA and mtDNA is growing, as is the list 
of diseases associated with these mutations. However, there is no clear link between a 
particular genotype and phenotype. While a single mutation may present in a variety of 
clinical conditions, a single disease may be caused by a range of mutations. There are a 
number of different factors that will affect the severity, tissue distribution, and age of 
onset of any mitochondrial disease. 
1.1.5.7.1 Heteroplasmy and Homoplasmy 
Unlike nuclear DNA, the mitochondrial genome exists in multiple copies within a single 
mitochondrion, and therefore in thousands of copies within a single cell. This can lead to 
a phenomenon termed heteroplasmy. This was noted when mtDNA mutations were first 
linked with mitochondrial disease. Holt and colleagues noted a patient harbouring two 
populations of mtDNA, one WT and one that was “partially deleted” (Holt et al., 1988). 
Normally all copies of mtDNA within a cell are the same, a situation termed homoplasmy. 
However the mitochondrial genome is prone to mutations and if the genomes within a 
cell are different it is said to be heteroplasmic (Figure 1.13). A homoplasmic cell could 
consist of either 0% or 100% mutant genomes, a heteroplasmic cell will contain anything 
in between. Heteroplasmy is normally defined as the percentage of mtDNA with a 
mutation. A disease causing mtDNA mutation can be either homoplasmic or 
heteroplasmic. While heteroplasmy and homoplasmy are usually referred to in relation to 
disease causing mutations, a recent study has demonstrated that many people are 
heteroplasmic for mitochondrial polymorphisms. Furthermore, these changes increase 
with age (Sondheimer et al., 2011). 
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When cells divide during mitosis, the mutant genomes can segregate in any ratio to the 
two daughter cells. This can result in marked variations between different tissues in terms 
of how much mutation they contain, and therefore result in varying phenotypes and age 
of onsets in patients with the same genetic mutation. The heteroplasmy levels are very 
important for patients as they have been linked to the frequency of clinical features 
(Chinnery et al., 1997). 
It is difficult to obtain a general consensus on how heteroplasmy levels change in a 
patient over time. It is well known that mutations may be lost, and heteroplasmy levels 
changed over time in rapidly dividing tissues, for example blood. However, it is harder to 
examine changes in post mitotic tissue, such as in the brain or muscle. One group  has 
reported an increase from 70% to 90% in a tRNA mutation in the muscle of a 
mitochondrial myopathy patient over twelve years (Weber et al., 1997). However, a 
patient in our lab with the “common deletion” has remained at approximately 70% 
heteroplasmy over thirteen years (unpublished observations). 
 
 
Figure 1.13 Heteroplasmy and homoplasmy. The multi copy nature of mtDNA can result in cells 
containing mixtures of WT and mutated mtDNA. If all the copies of mtDNA in a cell are the same 
then the cell is said to be homoplasmic. If the copies differ then the cells are heteroplasmic. 
Heteroplasmy is quite common in mitochondrial disease, where patients often harbour a mixture of 
WT and mutated mtDNA. 
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1.1.5.7.2 Threshold 
The presence of heteroplasmy in a cell leads to another interesting phenomenon in 
mitochondrial genetics, that of threshold. A decrease in mitochondrial function caused by 
mutant mtDNA can initially be compensated for by the WT mtDNA in the mitochondria or 
even through an increase in glycolysis. This is partly attributable to the excess of enzymes, 
mRNAs, tRNAs, and other factors required by the mitochondria for normal function. 
Eventually the healthy mitochondria are unable to compensate further and at this point a 
biochemical defect is expressed in the cells (Figure 1.14) (Rossignol et al., 2003). The 
amount of delete DNA required for the biochemical defect to be observed is the 
threshold level and is given as a percentage of total mtDNA. 
The threshold varies depending on the organ affected, which is partly attributable to the 
differing energy requirements of the tissue. In addition, different complexes of the 
respiratory chain appear to have different thresholds in different tissues, so depending on 
the complex affected by the mtDNA mutation, the tissue may be more or less affected 
(Rossignol et al., 1999). 
The tissue specificity effect was nicely demonstrated by Greaves and colleagues, who 
examined threshold levels in extra-ocular muscles (EOM) and the vastus lateralis, in 
patients with CPEO. The EOMs demonstrated greater numbers of COX deficient fibres, 
which was caused by a lower level of heteroplasmy than needed in the vastus lateralis 
muscle fibres to elicit the same COX deficiency. They also noted that a greater number of 
WT mtDNA molecules were needed in the EOM to maintain COX activity, suggesting that 
the percentages of WT and delete molecules may not be as important as the absolute WT 
mtDNA copy number. The greater metabolic demand of the EOM was hypothesised to 
account for the different threshold values (Greaves et al., 2010b). 
The threshold level also varies with mutation type. With the m.8344A>G mutation linked 
to myoclonic epilepsy with ragged red fibres (MERRF), it is around 90% (Shoffner et al., 
1990), while a report examining the m.3243A>G mutation suggested it is between 50-65% 
(Jeppesen et al., 2006a). Threshold values between 50-85% have been reported for 
mtDNA deletions (Porteous et al., 1998, Sciacco et al., 1994, Rossignol et al., 2003). 
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Figure 1.14 Threshold. Heteroplasmy within a cell leads to a threshold effect. While a small 
amount of mutant mtDNA can be tolerated by the cell due to a functional redundancy, as the 
levels increase the cell is unable to compensate further and a biochemical defect is 
displayed. This can be shown with complex IV histochemistry (see section 2.2.5.2); a small 
amount of mtDNA mutation still yields a brown product in a muscle fibre, demonstrating no 
biochemical defect. Once the threshold level is passed the cell can no longer cope and the 
muscle fibre appears blue, suggesting an absence of complex IV activity. 
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1.1.5.7.3 The MtDNA Bottleneck 
The first experimental evidence of an mtDNA bottleneck was provided by Hauswirth and 
Laipis (1982). They examined segregation of an mtDNA polymorphism that introduced an 
extra HaeIII restriction enzyme site in the mitochondrial genome. Two mitochondrial 
genotypes, on the basis of this polymorphism, were shown to exist in the progeny of a 
single female cow. While they considered the possibility of mutations, and paternal 
leakage, their conclusions were that an mtDNA bottleneck had caused the variations in 
genotype observed in the female cow’s descendants. If the original cow had been 
heteroplasmic for the polymorphism then amplification of a few of her mtDNA copies 
could create differing genotypes (Hauswirth and Laipis, 1982). 
The bottleneck serves an important evolutionary function, as it reduces the number of 
mutations that can be inherited from a mother to child. The mtDNA is prone to mutations 
and without a bottleneck these would be passed on to the child. In terms of 
mitochondrial disease the bottleneck is important for patients as it can result in marked 
differences between mothers and children in their heteroplasmy levels (Figure 1.15) 
(Larsson et al., 1992, Blok et al., 1997). This makes giving advice about pregnancy to 
women with mitochondrial mutations somewhat difficult. 
There is ongoing debate regarding the exact mechanism of the mtDNA bottleneck. Cao et 
al. (2007) have suggested it occurs through the aggregation of mtDNA into segregating 
units which would be inherited. A year later Cree et al. (2008) proposed it was 
attributable to a decrease in mtDNA copy number followed by segregation of the 
remaining genomes. Finally, Wai et al. (2008) have suggested it is attributable to selective 
amplification of a subpopulation of mtDNA. These different theories are discussed further 
in chapter 6. 
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Figure 1.15 The mtDNA bottleneck. Fertilization of a heteroplasmic oocyte can 
result in a bottleneck effect. Amplification of a small population of genomes can 
result in extremely varied heteroplasmy levels in terms of mtDNA mutations in 
resultant cells, and consequently in progeny. 
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1.1.5.7.4 Clonal Expansion 
Clonal expansion is the amplification of mtDNA mutations within tissues. Through this 
mechanism a mutation in a single mtDNA can increase within either a mitotic or post 
mitotic cell. If the level of the mutation supersedes the threshold value then the cell will 
demonstrate a biochemical defect. If a mutation has segregated at birth to many cells 
then it may eventually expand to cause problems in the tissue. 
An early hypothesis for the mechanism of clonal expansion suggested that mtDNA 
containing a deletion was able to replicate faster than a full size WT mtDNA (Wallace, 
1992). This hypothesis gained some backing when it was shown that mtDNA containing a 
deletion was able to repopulate cells faster that WT mtDNA following a depletion assay 
similar to that described in chapter 6. This pattern, however, was not observed for 
mtDNA harbouring a point mutation (Diaz et al., 2002). Evidence against this smaller 
replicating molecule hypothesis comes from findings that the whole replication process is 
complete in under two hours, which is shorter than the time between replications 
(Clayton, 1982). 
A mechanism that would explain both the clonal expansion of mtDNA deletions and point 
mutations is the “sick mitochondria” theory. This involves mitochondria with a respiratory 
chain defect proliferating in order to compensate for their impairment. This was 
suggested after experiments revealed the preferential replication of mtDNA with the 
m.3243A>G mutation over WT mtDNA (Yoneda et al., 1992). 
Another possible theory is random genetic drift. MtDNA is subject to genetic drift, with 
molecules being chosen randomly to replicate (Birky, 1994). Using a computer simulation 
to model random drift in post mitotic cells, Elson et al. (2001) demonstrated that relaxed 
replication was sufficient to result in clonal expansion (Elson et al., 2001b). 
An interesting field of research is currently examining the role of clonal expansion in 
ageing. As people age they accumulate mtDNA mutations in different tissues, including 
the colon (Greaves et al., 2010a), substantia nigra (Bender et al., 2006), and muscle (Bua 
et al., 2006). While these mutations may be at low levels in the tissue, within individual 
cells a mutation may clonally expand until a COX deficiency is observed. 
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1.1.6 Mitochondrial DNA Diseases 
1.1.6.1 Epidemiology 
Mitochondrial disease has historically been under diagnosed. The wide variety of clinical 
presentations, numerous causative genetic mutations, and non-Mendelian mode of 
inheritance, has resulted in mitochondrial disease not receiving adequate focus. 
Improvements in diagnostic tests, greater public awareness, and improved inter centre 
collaborations, have all helped provide a clearer picture regarding both the scale of 
mitochondrial disease and the requirements of its sufferers. 
A recent paper found that one in every two hundred people harbour a potentially 
pathogenic mtDNA mutation (Elliott et al., 2008). Thankfully, the number of people in 
which these mutations cause disease is considerably less. 
An early study examining the prevalence of the m.3243A>G mutation in a population of 
Finnish people found a one in six thousand occurrence of this particular point mutation 
(Majamaa et al., 1998). A later investigation examining the prevalence of mitochondrial 
disease in the North East of England suggested that one in ten thousand people have a 
symptomatic mitochondrial disease. Additionally, it was estimated a further one in six 
thousand children and adults are at risk of developing a condition (Schaefer et al., 2008). 
While the contribution of mitochondrial disease to morbidity is being increasingly 
recognised, the rate at which new mutations are being found suggests these numbers will 
increase further. 
1.1.6.2 Investigating Mitochondrial DNA Disease 
The diagnosis of mitochondrial disease can be somewhat problematic due to the 
multisystem nature of the condition. Initial investigations into suspected cases require 
extensive clinical assessment, with symptoms and family history being important 
considerations. 
Following this, blood tests can be performed to examine creatine kinase (CK), lactate, 
glucose levels, and blood counts. While some conditions can be diagnosed through such 
tests, a negative result does not preclude a mitochondrial disease. 
The gold standard for diagnosing mitochondrial disease is a muscle biopsy. This allows for 
histochemical, molecular, and biochemical analysis of the muscle. Histological analysis 
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often includes the cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) 
COX/SDH, analysis, which is explained further in chapter 2. When this staining is 
performed all fibres with a low or absent amount of mutated mtDNA will stain positive for 
COX (brown precipitate). If a fibre has a COX deficiency it will not pick up the stain. 
Further incubation with SDH will stain all the COX deficient fibres blue. This gives the 
muscle section the characteristic mosaic pattern of brown and blue fibres (Figure 1.16A). 
Another stain occasionally used is Gomori trichrome; this picks up subsarcolemmal 
accumulations of mitochondria, and stains them red (Figure 1.16B). These fibres 
demonstrate a characteristic red colour and are termed ragged red fibres (RRFs) (Taylor 
et al., 2004). 
Once suspected conditions have been narrowed down, molecular investigations can be 
performed to determine the exact genetic defect. The genetic mutation sought is very 
much determined by the clinical and muscle biopsy findings. Tests performed may include 
Southern blot and long range PCR to look for mtDNA rearrangements, or genetic 
sequencing to look for point mutations (Chinnery and Turnbull, 1997). 
Figure 1.16 Diagnostic muscle biopsies. A. Performing the COX/SDH histochemistry protocol on a biopsy 
from a patient with a mitochondrial disease may reveal a mosaic pattern of staining. With brown fibres 
indicating normal mitochondrial function (COX positive fibre), and blue fibres revealing impaired 
mitochondrial function (COX negative fibre). COX intermediate fibres are often visible, this corresponds 
to intermediate levels of mitochondrial function. B. A Gomori trichrome stain can reveal muscle fibres 
that have an abnormal subsarcolemmal accumulation of mitochondria, this appears red, and earns them 
the name ragged red fibres (RRF). Gomori trichrome image supplied by Gavin Falkous. 
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1.1.6.3 MtDNA Diseases 
Due to the ubiquitous nature of mitochondria, a disease can present in a plethora of 
different ways, with just about any system being vulnerable (Figure 1.17). Neurological 
presentations are quite common, but patients may also present with cardiomyopathy, 
liver failure, short stature, and a whole host of other symptoms. The next few pages will 
describe some of the common conditions associated with sporadically occurring single 
mtDNA deletions, which is the main mitochondrial mutation investigated in this research. 
In addition, a few other conditions will be described, demonstrating the wide clinical and 
genetic heterogeneity associated with mitochondrial disease. 
 
 
Figure 1.17 Mitochondrial disease phenotypes. While neurological symptoms of mitochondrial 
disease may predominate, just about any system in the body can be affected. This can result in 
delays in diagnosing mitochondrial disease, as patients are referred to various specialists for 
investigations. 
Chapter 1  Introduction 
51 
  
1.1.6.3.1 Chronic Progressive External Ophthalmoplegia (CPEO) 
A common presentation of mitochondrial disease, and the condition the patients in this 
study suffer from, is CPEO. Many CPEO patients harbour sporadically occurring single 
mtDNA deletions (Laforet et al., 1995), although it has also been associated with nuclear 
mutations resulting in secondary mtDNA mutations, and with mtDNA point mutations. 
While it can occur in combination with other symptoms, it may sometimes be given as a 
diagnosis in itself. 
The condition usually presents in the third or fourth decade of life and is caused by a 
progressive weakening of the extra-ocular muscles, resulting in a restriction of the eye 
movements. Patients will also experience ptosis, a drooping of the eye-lids (Laforet et al., 
1995). As the condition progresses patients may start to experience a more general 
myopathy, with exercise intolerance, muscle wasting, and weakness (Zeviani and Donato, 
2004). 
1.1.6.3.2 Kearns-Sayre Syndrome (KSS) 
KSS is a multisystem disorder that has traditionally been characterised by the “triad” of 
CPEO, pigmentary retinopathy, and onset before the age of twenty. Although proximal 
myopathy, cerebella ataxia, cardiomyopathy, and heart block may also occur. Muscle 
biopsies may demonstrate RRF and COX deficiency. While often linked to a sporadically 
occurring large scale single mtDNA deletion or duplication, other mutations have also 
been implicated (Pistilli et al., 2003, Zeviani and Donato, 2004). 
1.1.6.3.3 Pearson Marrow-Pancreas Syndrome 
This disease is a multisystem condition, presenting very early in life. Symptoms include 
vacuolization of marrow precursor cells, reduction of blood cells, sideroblastic anemia, 
and pancreatic dysfunction. It has been associated with both deletions and duplications 
of the mtDNA. Interestingly, if children are able to survive infancy they may proceed to 
develop a KSS phenotype (Rotig et al., 1995, Simon and Johns, 1999). 
1.1.6.3.4 Mitochondrial Encephalopathy Lactic-Acidosis and Stroke-Like Episodes 
(MELAS) 
MELAS is one of the commonest mitochondrial disorders (Chinnery and Turnbull, 2001). It 
is characterised by encephalopathy, stroke-like episodes caused by brain lesions, and 
lactic acidosis. Other neurological symptoms may be present including dementia and 
hearing problems. 
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It is most commonly associated with the maternally inherited m.3243A>G point mutation 
in the tRNALeu(UUR) gene. It was first identified by Goto et al. (1990) when they found the 
mutation in twenty six out of thirty one patients with MELAS (Goto et al., 1990). However, 
other mutations have also been implicated in this phenotype (Morten et al., 1993, 
Manfredi et al., 1995, Horvath et al., 2008b). All of these mutations were heteroplasmic 
and present in highly conserved nucleotide positions. 
1.1.6.3.5 Myoclonic Epilepsy with Ragged Red Fibres (MERRF) 
MERRF sufferers have a progressive myoclonus, epilepsy, cerebellar ataxia, and 
myopathy. Occasionally associated with MERRF are lipomas. These are benign tumours of 
adipose tissues that have a tendency to accumulate in the trunk and cause severe 
discomfort to sufferers. Muscle biopsies commonly demonstrate RRFs, attributable to the 
accumulation of mitochondria. It is frequently associated with the maternally inherited, 
heteroplasmic m.8344A>G mutation in the tRNA for lysine (Shoffner et al., 1990, Zeviani 
and Donato, 2004). 
1.1.6.3.6 Leber’s Hereditary Optic Neuropathy (LHON) 
One of the first diseases to be linked to an mtDNA point mutation, and indeed the 
commonest mitochondrial disease, is LHON (Chinnery and Turnbull, 2001). Affected 
individuals suffer a loss of central vision due to the degeneration of the retinal ganglions 
cells. 
The condition has been linked to three mitochondrial mutations, m.3460G>A, 
m.11778G>A, and m.14484T>C. The first of these mutations was found by Wallace et al. 
(1988). They reported the m.11778G>A point mutation and noted that it was necessary 
but not sufficient to cause the disease (Wallace et al., 1988). Since then investigations 
into this condition have focused on finding the disease modifier that is required for full 
phenotypic expression. 
The condition is maternally inherited but there is a propensity for males to be affected. 
This has resulted in suggestions that a modifier may be present on the X chromosome. 
Other factors investigated as possible co-conspirators are mtDNA haplogroup, nuclear 
genes, and hormones, in addition to a number of potential environmental factors 
including smoking, alcohol, head trauma, and chemical toxins (Yu-Wai-Man et al., 2011). 
However, the culprit still remains elusive. 
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1.1.6.4 Treatments and Therapies for Mitochondrial Disease 
Strides have been taken in recent years in both the diagnosis of mitochondrial disease 
and in understanding the pathological mechanisms underlying the conditions. However, 
treatments and therapies are still somewhat limited and geared toward symptomatic 
relief. 
1.1.6.4.1 Symptomatic Relief 
Surgery can help with some of the symptoms patients suffer from. CPEO patients with 
ptosis may have their eye lids lifted, lipomas may be excised from patients with MERRF, 
and pacemakers can be implanted in KSS patients with heart block. As a last resort organ 
transplantation can be performed. The diabetes that many MELAS and KSS patients suffer 
from can be managed, as can the seizures that are also common (Schon and DiMauro, 
2003, Horvath et al., 2008a). 
1.1.6.4.2 Genetic Counselling 
Genetic counselling is particularly helpful for patients wishing to have children. However, 
it can be very difficult to give definite answers on the probability of a condition being 
passed on. For example large scale single mtDNA deletions are often sporadically 
occurring and will not be transmitted, and since mitochondria are maternally inherited, 
defects of mtDNA in men will not be passed on. Knowledge about the type of mutation, 
heteroplasmy level, and probability of the mutation being transmitted will help clinicians’ 
counsel women and their partners. This highlights the necessity of further research 
identifying and examining the behaviour of the genetic mutations that cause 
mitochondrial disease. 
1.1.6.4.3 Preventing Transmission  
One area of therapy that is making rapid developments is the prevention of transmission 
of mitochondrial diseases. Pre-implantation genetic diagnosis involves the removal of a 
cell from the embryo and testing for the genetic defect, before selecting which embryos 
to put back. However, this decision can become difficult when embryos with low levels of 
mutation are generated. While the heteroplasmy is low, segregation of the mutation may 
still result in a symptomatic child. Prenatal diagnosis can also be performed using 
chorionic villus sampling or amniotic fluid. However, there are still questions regarding 
how representative these tissues are in the foetus (Poulton et al., 2009). 
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One avenue currently being explored by Craven et al. (2010) is pronuclear transfer. This 
involves the removal of the pronucleus from the fertilised egg and its transfer into 
another fertilised egg that has had its nucleus removed. This leaves behind the 
mitochondria that contain the mutation. Current investigations into this treatment 
involve determining how much “carry-over” of mitochondria there is from the original 
egg cell, and ensuring the technique is compatible with onward embryo development. 
1.1.6.4.4 Genetic Manipulation 
This approach is centred on changing the amounts or balance of WT and mutant mtDNA. 
Many attempts have been made to get WT mtDNA into the mitochondria, but the ability 
to scale up to the cellular and tissue level is still problematic. An alternative is to inhibit 
the replication of mutated mtDNA, thus allowing WT mtDNA to dominate within the cell, 
hopefully bringing the cell below threshold. However, these approaches are still to come 
to fruition (Chinnery and Turnbull, 2001). 
Another strategy to redress the imbalance of WT and mutated mitochondrial in patients 
with myopathy is resistance training. The theory behind this is discussed further in 
chapter 4, but briefly, it involves the activation of muscle stem cells through high intensity 
exercise that damages the muscle. Through the incorporation of new muscle cells that 
have lower or no mtDNA mutations the heteroplasmy level in the muscle will be 
favourably changed (Gardner et al., 2007). 
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1.2 Muscle 
Skeletal muscle is responsible for locomotion, postural stability, and assists with 
breathing. It’s remarkable structure and contractile ability allows it to perform these 
functions. When through injury, disease, disuse, or atrophy it ceases to work as 
efficiently, the consequences are disabling. 
1.2.1 Muscle Structure 
Muscle is organised into compartments by connective tissue. The muscle belly is 
surrounded by the epimysium, which separates it from other muscles. Within the muscle 
are many fascicles; these are bundles of muscle fibres that are enclosed by a perimysium. 
This allows the major blood vessels and nerves to penetrate the muscle between these 
fascicles. Surrounding the individual muscle fibres is the endomysium, and running 
between the fibres are capillaries (Figure 1.18A). 
Muscle fibres are composed of cylindrical structures called myofibrils and in mammals, 
are around 50-100µm in diameter. Surrounding the myofibrils are mitochondria, 
sarcoplasmic reticulum, and the t-tubule system. The myofibrils appear striated due to 
being comprised of sarcomeres, the contractile unit of the fibre. It is the number of 
sarcomeres that determines the length of the fibre, with each sarcomere being between 
2-2.5µm long at rest. 
The sarcomeres are separated from each other by a Z disk. These provide anchors for the 
thin filaments, which are composed of pairs of polymerised actin monomers. In addition, 
the thin filaments contain tropomyosin, a long filament protein lying in the groove 
created by the actin, which in turn contains troponin molecules attached to the filament. 
Between the thin filaments sit the thick myosin filaments. These are composed of myosin 
molecules, containing two globular heads attached to a long tail formed by two coiled α-
helices. The interaction between these two sets of filaments causes muscle contraction 
(Figure 1.18B) (Jones et al., 2009). 
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Figure 1.18 Muscle structure. A. Muscle is bound by connective tissue, mostly made up of 
collagen. The epimysium surrounds the whole muscle, then the perimysium divides the fibres 
up into fascicles and finally each fibre is surrounded by an endomysium. B. The contractile unit 
of the muscle fibre is the sarcomere. Z-lines delineate the boundaries of the sarcomere, and 
provide anchor points for the filaments. The “sliding filament” hypothesis of muscle contraction 
states that the thin filaments, composed of actin, slide over the thick myosin filaments and the 
sarcomere reduces in size. 
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1.2.2 Contraction 
Contraction of muscle occurs by a sliding filament mechanism. This hypothesis was first 
proposed by Huxley and colleagues back in the 1950s when experiments using the frog 
revealed a shortening of the observed striations (Huxley and Hanson, 1954, Huxley and 
Niedergerke, 1954). 
When an action potential arrives at the neuromuscular junction it stimulates the release 
of acetylcholine (Ach) from the endplate. When Ach binds to the receptors on the post 
synaptic membrane it stimulates the opening of voltage gated sodium channels and an 
action potential is generated in the muscle fibre. This passes through the sarcolemma 
which encloses the muscle fibres, and moves into the t-tubule system. The t-tubule 
system penetrates the muscle fibre and conducts the impulse from the surface of the 
fibre to its interior. The depolarisation of the t-tubules causes Ca2+ release from the 
sarcoplasmic reticulum which surrounds the myofibrils. 
The Ca2+ binds to the troponin on the thin filaments which causes a conformational 
change in the filament and exposes the myosin binding sites on the actin. The myosin 
heads bind to these sites and then pivot, which draws the thin filaments in. The 
dissociation of myosin from the actin requires the hydrolysis of a molecule of ATP. In 
order to terminate the contraction, the muscle fibre pumps Ca2+ back into the 
sarcoplasmic reticulum (MacIntosh et al., 2006). 
1.2.3 Embryological Origin 
Skeletal muscle originates from the somites that have divided off from the mesoderm. 
The somites then segment further into the sclerotome, which forms the vertebrae and 
cartilage, and the dermomyotome which will give rise to the dermis, and skeletal muscles. 
The epaxial myotome forms the muscles of the back, while the hypaxial myotome forms 
the muscles of the rest of the body. Muscle progenitor cells split from the 
dermomyotome to form the myotome (Figure 1.19). Progenitors migrate from both the 
dorsomedial and ventromedial lip of the somite, as well as the caudal and rostral borders 
(Gros et al., 2004). 
The formation of the myotome is dependent on Pax3, and the myogenic regulatory 
factors Myf4 and 5. The cells then proliferate and are expressing MyoD and Myf5. With 
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the up-regulation of myogenin they differentiate into myotubes (Buckingham et al., 2003, 
Buckingham, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.19 Muscle origins. Skeletal muscle originates from the mesoderm which 
segments into somites. These then give rise to muscle progenitor cells that split from 
the dermomyotome to form the muscle of the trunk and limbs. 
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1.2.4 Muscle Damage and Repair 
Muscle is a post mitotic tissue, and as such there is minimal turnover of nuclei. However, 
it does have the remarkable ability to repair itself in response to damage caused by injury 
or disease. 
The initial stage of repair is necrosis of the muscle fibre, which is helped by the disruption 
of the fibre sarcolemma. Increased calcium entry into the cell activates proteases that 
break down the structural proteins and lipid membranes (Jones et al., 1984). To clear up 
debris caused by the injury, inflammatory cells are mobilised. Neutrophils are first to 
respond to chemotactic signals released by the damaged fibre. Following neutrophil 
invasion of the area, macrophages arrive to clear up the debris using phagocytosis. One of 
the indicators of muscle damage is CK; this is released from the fibres after disruption and 
can often be detected in the blood (Charge and Rudnicki, 2004). 
After the degeneration of the muscle the next stage is regeneration. This is mediated by 
muscle stem cells (satellite cells). 
1.2.5 Satellite cells 
Satellite cells were first reported by Mauro (1961), after using EM to study muscle from 
frog. Satellite cells are mononucleated cells that sit under the basal lamina and on top of 
the sarcolemma. They protrude inwards into the muscle fibre and have been named 
based upon their location (Mauro, 1961). They have very little cytoplasm, and while they 
do have mitochondria, these are few in numbers, generally rounder, paler, and harbour 
fewer cristae than those in muscle (Roth et al., 2000). 
1.2.5.1 Satellite Cell Origins 
Satellite cells have the same embryological origins as skeletal muscle, in that they both 
derive from the somites. Gros et al. (2005) used electroporation to insert green 
fluorescent protein (GFP) into chick somites along with quail-chick grafting techniques to 
map the development of muscle precursor cells. They demonstrated that a population of 
cells translocated from the central dermomyotome into the myotome. The movement of 
the cells was preceded by a cell division, with one cell moving into the myotome and the 
other remaining in the dermomyotome (Gros et al., 2005). 
It is difficult to distinguish satellite cells from other myogenic cells during development. It 
is only after they have moved into position and have a basal lamina formed over them, 
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that they can be truly identified by their location. In mice the satellite cells move into 
position by E10.5, and the basal lamina forms between E16.5 -18.5 (Relaix et al., 2005). 
This is quite late considering the gestational time for mice is around 19-21 days. 
1.2.5.2 Satellite Cells and Muscle Repair 
Satellite cells are responsible for post natal muscle growth and regeneration (Figure 1.20). 
Within adult muscle, satellite cells account for between 1% to 7% of muscle nuclei (Kadi 
et al., 2005), although the levels may be much higher in postnatal muscle while it is still 
developing. 
Before activation, satellite cells are quiescent and have exited from the cell cycle. While 
quiescent they are expressing the transcription factor paired box 7 (Pax7), and in some 
muscles Pax3. In addition many quiescent cells also express the basic helix-loop-helix 
myogenic regulatory factor 5 (Myf5), the calcium-dependent cell adhesion molecule (M-
cadherin), the hepatocyte growth factor receptor (c-met), and the neural cell adhesion 
molecule (NCam) also known as CD56/Leu19 (Negroni et al., 2006). 
After muscle injury, satellite cells are activated through signals received from the 
damaged muscle fibre and possibly from the inflammatory cells that have been tasked 
with cleaning up the remnants of the damage. They start to proliferate and are then 
referred to as muscle precursor cells or myoblasts. At this stage they are expressing Pax7, 
Myf5, and myogenic differentiation factor 1 (MyoD). Their remarkable proliferative ability 
was demonstrated by single myofibre grafts into radiation-ablated mouse muscle. A 
single fibre containing as few as seven satellite cells was able to generate over one 
hundred muscle fibres, in addition to repopulating the host muscle with new satellite cells 
(Collins et al., 2005). 
The myoblasts then head towards differentiation, which involves their fusion into long 
cells referred to as myotubes. At this stage myogenin becomes important, and Pax7 is 
now down regulated (Olguin and Olwin, 2004).  
Satellite cells are the muscle stem cell and as such need to maintain an adequate supply 
for the muscle. After activation the cells divide asymmetrically and one of the resultant 
daughter cells returns to quiescence under the basal lamina after exiting from the cell 
cycle. This cell will continue to express Pax7, but will down regulate MyoD (Zammit et al., 
2004). 
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Figure 1.20 Muscle regeneration. In response to injury satellite cells are activated. They express Pax7, Myf 5, 
and MyoD. After division one daughter cell will down regulate MyoD and return to quiescence. The other will 
continue to express MyoD and proliferate. With the induction of myogenin, the myoblasts commence 
differentiation into myotubes, which are able to fuse into the damaged muscle fibre to repair it. 
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1.2.5.3 Satellite Cell Heterogeneity 
There have been suggestions that other cells may contribute to the satellite cell pool. 
Satellite cells cultured from mouse muscle have been shown to possess characteristics of 
bone-marrow derived hematopoietic stem cells, and are thought to arise from the 
hematopoietic system (Jackson et al., 1999, McKinney-Freeman et al., 2002). While other 
stem cells have been shown to have myogenic potential, including mesoangioblasts 
(Sampaolesi et al., 2003), and adult bone marrow derived cells (LaBarge and Blau, 2002). 
However, while these cells may localise to the satellite cell position and display some 
characteristics of muscle progenitor cells, they are not innately myogenic and may require 
modification in order to contribute to regeneration (Sherwood et al., 2004, Meng et al., 
2010). 
While many experiments examining satellite cells have used mice, some caution must be 
observed. Studies have suggested that adult muscle fibres from both mice and humans 
have similar numbers of satellite cells, but the markers used to identify them may be 
species dependent. For example, CD34 marks satellite cells in mice but not in humans, 
and NCam is expressed in quiescent satellite cells in humans but is only present in 
activated cells in mice (Tedesco et al., 2010, Boldrin et al., 2010). 
1.2.5.4 Satellite Cells as Therapy 
One particular muscle disease where the potential therapeutic use of satellite cells has 
been extensively investigated is Duchenne’s Muscular Dystrophy (DMD). This is a severe 
X-linked recessive muscular dystrophy that affects about one in three and a half thousand 
male births. It is caused by a defect in the gene for dystrophin (Hoffman et al., 1987), 
which is an important protein for plasma membrane integrity. The protein is important in 
linking the muscle fibre cytoskeleton to the extracellular matrix. Disruption of dystrophin 
results in tears in the sarcolemma which allow Ca2+ into the cells, with the damaged fibre 
undergoing necrosis. The injured fibre then requires satellite cells to repair it. However, 
the repaired fibre will still lack the dystrophin protein and there will be subsequent cycles 
of degeneration and regeneration. 
For this reason, the possibility of using donor myogenic cells has been extensively 
researched. This involves injecting expanded myoblasts from non-infected individuals into 
the muscle of sufferers. Problems associated with this technique are rejection by the 
host, lack of migration of the introduced cells, fusion of the cells into host muscle, and 
Chapter 1  Introduction 
63 
  
replenishment of the satellite cell pool. Although it has been shown that 
immunocompromising the host muscle improves migration, rejection, and integration of 
the introduced myoblasts (Smythe et al., 2000). In addition it has been shown that 
transplanting human foetal muscle precursor cells into mice can result in functional 
satellite cells that repopulate the stem cell compartment and can form functional 
myoblasts (Ehrhardt et al., 2007). More recently, irradiating the host muscle aided the 
restoration of dystrophin in both young and old mdx mice by donor satellite cells (Boldrin 
et al., 2009). However, the problem of delivering myoblasts throughout the body still 
remains. 
Another dystrophy that may benefit from satellite cell derived progeny is fascio-scapulo-
humeral muscular dystrophy. This condition commonly affects the face, shoulder, and 
upper arm muscles, with sparing of the lower body. This has opened up the possibility of 
injecting myoblasts derived from the patients themselves into the affected muscles to 
restore function. The small areas affected and use of patient tissue would overcome 
problems of rejection and migration faced by attempts to transplant muscle precursor 
cells in other dystrophies (Cooper et al., 2006). 
The research described in this project is also investigating the use of muscle satellite cells 
to ameliorate a muscle condition. Mitochondrial myopathies are a common feature of 
mitochondrial disease, with patients often presenting with proximal weakness and 
exercise intolerance. Patients may progress to display other organ involvement or the 
condition may be confined to muscle, with more distal muscles becoming involved. Other 
symptoms may include muscle pain, cramps, and stiffness. These symptoms are caused 
by the inability of the mitochondria to generate the energy required by the muscles. The 
satellite cell mediated treatment for mitochondrial myopathies involves the replacement 
of dysfunctional mitochondria with WT ones through the incorporation of myoblasts with 
healthy mitochondria into the muscle. This approach involves using the patient’s own 
satellite cells to repair the muscle and as a result there will be no problems with host 
rejection or the generation of new muscle stem cells. 
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1.3 Aims of this Research 
Mitochondrial DNA mutations have been shown to be a significant cause of disease. 
Conditions can range from the quite mild to devastating. While the list of causative 
mutations is growing exponentially, the possible sources of therapy are not as extensive. 
Developing treatments and therapies for patients with mitochondrial disease is therefore 
paramount. 
Resistance training has been hypothesised to help patients with sporadically occurring 
mtDNA mutations. This is based on findings of low or absent levels of mtDNA mutations 
in the proliferating myoblasts of patients with sporadically occurring conditions (Fu et al., 
1996, Weber et al., 1997). On the basis of these findings it has been hypothesised that 
muscle stem cells (satellite cells) contain little or no mutation. The rationale behind 
resistance training is that through the activation and incorporation of developing muscle 
cells with low levels or absence of mutation, the heteroplasmy levels in muscle of 
affected patients will be changed. This should help ameliorate some of the muscle 
symptoms patients experience. 
The aim of this research is to test the theory behind the rationale for using resistance 
training as a therapy for patients with sporadically occurring mtDNA mutations. It aims to 
examine myoblast precursors and determine if mtDNA mutations are absent from the 
satellite cells. In addition it is interested in establishing the reasons why mutations may 
be absent from either the satellite cells or myoblasts. It is hoped by revealing the 
mechanisms of any loss it will be possible in the future to predict which patients will 
benefit from performing resistance training to adjust their heteroplasmy levels. 
A further aim of this research is to investigate the possibility that patients with 
mitochondrial myopathies may exhaust their satellite cell pool. This could occur through 
excessive turnover of muscle fibres due to the myopathy, with a resultant increase in the 
cycles of degeneration and regeneration this causes. If resistance training is to be offered 
as a treatment for these patients it is important that this has no detrimental effect in 
terms of stem cell numbers. 
.
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Chapter 2 Materials and Methods 
2.1 Equipment, Consumables, and Reagents 
2.1.1 Equipment 
ABI 3130xI Genetic Analyzer    Applied Biosystems 
ABI Step One Plus Real-Time PCR System  Applied Biosystems 
Autoclave      Astell 
Balance: Sartorius Basic    Sartorius 
Bench-top microcentrifuge PCV-2400  Grant-Bio 
Bench-top centrifuge 1-14    Sigma 
Bench-top centrifuge 5417 R    Eppendorf 
Binder general purpose incubator   Philip Harris 
Cerenkov counter, type 6-20    Mini Instruments 
Cryostat (Cryo-star HM 560M)   Microm International 
Dry heat block      Techne 
Electrophoresis power supply model 250EX  Life Technologies 
Horizontal agarose gel electrophoresis systems Amersham Biosciences 
Hot water bath     Techne 
Laminar flow hood     Jencons-PLS 
Luminometer TD-20e     Turner 
Microflow biological safety cabinet   Bioquell 
Nanodrop ND-1000 spectrophotometer  Labtech International 
3510 pH meter     Jenway 
Olympus microscope BHX54    Olympus 
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PhosphorImager, Storm 860    Molecular Dynamics 
Roche Lightcycler     Roche 
Rotating hybridisation oven     Hybaid 
Thermal cycler (9700)     Applied Biosystems 
UV gel documentation system and  
AlphaImage series 2200 Software   Flowgen 
Axioplan 2iE Light microscope   Zeiss 
AxioCam HRc digital camera    Zeiss 
AxioVision imagecapture software   Zeiss 
 
2.1.2 Consumables 
0.2ml PCR tubes     Biogene 
1.5ml microcentrifuge tubes    Biogene 
2.0ml microcentrifuge tubes     Biogene 
Graduated filter tips     Starlabs 
Coverslips (22x22mm, 22x40mm, 22x50mm) Merck 
Cellstar® Disposable Pipettes    Greiner 
Eppendorf Biopipette (P1000, P200, P20, P10) Eppendorf 
Falcon tubes (15ml and 50ml)   Costar 
Gel extraction kit      Qiagen 
Lightcycler capillaries     Roche 
Microscope slides (76x26x1.0-1.2mm)  Merck 
Tissue extraction kit     Qiagen 
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Cellstar® tissue culture flasks (25cm3, 75cm3) Greiner  
Whatman Grade IV filter paper   Merck 
10ml universal tubes     Greiner 
96-Well Fast Optical Reaction Plates   Applied Biosystems 
Cap strips, domed     Eppendorf 
96-well PCR plate     Starlabs 
 
2.1.3 Chemicals and Reagents 
2.1.3.1 Tissue Preparation 
Iso-pentane  Merck 
Liquid nitrogen  BOC 
OCT cryoembedding matrix  Raymond Lamb 
2.1.3.2 Histological and Histochemical Reagents 
Avidin/ Biotin Blocking Kit  Vector Laboratories 
Catalase  Sigma 
Cytochrome c  Sigma 
3. 3’diaminobenzidine tetrahydrochloride  Sigma 
DPXTM Mountant  Merck 
Ethanol Analar  Merck 
HistoclearTM  National Diagnostics 
Hydrogen peroxide  BDH 
Nitro blue tetrazolium  Sigma 
Rabbit anti-mouse HRP conjugated antibody DakoCytomation 
Methanol Analar  Merck 
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Paraformaldehyde  Sigma 
Pax7 (IgG1) primary antibody Developmental Studies Hybridoma 
Bank 
Phosphate buffered saline tablets  Oxoid 
Sodium azide  Sigma 
Sodium chloride  Sigma 
Sodium dihydrogen phosphate  Sigma 
Sodium succinate  Sigma 
Triton X-100  Sigma 
X-Cell-Plus HRP detection with DAB  A. Menarini diagnostics 
2.1.3.3 Polymerase Chain Reaction and Sequencing Reagents 
Amplitaq Gold DNA polymerase  Applied Biosystems 
BigDye Terminator v3.1 cycle sequencing kit  Applied Biosystems 
Bovine serum albumin  New England Biolabs 
Deoxynucleotide triphosphates  Rovalab 
DMSO (molecular biology grade)  Sigma 
ExoSAP-IT  GE Healthcare 
Expand Long Template PCR system  Roche 
HiDi  Applied Biosystems 
SYBR Green  Invitrogen 
Tamra labelled probe  Applied Biosystems 
TaqMan® mastermix  Roche 
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2.1.3.4 Gel Electrophoresis Reagents 
Agarose MP  Roche 
Bromophenol blue  Sigma 
1Kb DNA ladder  Gibco BRL 
24Kb DNA ladder  Fermentas 
Ethidium bromide  Merck 
GelRed Nucleic Acid Stain  Biotium 
Hyperladder IV  Bioline 
Sodium dodecyl sulphate (SDS)  BDH 
Tris acetate EDTA (TAE:x10)  Sigma 
2.1.3.5 Southern Blot Reagents 
[α-32P]-dCTP (3,000 Ci/mmol)  Perkin Elmer 
BamHI restriction enzyme  New England Biolabs 
Dextran sulphate sodium salt  Pharmacia 
Dithiothreitol (DTT)  Sigma 
Ethylenediaminetetraacetic acid (EDTA)  Sigma 
Hybond XL nylon membrane  Amersham Pharmacia 
Hydrochloric acid (HCl)  BDH 
Klenow enzyme  New England Biolabs 
Multiprime kit  Amersham Pharmacia 
Random hexamers Pd (N) 6 5’PO4 Na
+salt  Pharmacia 
Salmon testes DNA (10mg/ml)  BDH 
Sephadex G-5- Nick Column  Amersham Pharmacia 
SnaBI restriction enzyme  New England Biolabs 
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Sodium chloride (NaCl)  BDH 
Sodium hydroxide (NaOH)  BDH 
2.1.3.6 Tissue Culture Reagents 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco 
Foetal calf serum  Gibco 
Gentamicin  Gibco 
L-Glutamine  Gibco 
MycoAlert mycoplasma detection kit  Lonza 
Penicillin and streptomycin solution (Pen-Strep) Gibco 
Pyruvate  Sigma 
Skeletal muscle cell growth medium  PromoCell 
Trypsin  Gibco 
Uridine  Sigma 
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2.2 Methods 
2.2.1 Ethics 
Approval for this research was granted by the Newcastle and North Tyneside Local 
Research Ethics Committees 2202/205 for Doug Turnbull from 2002 to the end of 2012. 
2.2.2 Biopsies 
Muscle biopsies were performed by Dr Grainne Gorman of the Biomedical Research 
Centre using the needle biopsy technique. To obtain muscle samples, biopsies were taken 
from the mid-portion of the vastus lateralis. Samples for satellite cell isolation were place 
in solution A (30mM HEPES,130mM NaCl, 3mM KCl, 11mM Glucose, 0.567mg phenol red 
dissolved in 500ml of dH2O) for storage until Fluorescently Activate Cell Sorting (FACS) 
could be performed. Samples for molecular biology studies were snap frozen in pre-
cooled isopentane and stored at -80oC. Samples for histochemistry were mounted on 
Whatman grade IV filter paper with OCT adhesive and also snap frozen in isopentane. 
A small portion of the sample was transferred to the Newcastle MRC Centre for 
Neuromuscular Diseases Biobank for myoblast culture. 
2.2.3 Cryostat Sections 
Muscle cryostat sections were cut from frozen tissue using a Cryo-star HM 560 cryostat. 
Tissue was orientated transversely and sections of 12µm were cut and mounted onto 
slides. Sections were left to air dry for one hour and then stored at -20oC until required. 
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2.2.4 Isolation of Satellite Cells 
2.2.4.1 Cell Dissociation 
To dissociate satellite cells from the muscle samples FACS sorting was performed. The 
muscle sample was placed in a Medicon (BD Biosciences) with approximately 500µl of 
sterile phosphate buffered saline (PBS), and placed into a Medimachine (BD Biosciences) 
for approximately fifteen seconds. The Medicon, consisting of a blade and grid, was 
placed in the Medimachine which propels the blade. The resultant cell solution passes 
through the grid, leaving any connective tissue on top. This allows for a sterile, automated 
cell dissociation system. The cell solution was aspirated with a 5ml syringe, and to remove 
muscle fibres it was passed through a 30µm filter (CellTrics®, Partec) into a FACS sorting 
tube. Cells were then counted using a Beckman Coulter Cell Viability Analyser. 
Phycoerythrin (PE) labelled Mouse Anti-Human CD56 IgG1 (BD Pharmingen
TM), recognising 
the Neural Cell Adhesion Molecule (NCam), was added to the cells (10µl antibody per 
million cells) to incubate in the dark for thirty minutes. The sample was then washed 
using the BD Lyse Wash Assistant (BD Biosciences). This centrifuges the cells to the wall of 
the tube and washes them using a buffer, removing residual PBS or solution A. The cells 
were then immediately FACS sorted. 
2.2.4.2 Fluorescently Activated Cell Sorting (FACS) 
CD56 positive (CD56+) cells were sorted using a FACS Aria (BD Biosciences). The FACS Aria 
takes up the sample and uses laminar flow with sheath fluid to create a stream of cells. 
The cells then pass through the optimal point of light source and are interrogated with a 
laser. This allows data on light scatter (forward and side) and fluorescence to be 
collected. 
The PE labelled Mouse Anti-Human CD56 IgG1 was excited at 488nm by the FACS Aria and 
a signal was emitted by the fluorescently labelled cells at 585nm. This signal was detected 
by the machine which then sorted the cells into CD56+ and CD56-. The CD56+ cells were 
collected in a microcentrifuge tube, centrifuged at 1500rpm (166g) for five minutes, the 
supernatant was pipetted off and the cells stored at -20oC until needed. 
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2.2.5 Histochemistry 
2.2.5.1 Haematoxylin and Eosin (H & E) Staining 
H & E staining was routinely used to visualise tissue morphology. In order to stain muscle 
nuclei, haematoxylin staining was performed. The oxidised form of haematoxylin; 
hemalum, gives a blue colour when added to sections after becoming bound to arginine 
rich nucleoproteins such as histones. While eosin, an acidic dye, stains eosinophilic 
structures pink. In the case of muscles sections, this will mostly be the cytoplasm of the 
fibre which is basic. 
In order to perform the staining, sections were defrosted in slide mailers for thirty 
minutes, and then air dried for one hour. The sections were then fixed in formal calcium 
for fifteen minutes, and rinsed in tap water. The slides were totally immersed in 
haematoxylin for one minute, and then rinsed in tap water to blue the nuclei. Once the 
water ran clear the sections were placed in eosin (1% eosin yellowish, 0.4% erythrosine B, 
0.2% phloxin B in dH2O) for thirty seconds, and then washed again in tap water. 
To dehydrate the sections, the slides were passed through a graded ethanol series (75%, 
95%, 2 x 100%), being left in the final 100% solution for ten minutes. They were then 
cleared through two stages of histoclear, mounted using DPX mountant and a cover slip 
was applied. 
2.2.5.2 Dual Cytochrome c Oxidase (COX) and Succinate Dehydrogenase (SDH) 
Histochemistry 
COX/SDH histochemistry (Old and Johnson, 1989) was performed on frozen muscle 
sections to assess the activity of complexes II and IV. Through combining these two stains 
it was possible to identify COX deficient fibres. COX deficient fibres will not demonstrate 
the brown reaction product (oxidised DAB) during the first incubation, but will stain blue 
following the second incubation with SDH. This is because SDH is encoded by the nuclear 
genome so any mtDNA mutations will not affect its activity, while mtDNA mutations will 
affect the activity of complex IV and prevent DAB oxidation. 
Muscle sections were defrosted in slide mailers for thirty minutes, and then air dried for 
one hour. All staining and incubations were carried out in a humidified chamber. The COX 
incubation medium was prepared by adding 200µl of 500µM cytochrome c to 800µl of 
5mM 3.3’diaminobenzidine (DAB) with approximately 20µg of catalase enzyme. The 
solution was then vortexed and 200µl per section was added to the slides. The sections 
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were incubated for forty five minutes at 37oC and then immersed in PBS three times to 
wash.  
The SDH incubation medium was prepared by adding 100µl of 1.3M sodium succinate, 
100µl of 2mM phenazine methosulphate (PMS) and 10µl of 100mM sodium azide to 
800µl of 1.875mM NitroBlue tetrazolium (NBT). The mixture was vortexed and 200µl was 
added to the sections. Again, the sections were incubated for forty five minutes at 37oC, 
before being immersed three times in PBS to wash. 
The sections were dehydrated by passing the slides through a graded ethanol series (75%, 
95%, 2 x 100%), being left in the final 100% solution for ten minutes. They were then 
cleared through two stages of histoclear, mounted using DPX mountant and a cover slip 
was applied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2  Materials and Methods   
75 
  
2.2.6 Immunohisochemistry 
All immunohistochemistry protocols, unless otherwise stated, were performed on the 
bench at room temperature. A control muscle section, without any primary antibody was 
included with the staining to check for any cross reactivity. All brightfield images were 
taken on a Zeiss Axioplan 2 microscope using AxioVision 4.8.1 software. 
2.2.6.1 Pax7 Staining 
Pax7 is a nuclear marker expressed in quiescent satellite cells, and is down regulated as 
cells head towards differentiation (Buckingham, 2006). Pax7 stained satellite cells within a 
muscle section are visible as brown (DAB) nuclei around the periphery of the fibres. Pax7 
staining was performed on muscle sections to enable satellite cell counting in patients 
with mitochondrial myopathies and control subjects. 
Muscle sections were defrosted in slide mailers for thirty minutes and then air dried for 
one hour. A hydrophobic pen was used to draw around the sections to stop solutions 
from dispersing around the slide. The sections were then fixed in 4% paraformaldehyde 
(PFA) for thirty minutes, before rinsing in distilled water to remove excess PFA. 
Antigen retrieval was performed on the sections by continuously submersing the slides in 
and out of boiling EDTA (pH 8) for one minute. This helps break protein bonds and brings 
the antigens to the surface. They were placed in distilled water and then into 3% H2O2 for 
thirty minutes to block any endogenous peroxidase. After washing in distilled water they 
were given a further three washes. This consisted of tris buffered saline (TBS)(pH 7.4) 
being pipetted onto the sections for five minutes twice, and then tris buffered saline with 
tween (TBST) (pH 7.4) being applied once for five minutes. Tween is a detergent that 
helps the solution spread evenly around the slide. 
Then a blocking solution of 1% normal goat serum (NGS) in TBS was made, of which 100µl 
was applied to the sections for thirty minutes. This was to block non-specific goat 
antibody binding sites, as the secondary antibody was raised in goat. The primary 
antibody, Pax7 (IgG1) (Developmental Studies Hybridoma Bank), was made up at a 1:50 
dilution in TBS, and 100µl per section was applied to the slides. The slides were then 
either left at 4oC overnight or at room temperature for ninety minutes. 
The primary antibody was washed off with two five minute washes in TBS and one five 
minute wash in TBST, before a secondary antibody was applied. 100µl of anti-mouse IgG–
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biotinylated antibody (raised in goat; Vector Laboratories) was applied at a 1:200 dilution 
in 1% NGS, for thirty minutes. While the sections were incubating a 
streptavidin/biotinylated (ABC) solution (Vector Laboratories) was made by adding one 
drop of solution A and one drop of solution B to 5ml of TBS. After the sections had been 
washed in TBS and TBST, 100µl of the ABC solution was added for thirty minutes. The 
next two washes consisted of TBS being pipetted onto the sections for five minutes, and 
then the slides were immersed in distilled water. To visualise the staining, 3,3-
diaminobezidine (DAB) was used. This was made up by adding one DAB and one urea 
hydrogen peroxidase tablet to 5ml of nanopure water and vortexing until they dissolved. 
100µl of this solution was applied for six minutes. 
The slides were washed in distilled water and counter stained with haematoxylin for one 
minute to visualise nuclei. They were then washed in tap water until it ran clear, and put 
through a graded ethanol series to dehydrate, (75%, 95%, 2 x 100%), being left in the final 
100% solution for ten minutes. They were cleared through two stages of HistoclearTM, 
mounted using DPX mountant and a cover slip was applied. 
2.2.6.2 Neural Cell Adhesion Molecule (NCam) Staining 
NCam is a transmembrane protein expressed in satellite cells that serves as a cell surface 
marker. It is important for cell adhesion and is expressed in satellite cells, as well as 
regenerating muscle fibres. Any satellite cells in a muscle section are visible by the 
presence of a stained halo around the outside of the nuclei. NCam staining was 
performed in order to determine which fibres in a muscle section were regenerating. 
Methods for defrosting, fixing, antigen retrieval, blocking endogenous peroxidases, and 
blocking with NGS, were as they were for Pax7 (section 2.2.6.1). The primary antibody, 
NCam (IgG1) (gift from Eric Shoubridge) was made up at a 1:50 dilution in TBS, and 100µl 
per section was applied to the muscle sections. The slides were then left at 4oC overnight 
or alternatively at room temperature for ninety minutes. 
Methods for visualising the staining with a secondary antibody, ABC solution, and DAB 
were the same as they were for Pax7 (section 2.2.6.1). The slides were then washed in 
distilled water and counter stained with haematoxylin for one minute to visualise nuclei. 
They were then washed in tap water until it ran clear, and put through a graded ethanol 
series to dehydrate, (75%, 95%, 2 x 100%), being left in the final 100% solution for ten 
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minutes. They were then cleared through two stages of histoclear, mounted using DPX 
mountant and a cover slip was applied. 
2.2.6.3 Complex I Subunit 20kDa Staining 
Complex I subunit 20kDa (complex I:20) reacts against NDUFB8, which will have an 
impaired entry into the complex I assembly pathway if the mtDNA encoded ND4 is 
deficient. This is because a problem with ND4 impairs complex I assembly at an early 
stage and prevents incorporation of NDUFB8 at a later time point (Perales-Clemente et 
al., 2010). Complex I:20 staining was performed on muscle biopsy sections to determine 
which muscle fibres were complex I deficient. 
Methods for defrosting, fixing, antigen retrieval, and blocking of endogenous peroxidase, 
were as they were for Pax7 (section 2.2.6.1). The method of visualisation used for this 
antibody does not require the addition of a secondary antibody to the sections, which for 
previous protocols has been raised in goat. As a result the use of this antibody does not 
require a blocking step of 1% NGS. 
The primary antibody, complex I subunit NDUFB8 monoclonal antibody (IgG1) 
(MitoSciences) was made up in TBS at a 1:600 dilution, and 100µl was added to the 
muscle sections. The slides were then either left at 4oC overnight or at room temperature 
for ninety minutes. After antibody incubation the slides were washed twice for five 
minutes in TBS, and once for five minutes in TBST. A Universal Probe, recognising the 
mouse epitope of the primary antibody, was added to the sections for thirty minutes. 
After a further wash, a horseradish-peroxidise (HRP)-polymer solution was added to the 
section for thirty minutes. This binds to the Universal Probe and amplifies the signal, thus 
increasing the sensitivity of the protocol. The slides were then washed twice in TBS and 
immersed in distilled water. To visualise the staining 3,3-diaminobezidine (DAB) was used, 
made up as previously stated (section 2.2.6.1). 
The slides were washed in distilled water and counter stained with haematoxylin for one 
minute to visualise nuclei. They were washed in tap water until it ran clear, and put 
through a graded ethanol series to dehydrate, (75%, 95%, 2 x 100%), being left in the final 
100% solution for ten minutes. They were then cleared through two stages of 
HistoclearTM, mounted using DPX mountant and a cover slip applied. 
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2.2.7 Cell Culture 
2.2.7.1 Myoblasts 
In order to determine what happens to mtDNA deletions as muscle cells develop into 
myotubes, myoblast cultures were performed. At the time of biopsy a small sample of 
muscle was transferred into the MRC Centre for Neuromuscular Diseases Biobank, where 
myoblast cultures were set up by the biobank technician Mojgan Reza. 
Briefly, the sample was transferred to a Petri dish containing ATE (solution A 49.7ml, 
trypsin 0.5ml, EDTA 0.2ml), and cut up using a scalpel. The sample, along with 10ml of 
ATE was transferred to a Wheaton flask with a magnetic flea which was placed in a beaker 
containing water warmed to 37oC. The beaker and Wheaton flask went on a magnetic 
stirrer for fifteen minutes. Once the fragments had settled the liquid was poured off into 
a Falcon tube. This process was repeated a further two times. The Falcon tubes were 
centrifuged at 160g for ten minutes and the supernatants discarded. Each pellet was 
suspended in 2ml of skeletal muscle cell medium (SKCM) (PromoCell), combined, and 
transferred to a Petri dish and placed in the incubator at 37oC, 5% CO2. The medium was 
changed every two to three days. After around two weeks the cells were trypsinised and 
placed in a T25 flask and transferred from the biobank to the Mitochondrial Research 
Group. Once received, the myoblasts were cultured further and eventually differentiated 
into myotubes. Cells were grown in SKCM supplemented with 10% foetal calf serum (FCS), 
1.5% L-glutamine, and 0.06% of gentamicin. 
2.2.7.2 Passaging and Harvesting Cells 
When cells were about 85% confluent the media was aspirated off, and the cells washed 
with 5ml of PBS to remove all traces of FCS. The PBS was removed and 2ml of trypsin was 
added to the flask. This was placed back in a humidified incubator at 37oC, 5% CO2, for 
approximately five minutes until the cells had detached from the growing surface and 
were free floating. Following this, 5ml of serum containing media was added to the flask 
to quench the trypsin and the cells were transferred to a 10ml universal tube. The cells 
were then centrifuged at 160g for five minutes. The supernatant was discarded and the 
cell pellet re-suspended in 10ml of SKCM. Some of the cells were then added to a T75 
flask and the media made up to 20ml. Cells for harvesting were placed in a 
microcentrifuge tube and re-centrifuged at 160g, the supernatant discarded and the 
resultant pellet frozen at -20oC until DNA extraction could be performed. 
Chapter 2  Materials and Methods   
79 
  
2.2.7.3 Freezing Cells 
The cells were harvested as stated in the previous section, and those for freezing were 
placed in a microcentrifuge tube, spun at 166g for a further five minutes and the 
supernatant discarded. 2ml of freezing medium (DMEM 70%, FCS 20%, dimethyl sulfoxide 
(DMSO) 10%, all sterilised through a 0.22µm filter), was added to the pellet, the cells 
were re-suspended and then transferred to a cryotube, which was quickly placed in the -
20oC freezer. The cells were then placed at -80oC for twenty four hours before being 
transferred to liquid nitrogen for long term storage. 
2.2.7.4 Differentiation of Myoblasts to Myotubes 
Differentiation of myoblasts was achieved through the changing of SKCM for a reduced 
serum medium. When myoblasts were about 80% confluent the medium was removed 
and the cells washed with PBS. 15ml of differentiating medium (98% DMEM, 2% horse 
serum) was added to the flask which was then returned to the incubator. After about five 
days myotubes were visible in the flask. These are elongated multinuclear cells that 
appear to line up alongside each other (Figure 2.1). The myotubes were then harvested 
and pelleted as described previously (section 2.2.7.2) and frozen until DNA could be 
extracted. 
Chapter 2  Materials and Methods   
80 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Images of myoblasts and myotubes. A. Myoblasts before the addition of 
differentiation medium. All cells have a single nucleus and are still dividing. B. After 
the addition of differentiation medium cells start to line up and fuse together, 
myotubes with multiple nuclei can be observed. 
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2.2.7.5 Counting Cells 
When cells were harvested and re-suspended in 10ml of fresh SKCM they were also 
counted. A cover slip was applied to a haemocytometer and 15µl of cell sample was 
pipetted on the edge of the cover slip and drawn up via capillary action. Using x10 
magnification, the microscope was focused onto the grid lines to view the cells. The four 
corners of the haemocytometer contain a grid of sixteen squares, in which all cells were 
counted. Any cell positioned on the left hand or bottom boundary was included in the 
counts, while those on the right hand and upper boundaries were not included. The 
counts for the four corners were then averaged. The average number of cells for the four 
corners of the haemocytometer was multiplied by 104 to give the number of cells per ml. 
2.2.7.6 DNA Extraction of Cultured Cells 
DNA was extracted from myoblasts and myotubes using a Qiagen DNeasy Blood & Tissue 
Kit according to manufacturer’s instructions for the ‘Purification of Total DNA from 
Animal Blood or Cells’ (Spin-column Protocol). DNA was eluted from the column in 40µl of 
dH2O after two minutes incubation, and stored at -20
oC. In order to determine the DNA 
concentration of the samples 1µl was loaded onto a NanoDrop® ND-1000 
Spectrophotometer to give a value of ng/µl. Samples were stored at -20oC until needed. 
2.2.7.7 Mycoplasma Testing 
At the first passage after receiving myoblasts from the biobank all cells were tested for 
mycoplasma using the MycoAlert® Mycoplasma Detection Kit (Lonza). The cells being 
cultured were primary human cell lines, in which mycoplasma is a common problem as it 
is present on the skin of most people. When the medium was aspirated off 5mls were 
transferred to a 10ml universal tube, sealed with Parafilm, and stored at 4oC until testing. 
In order to perform the mycoplasma test, 2ml of media were transferred into a 
microcentrifuge tube and spun at 166g for five minutes to pellet any contaminating cells. 
Whilst being careful not to pipette any air bubbles, 25µl of clear supernatant was 
transferred to a luminometer cuvette. Then 25µl of MycoAlert® Reagent was added to 
the cuvette and the sample left for five minutes. The tube was then placed in the 
luminometer and three readings were taken to give an average. After this, 25µl of 
MycoAlert® Substrate was added to the sample and left for ten minutes, before a final 
three readings were taken on the luminometer. The ratio between the readings was 
taken by dividing the substrate result by the reagent results. Providing this ratio was 
below one, the cells could be considered to be mycoplasma free. 
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2.2.7.8 Seeding Cover slips 
In order to perform immunofluorescence and COX/SDH on the myoblasts, cells were 
grown on cover slips to aid staining. Autoclaved circular cover slips were placed into each 
well of a six well plate. After harvesting, cells were re-suspended in 3ml of medium. To 
the centre of each cover slip 500µl of cell containing medium was pipetted, before placing 
the plate back into the incubator to allow the cells to adhere to the cover slip. After one 
hour a further 1.5ml of medium was added to the wells and the plate returned to the 
incubator. 
2.2.7.9 Immunofluorescent Staining of Myoblasts 
In order to confirm the purity of the myoblast culture, cells were labelled for desmin. 
Desmin is an intermediate filament found in the sarcomeres of striated muscle cells. 
Medium was removed from the wells and the cells washed in 2ml of PBS. The cells were 
then fixed in 4% PFA for ten minutes in the laminar flow hood. PFA was removed from the 
wells and the cover slip washed three times in PBS to remove any excess PFA. The cover 
slips were then removed from the wells and adhered to a slide using nail varnish to aid 
staining, which was performed at the bench. Cells were blocked in 5% NGS in PBST (to 
permeabilise the membrane) for one hour. Monoclonal mouse anti-human desmin IgG1 
(Dako) was diluted in blocking reagent 1:100 and added to the cells for one hour at room 
temperature. Following this, the cells were washed three times in PBST, each time for five 
minutes, and Alexa Fluor® -488 goat anti-mouse (FITC) (1:100 in blocking reagent) was 
applied for one hour, again at room temperature. Cells were then washed once in PBST 
and twice in PBS. Nuclei were visualised using VECTASHIELD® Mounting Medium with 
DAPI. 
2.2.7.10 Immunofluorescent Labelling of Fibroblasts 
Fibronectin staining was performed to determine if cultured cells were fibroblasts. 
Fibronectin localizes to the matrix of cultured human fibroblasts. 
Medium was removed from the wells and the cells washed in 2ml of PBS. The cells were 
then fixed in 4% PFA for ten minutes in the tissue culture hood. PFA was removed from 
the wells and the cells washed three times in PBS to remove any excess PFA. The cover 
slips were then removed from the wells, attached to slides using nail varnish, and 
transferred to the bench. Cells were blocked in 5% NGS in PBST (to permeabilise the 
membrane) for one hour. Monoclonal anti-fibronectin antibody IGg1 (Sigma-Aldrich) 
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made in mouse, diluted 1:200 in blocking reagent was added to the cells for one hour at 
room temperature. Following this, the cells were washed three times in PBST, each time 
for five minutes, and Alexa Fluor® -488 goat anti-mouse (FITC) (1:100 in blocking reagent) 
was applied for one hour, again at room temperature. Cells were then washed once in 
PBST and twice in PBS. Nuclei were then visualised using VECTASHIELD® Mounting 
Medium with DAPI. Images were taken on a Zeiss Axioplan 2 microscope using AxioVision 
4.8.1 software. 
2.2.7.11 COX Staining on Myoblasts 
COX staining was performed in order to determine the enzymatic activity of the cultured 
myoblasts from patients. 
Cells were grown on cover slips in six well plates. The medium was removed from the 
wells and the cells washed in PBS. The cover slips were removed from the wells and 
mounted on slides; all subsequent steps were performed at the bench. The COX 
incubation medium was prepared as previously described (section 2.2.5.2) and 
approximately 250µl were added to each cover slip in order to ensure all the cells were 
covered. The slides were then incubated for ninety minutes at 37oC, before being washed 
three times in PBS. 
The cover slips were then dehydrated in an ethanol series, placed in HistoclearTM, and 
then removed from their slides before being re-mounted using DPX mountant on fresh 
slides. 
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2.2.8 Molecular Biology Techniques 
2.2.8.1 DNA Extraction 
Muscle homogenate DNA was extracted using the EZ1® Advanced Workstation and the 
Qiagen EZ1® DNA Tissue Kit by the Newcastle Mitochondrial Diagnostic Service. 
2.2.8.1.1 Qiagen Kit 
DNA was extracted from CD56+ and myoblasts cells using a Qiagen DNeasy Blood & 
Tissue Kit according to manufacturer’s instructions for the ‘Purification of Total DNA from 
Animal Blood or Cells’ (Spin-column Protocol). DNA was eluted from the column in 40µl of 
water after two minutes incubation, and stored at -20oC. DNA concentrations were 
determined using the NanoDrop® ND-1000 Spectrophotometer. 
2.2.8.1.2 Lysis Method 
Single cell DNA extraction was carried out using a lysis method in a ninety six well plate. 
The lysis medium consisted of 50µl of 500nM Tris-HCL, 250µl of 1% Tween 20, 190µl of 
autoclaved nanopure water and 5µl of proteinase K (20mg/ml). To each cell 15µl was 
added, and the plate was lightly shaken, the cells were then incubated at 55oC for two 
hours before a final proteinase K inactivation step of heating to 95oC for ten minutes. 
Samples were stored at 4oC until required. 
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2.2.8.2 Standard Polymerase Chain Reaction (PCR) 
2.2.8.2.1 Standard PCR 
Standard PCR reactions were performed in order to amplify fragments of mtDNA for DNA 
sequencing and to generate template DNA for SYBR Green assay optimisation (see section 
4.3.1). 
Standard PCR’s were set up on the bench and performed in 25µl volumes. The reaction 
mixture consisted of 16.87µl of autoclaved water, 2.5µl of 10 x dNTP’s (ROVALAB), 2.5µl 
of 10 x PCR buffer (10mM Tris-HCl pH8.3 15mM MgCl2, 50mM KCL, 0.001% w/v gelatine), 
0.13µl of AmpliTaq Gold® DNA polymerase (Applied Biosystems), and 1µl of both forward 
and reverse primer (20µM) (Table 2.1). 1µl of wild type (WT) blood DNA was used as a 
positive control, while 1µl of dH2O was used as a negative control. Reactions were carried 
out in a GeneAmp® PCR System (Applied Biosystems) thermal cycler under the following 
cycling conditions: 95oC for ten minutes, thirty cycles of: 94oC for forty five seconds 
(denaturing), 58oC for forty five seconds (annealing), and 72oC for one minute (extension), 
with a final extension of 72oC for eight minutes. 
2.2.8.2.2 Gel Electrophoresis 
Results of the PCR were then visualised using gel electrophoresis and a 1% agarose gel. To 
make the gel, 1g of powdered agarose was added to 100ml of 1 x TAE buffer with 2µl of 
ethidium bromide added to stain the DNA. The mixture was then heated in a microwave 
to dissolve the agarose and once cooled the gel was poured. To each well 5µl of PCR 
product, combined with 0.5µl of loading dye (0.25% bromophenol blue, 0.25% xylene 
cyanol, 30% glycerol in dH2O), was added. An appropriately sized ladder was also loaded 
onto the gel to allow for an estimation of the product size. The gel was run for thirty 
minutes at 70V in a tank containing 1xTAE buffer, and bands were visualised on the UV 
gel documentation system. 
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2.2.8.3 Long Range PCR 
In order to amplify large sections of DNA and enable detection of mtDNA deletions, a 
two-step long range PCR method was employed (Expand Long Range Template PCR 
System®, Roche). A first round PCR was carried out using primers (nt.5855-nt.5875, 
nt.129-nt.110) (Table 2.1) to amplify a ~10.8kbp fragment. The master mix consisted of 
1µl of DNA template, 5µl reaction buffer 3 (Roche), 8.75µl 0.35mM dNTPs, 10µl 1mg/ml 
bovine serum albumin (BSA), 0.7µl Expand Taq (Roche), 1.5µl of both forward and reverse 
primers 10pmol/µl, and 21.55µl dH2O, to give a 50µl reaction mixture. Reactions were 
performed on a thermal cycler under the following conditions: three minutes at 93oC; ten 
cycles of 93oC for thirty seconds, 58oC for thirty seconds, and 68oC for twelve minutes; 
twenty cycles of 93oC for thirty seconds, 58oC for thirty seconds, and 68oC for twelve 
minutes with an additional five seconds for every cycle. Then there was a final extension 
of eleven minutes at 68oC. 
The samples were then diluted in dH2O to give a DNA template, from which 1µl was taken 
for the second round of PCR. This time primers were used to generate a fragment of 
~10.2kbp (nt.6358-nt.6377, nt.019-nt.001), all other reaction reagents were as for the 
first round. Cycling conditions were also kept the same. The amplified products were 
separated on a 0.7% agarose gel, with 10µl of product being combined with 0.5µl of 
loading dye, and run for two hours at 50V. 
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Table 2.1 Primer pairs. Primers used to amplify the mitochondrial genome. The primers amplify the 
genome in thirty six overlapping fragments, with each primer pair generating a product of around 
600bp.  
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2.2.8.4 DNA Sequencing 
This was performed on the mtDNA D-loop in order to ascertain sample identity and also 
to determine mtDNA break points for patients involved in this study in cases where they 
were not already known. 
2.2.8.4.1 D-Loop 
The D-loop region of sample mtDNA was amplified using standard PCR methods and 
primers D1 forward (nt.15758-nt.15777) reverse (nt.019-nt.001), D2 forward (nt.16223-
nt.16244) reverse (nt.129-nt.110), D3 forward (nt.16548-nt.16569) reverse (nt.389-
nt.370), and D4 forward (nt.323-nt.343) reverse (nt.771-nt.752) (Table 2.1). After running 
the samples on a thermal cycler under standard PCR conditions (see section 2.2.8.2.1), 
the products were visualised on an agarose gel and any portions unamplified were 
repeated. The PCR products were then sequenced. 
2.2.8.4.2 MtDNA Deletion Break Points 
50µl of long range PCR product were run on a 0.7% agarose gel. These DNA bands were 
then excised from the gel using a scalpel and UV box, before having the DNA extracted 
using the Qiagen Gel Extraction Kit, as per manufacturer’s instructions. 
2.2.8.4.3 Purification of PCR Products 
5µl of each product was pipetted into a ninety six well plate over ice and 2µl of ExoSap-IT 
(VWR) was added to each sample. A sealing mat was applied to the plate, which was then 
vortexed and pulse spun down. The mixture was incubated in a thermal cycler at 37oC for 
fifteen minutes, followed by a fifteen minute inactivation step at 80oC. The ExoSap-IT uses 
exonuclease I and shrimp alkaline phosphatase to remove any unreacted dNTPs and 
primers in the PCR mixture that could otherwise interfere with the DNA sequencing 
analysis. 
2.2.8.4.4 Cycle Sequencing 
A master mix comprising 7µl of dH2O, 3µl of 5 x sequencing buffer, 1µl of Universal 
forward primer, and 1µl of BigDyesv3.1, was created, 12µl of which was added to each 
well of the plate containing a sample. The plate was sealed with strip caps and placed in a 
thermal cycler under the following conditions: 96oC for one minute, then twenty five 
cycles of 96oC for ten seconds, 50oC for five seconds, and 60oC for four minutes. 
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2.2.8.4.5 Precipitation and Sequencing 
Precipitation was performed to concentrate and de-salt the DNA. EDTA was diluted to a 
working concentration of 125mM and 2µl was added to each sample, and tapped down 
into the well. 2µl of 3M sodium acetate was then added to the well and the plate pulse 
spun down. The salt nature of the sodium acetate neutralises the negative charges on the 
DNA making them less hydrophilic and thus less soluble in water.  
Following this, 50µl of 100% EtOH was added to the wells to facilitate the precipitation, 
and the plate inverted four times and left at room temperature for fifteen minutes. The 
plate was then centrifuged at 2090g for thirty minutes, before the supernatant was 
discarded through a brief upside down spin on white paper. Then 70µl of 70% EtOH was 
added to the samples to wash any residual salt from the pelleted DNA, and the plate 
centrifuged at 1650g for fifteen minutes. Again the supernatant was discarded through an 
upside down spin and the plate was left to dry in the dark for fifteen minutes. 
10µl of HiDiTM formamide was added to each well and the samples were incubated at 
95oC for two minutes to separate the DNA strands, the plate was then placed on ice. The 
HiDi helps with this denaturation by lowering the melting point of the DNA. The plate was 
then placed in an ABI 3130xl Automated DNA Sequencer to run. Using SeqScape software, 
the fragments were aligned and compared to the Cambridge Reference Sequence 
(Anderson et al., 1981). 
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2.2.8.5 Real Time PCR (qPCR) 
2.2.8.5.1 MTND1/MTND4 qPCR TaqMan® Assay 
The MTND1/MTND4 qPCR multiplex assay (Krishnan et al., 2007) was used to determine 
mtDNA deletion levels in patients. MtDNA contains a region that is seldom deleted in 
patients with sporadically occurring large scale deletions, this is the ND1 region. The ND4 
region is however, absent in the majority of these patients (Figure 4.13). This assay uses 
fluorescent probes (VIC and FAM) along with primers for these specific regions, which are 
two complex I genes. By comparing the levels of fluorescence created by the probes once 
they have been freed of their quencher, it is possible to determine heteroplasmy levels. 
All qPCR reactions were set up in the UV hood in ninety six well plates. ND1 forward 
(L3485-3504, 5’-CCC TAA AAC CCG CCA CAT CT-3’), reverse (H3532-3553, 5’-GAG CGA TGG 
TGA GAG CTA AGG T-3’) and ND4 forward (L12087-12109, 5’-CCA TTC TCC TCC TAT CCC 
TCA AC-3’) and reverse (H12140-12170 5’ – CAC AAT CTG ATG TTT TGG TTA AAC TAT ATT 
T-3’) primers were reconstituted to 200pmol/µl for stock solutions, from which 1:20 
aliquots were made for a working stock of 10µM and kept at -20oC. The ND1 probe 
(nt.3506-nt.3529, 5’-CCA TCA CCC TCT ACA TCA CCG CCC-3’) contained a VIC reporter tag 
at the 5’ end and a TAMRA non fluorescent quencher molecule at the 3’ end. While the 
ND4 probe (nt.12111-nt.12138, 5’-CCG ACA TCA TTA CCG GGT TTT CCT CTT G) contained a 
reporter FAM tag at the 5’ end and a TAMRA quencher at the 3’ end. Probes were diluted 
to 5µM stock concentration. 
While the probe is intact no fluorescent signal is generated. Once the probe and primers 
have annealed the 5’nuclease of the DNA polymerase cleaves the quencher from the 
fluorescent tag and a signal is emitted (Figure 4.12). 
The master mix consisted of 12.5µl of TaqMan® Universal MasterMix, 0.5µl 5µM ND1 
probe, 0.5µl 5µM ND4 probe, 0.75µl 10µM of ND1 forward and reverse primer, 0.75µl 
10µM of ND4 forward and reverse primer, and 7.5µl of dH2O. This was added to 1µl of 
sample DNA, to give a 25µl reaction volume. The plate was sealed using a MicroAmp™ 
Optical Adhesive Film and pulse spun down. The plate was then transferred to an ABI Step 
One Plus Real Time PCR System. Cycle conditions were two minutes at 50oC, ten minutes 
at 95oC, followed by forty cycles of fifteen seconds at 95oC and sixty seconds at 60oC. 
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The results were exported from the machine and analysed using Microsoft Excel. The 
proportion of wild type (WT) mtDNA to delete mtDNA was determined using the ΔCt 
method (2-ΔCt), where Ct is calculated as (CtND1-ND4) (Krishnan et al., 2007, He et al., 2002). 
Ct is the cycle threshold, defined by the number of cycles required for the level of 
fluorescence to cross the threshold which is set in the exponential phase of the 
amplification (Figure 4.3). A blood sample was also run, the ΔCt of which was subtracted 
from the sample results. 
2.2.8.5.2 18S rRNA Assay to Determine Relative Copy Number 
The 18S assay is able to determine relative amounts of mtDNA to a nuclear marker. The 
18S rRNA gene is present in multiple copies in the nuclear genome and since the mtDNA 
copy number is determined relative to this unknown amount, it is not possible to quantify 
absolute mtDNA copy number using this method. Primers were used to amplify up the 
ND1 region (see section 2.2.8.5.1), and the 18S region (Forward 5’-GCC GCT AGA GGT 
GAA ATT CTT G-3’, Reverse 5’-CAT TCT TGG CAA ATG CTT TCG-3’), working concentration 
10µM. The ND1 probe along with a 5’ tagged FAM 18S probe (5’-CCG GCG CAA GAC GGA 
CCA GA-3’) were used at 5µM concentrations. 
The ND1 master mix consisted of 12.5µl of TaqMan® Universal MasterMix, 0.75µl of ND1 
forward and reverse primer, 0.5µl of ND1 Vic tagged probe, and 7.5µl of dH2O. This was 
added to 1µl of sample DNA, to give a 25µl reaction volume. The 18S master mix 
consisted of 12.5µl of TaqMan® Universal MasterMix, 0.75µl of reverse primer (10µM), 
0.13µl of forward primer (10µM), 0.5µl of probe (5µM), and 10.12µl of dH2O. The ND1 
and 18S reactions were set up in parallel, in triplicate. The plate was sealed using a 
MicroAmp™ Optical Adhesive Film and centrifuged down. The plate was then placed in an 
ABI Step One Plus Real Time PCR system. Cycle conditions were two minutes at 50oC, ten 
minutes at 95oC, followed by forty cycles of fifteen seconds at 95oC and sixty seconds at 
60oC. MtDNA copy number was calculated using the equation R=2-ΔCt (He et al., 2002). 
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2.2.8.5.3 SYBR Green qPCR 
The MTND1/MTND4 qPCR TaqMan® assay has a lower threshold of detection sensitivity 
of around 30% heteroplasmy, so any cells with less than 30% delete mtDNA will not give 
an accurate result. In order to determine levels of delete mtDNA below this threshold, 
deletion specific SYBR Green qPCR assays were utilised. SYBR Green is a fluorescent dye 
that binds to all double stranded DNA in a PCR reaction and will fluoresce once bound. As 
the DNA polymerase amplifies the target sequence, the dye will bind to all new double 
stranded DNA formed, and an increase in fluorescence will be registered. 
Three deletion specific SYBR Green assays were optimised for this research; the details of 
specific assays are described in chapter 4. Here, the general method for optimising and 
performing the assay is described. 
Depending on the size and position of the mtDNA deletion, primers were chosen to 
generate an approximately 600bp fragment of the patient’s mtDNA that incorporated 
their deletion break points. This template DNA was then serially diluted down to 1 in 1012. 
Primers were designed using Primer 3 (v.0.4.0) (Rozen and Skaletsky, 2000), that would 
amplify up an approximately 100bp fragment of either wild type (WT) mtDNA or mtDNA 
containing a deletion. Primers were reconstituted in dH2O to a 200pmol/µl concentration 
for a stock solution; 1:20 aliquots were then taken to give a 10µM working concentration. 
All reactions were set up in a UV hood after UV treatment of all water and assay 
consumables. Pairs of primers were designed that would selectively amplify up either WT 
mtDNA or deleted mtDNA. The master mix consisted of 12.5µl of Platinum®SYBR®Green 
qPCR SuperMix-UDG, 0.5µl of both forward and reverse primers, and 10.5µl of dH2O. The 
MgCl2 concentration was optimised for different assays, 0.5µl of MgCl2 was added to 
increase the MgCl2 concentration to 4mM, without this addition the reaction was 
performed at 3mM. Master mix was added to 1µl of sample DNA. Assays were optimised 
for primer and MgCl2 concentrations, as well as annealing temperatures. 
Reactions were initially set up in LightCycler Capillaries and performed on the Roche 
LightCycler. Later assays were carried out in a ninety six well plate and performed on the 
ABI Step One Plus Real Time PCR system. Cycling conditions were optimised for each 
assay but generally consisted of a ten minute hold at 95oC followed by forty cycles of: 
95oC for fifteen seconds and 60oC for one minute (primer dependent). This was followed 
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by a melt curve analysis of 95oC fifteen seconds, 60oC one minute followed by a 0.3oC per 
fifteen second increase up to 95oC. 
Once conditions had been optimised for both the WT and delete mtDNA reactions, a 
percentage deletion curve was generated through diluting template delete mtDNA with 
WT mtDNA. This provided a set of standards which were run in duplicate or triplicate with 
every assay. The results were exported and analysed using Microsoft Excel. The 
percentage deletion (log) was plotted against ΔCT(CtDel-WT) and the equation of the line 
was generated from a line of best fit. The ΔCT value of the samples could be inserted into 
the equation to determine the percentage of delete mtDNA. 
2.2.8.6 Southern Blot 
In order to determine if one of our patients harboured an mtDNA duplication a Southern 
blot was performed. 
2.2.8.6.1 Linearization of DNA and Gel Electrophoresis 
This was performed using a restriction digest. 2-3µg of whole DNA were digested using 
either SnaBI (nt10736) or BamHI (nt14258) (New England Biolabs) at 37oC for ninety 
minutes. The digest contained 17µl of DNA/H2O mix, 2µl of 10x buffer, and 1µl of enzyme. 
Following digestion, the samples and a 1kb ladder were run on a 0.7% agarose gel, 
containing ethidium bromide, for sixteen to twenty four hours at 30V. The gel was 
photographed using the gel documentation system along with a fluorescent ruler to allow 
an estimation of the size of the bands. The size of the gel was measured and a corner of 
the gel was nicked to correspond with the membrane. 
2.2.8.6.2 Southern Blotting 
The DNA was denatured by soaking the gel in 0.25M HCL for ten minutes and the excess 
HCL removed by rinsing in dH2O. To neutralise the gel it was agitated in 0.4M NaOH/0.6M 
NaCl for thirty minutes, and then in 1.5M NaCl/0.5M Tris-HCL pH 7.5 for thirty minutes. 
GeneScreen membrane was cut to the same size as the gel and pre-wet in dH2O for a few 
seconds. It was then equilibrated in 10x sodium citrate, sodium chloride solution (SSC) for 
fifteen minutes. This consisted of 3M NaCl and 0.3M sodium citrate dissolved in 800mls of 
dH2O, adjusted to pH 7 and then made up to 1000ml. The DNA was transferred to the 
positively charged nylon membrane from the gel via capillary action, using an overnight 
Southern blot with 10x SSC as the transfer solution. 
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After the transfer was complete, the membrane was removed from the blot and then 
agitated in 0.4M NaOH for one minute in order to denature the DNA. The membrane was 
then neutralised in 0.2M Tris-HCL pH 7.5/1x SSC for one minute. DNA was cross linked to 
the membrane through exposure to UV light for four and a half minutes.  
2.2.8.6.3 Probe Generation  
The probe was provided by Emma Blakely of the Newcastle Mitochondrial Diagnostic 
Service. A PCR fragment of about 2000bp was generated to correspond to the mtDNA D-
loop region. This was run on a 1% agarose gel and the bands extracted using the Qiagen 
Gel Extraction Kit. The DNA was then denatured and re-natured in the presence of 
random hexamer sequences. These hexamers are incorporated into the DNA and act as 
primers for a reaction incorporating 32P into the probe. The probe was purified by running 
it through a NICKTM column (GE Healthcare); these are designed for the purification of 
radioactively labelled DNA fragments from unincorporated nucleotides. 
2.2.8.6.4 Hybridisation 
The membrane was placed into an autoclaved hybridisation tube and had 10ml of pre-
hybridisation solution added (10% dextran sulphate, 1% SDS, 1mM NaCl); it was then 
rotated for one hour at 65oC. Sheared salmon sperm DNA (100µg/ml) was added to the 
probe and the mixture incubated at 95oC for three minutes to denature the DNA. The 
DNA present in the sheared salmon sperm binds to the membrane to prevent none 
specific binding of the probe. The probe was then added to the centre of the 
hybridisation tube and hybridisation was performed overnight at 65oC in a rotating oven. 
2.2.8.6.5 Removal of Non-Specific Radioactivity and Imaging of bands 
Following incubation the membrane was subjected to six washes; 2xSSC at room 
temperature for five minutes twice, 2xSSC + 1% SDS 65oC for thirty minutes twice, and 
0.1x SSC at room temperature for three minutes twice. The membrane was then wrapped 
in saran wrap and exposed to a phosphoimage screen and left for at least six hours. The 
bands were imaged on a phosphoimager machine.  
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Chapter 3 Sample Source, Isolation, and Analysis 
3.1 Introduction 
In patients with mitochondrial disorders muscle (cardiac, smooth and skeletal) is a 
commonly affected tissue. It has been suggested that this could be attributable to the 
high energy demand of the tissue. In addition, muscle is a post mitotic tissue which could 
allow for the accumulation of mtDNA mutations over time that will not be lost through 
selection after cell division. 
Clinical manifestations of myopathy can include exercise intolerance, fatigue, muscle 
weakness, ptosis, and CPEO. In addition, patients may experience muscle cramps, pain, 
and stiffness. Histological investigation of muscle from these patients often demonstrates 
RRF and COX negative blue fibres (Larsson and Oldfors, 2001). Mitochondrial myopathies 
have been associated with mtDNA rearrangements, and specifically with sporadically 
occurring large scale single mtDNA deletions (Holt et al., 1988, Zeviani et al., 1988). 
Therapies for patients with mitochondrial myopathies are limited, and are mainly geared 
towards managing symptoms. Advice regarding stretching, posture, and help obtaining 
aids to assist with everyday tasks may be provided. In addition, patients have been given 
antioxidants, for example vitamin C, and respiratory chain co-factors, for example 
succinate and co-enzyme Q10. However, the benefits of these treatments are still 
debateable (Chinnery et al., 2006). 
One approach that has been suggested for patients harbouring sporadically occurring 
mutations is resistance training (Taivassalo and Haller, 2004). The theory behind this 
suggestion is discussed in detail in chapter 4. 
In order to determine the effects of exercise training on patients with mitochondrial 
myopathies, our lab is currently performing an exercise intervention in a group of patients 
harbouring a sporadically occurring large scale single mtDNA deletion. The biopsies being 
performed for this trial not only provided a source of muscle, but also allowed for current 
research investigating the theory behind the use of resistance training in patients with 
sporadically occurring mtDNA mutations. In order to test this theory, satellite cells 
needed to be isolated and characterised from these patients. 
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3.2 Aims  
This aims of this chapter are to describe the methods used to obtain satellite cells from 
exercise trial patients, and optimisation steps performed to ascertain how myogenic 
these cells were. In addition it will also describe some of the initial molecular techniques 
performed on the samples to characterise the mutation and ensure sample identity. 
3.3 Methods 
3.3.1 Exercise Trial 
Muscle samples for this study have come from eight patients enrolled on an exercise trial 
at Newcastle University. This trial was designed to assess the effects of both resistance 
and aerobic training on patients harbouring a sporadically occurring large scale single 
mtDNA deletion. Patients underwent an initial assessment involving strength testing, 
needle muscle biopsy, and an MRI scan. They undertook six months of resistance training, 
a follow up assessment, and were then given a six month aerobic exercise program 
before a final assessment (Figure 3.1). 
Resistance training was carried out three times per week and patients performed three 
sets of eight repetitions of their 80-85% one repetition maximal. The exercise was 
performed on a standard leg extension weight-stack piece of equipment designed to 
primarily exercise the quadriceps muscle group. Patients were asked to perform the 
exercise in order to maximise the eccentric contraction phase of the movement. This is 
muscle contraction that involves the muscle lengthening as it is active, and is thought to 
induce micro damage. 
Aerobic exercise was performed on a stationary bike three times a week at an intensity 
allowing patients to work at 70-80% of their maximal heart rate. 
3.3.2 Patients 
Eight patients (two female: mean age 46 ±15 years; six male: mean age 42.5 ± 10 years) 
were enrolled on the trial. All patients suffered myopathy with CPEO, and in most cases 
exercise intolerance and ptosis. The mean age of onset was 23.1 ± 11.3 years old (Table 
3.1). 
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Figure 3.1 Flow diagram of exercise interventions. Eight patients with a single mtDNA deletion were 
given baseline evaluations and a fifty two week exercise program. At regular intervals samples were 
taken for molecular and histochemical analyses. Strength testing was also performed. 
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Table 3.1 Clinical symptoms of patients enrolled on the exercise trial. All patients displayed 
symptoms of myopathy, with chronic progressive external opthalmoplegia (CPEO) and either 
ptosis or exercise intolerance. The age range at the time of intervention was 31-58, and age 
of onset varied from 9 to 37. SVT = supraventricular tachycardia 
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3.4 Methods Optimisation and Results 
3.4.1 Sample Isolation 
Many studies examining sporadically occurring mtDNA mutations in patients have 
investigated cultured myoblasts from muscle biopsies and found no mutation in these 
cells. They have suggested this may be because the mutations are not present in the 
satellite cells (Fu et al., 1996, Weber et al., 1997). However, sporadically occurring mtDNA 
mutations are known to be lost or lower in rapidly dividing cells (Moraes et al., 1989a, 
Bonod-Bidaud et al., 1999) and it was necessary to ensure that there would be no 
selection occurring in the cells used for this study. Any period of selection acting on the 
myoblasts prevents inferences about the mutational status of the satellite cells. It was 
decided to obtain satellite cells through FACS sorting on the basis of CD56, a marker of 
these stem cells. 
Patients underwent a biopsy of the vastus lateralis to obtain a muscle sample. This is one 
of the muscles in the quadriceps group, and is being exercised during the trial. The sample 
was then placed in a Medicon and a Medimachine to dissociate the cells, as described in 
chapter 2. The cell solution was passed through a filter to remove any residual muscle 
fibres and the cells counted on an automated cell counter (Figure 3.2). 
Depending on the number of cells obtained, between 10-20µl of human PE labelled CD56 
IgG1 antibody was added to the solution. This antibody recognises the neural cell 
adhesion molecule (NCam) on the surface of satellite cells. The sample was then sorted 
into CD56 positive (CD56+) and CD56 negative (CD56-) fractions using the FACS Aria 
machine. The sorting of the sample with the FACS Aria was performed by Ian Dimmick of 
the North East Stem Cell Institute (NESCI). Two samples were passed through the 
machine, one with the antibody added, and one without; it was then possible to 
determine the fluorescent cell population we wanted to isolate (Figure 3.3). 
First a gate was drawn to discard any particularly large or small cells as these were 
thought to be debris (Figure 3.3A&G). Then the samples were gated allowing only single 
cells to flow through the machine. This reduces contamination as it stops the collection of 
non-fluorescent cells that are stuck to fluorescent cells, and is carried out on the basis of 
side scatter (SSC) which is a measurement of granularity (Figure 3.3 B&H). From the 
singlets it was possible to gate out any DAPI positive cells (Figure 3.3 C&I), which 
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correspond to dead cells. Dead cells will have permeabilised membranes which will take 
up the DAPI. This was performed to aid culturing of the cells after the sort. Then from the 
remaining cells the highly fluorescing ones (Figure 3.3D) were selected as our CD56+ 
fraction. 
As can be seen from the gate areas of the collected CD56+ and CD56- cells (Figure 3.3 
F&L), even without the antibody a few auto-fluorescing cells are visible. This will mean 
that a few CD56- cells will have been collected in the CD56+ fraction. However, the vast 
majority of the cells collected were CD56+. 
While all patients were originally due to undergo three biopsies, this has not been 
possible in all cases. Patients 1 and 4 dropped out of the trial before the final biopsy. The 
sample obtained from patient 8’s first biopsy was not sufficient to undergo FACS sorting, 
and patients 6, 7, and 8 will undergo further biopsies in the coming year. In addition there 
was not always enough of the sample to provide muscle for the Newcastle MRC Centre 
for Neuromuscular Disease Biobank, and consequently myoblasts have not always been 
available. The muscle sample sizes varied between patients, as did the number of cells 
isolated (range 0.025x106 to 27.98x106), and the numbers of CD56+ cells obtained (range 
1251 to 36136) (Table 3.2). 
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Figure 3.2 Image of cells dissociated using a Medicon and Medimachine. After dissociation the 
cells were counted on a Beckman Coulter Cell Viability Analyser, which captures up to fifty images 
of the cells. This image shows isolated cells (arrow heads), demonstrating the ability of the Medicon 
to give a well dissociated sample. The average diameter of the cells ranged from 3.4 to 7.99 microns 
with an average of 5.8 ± 1.05 microns. 
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Figure 3.3 FACS sorting of CD56+ and CD56- cells. A-F with CD56, G-L with no CD56. A &G Whole cell populations with cells at the extreme end of the scales 
gated out. B & H Only cells passing through the detector as singlets were collected. C & I Dead cells were excluded on the basis of DAPI uptake. D & J 
Fluorescence levels (horizontal axis) of remaining cells, with D showing a clear highly fluorescing population of cells. E & K Separation of cells collected in 
terms of fluorescence level, the blue fraction is what was collected as CD56+. F & L Positioning of the gates to collect CD56+ and CD56- cells. While a clear 
distinction between the stained and unstained populations can be observed, some auto fluorescing cells will have been collected in the CD56+ sample. SSC 
Side scatter (an indicator of granularity), FSC Forward scatter (an indicator of size), 4-488/585/42A Laser excitation and antibody fluorescing wavelengths, 
gives an indication of level of fluorescence, the further along the axis the higher the fluorescent signal. 
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Table 3.2 Numbers of cells isolated and numbers of CD56+ cells acquired. Cells 
were dissociated and sorted on the FACS Aria at the NESCI Core FACS Facility at 
the Newcastle Centre for Life. Numbers of cells dissociated and collected varied 
from patient to patient and biopsy to biopsy. 
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3.4.2 Characterising CD56+ Cells 
While antibodies recognising the NCam antigen have been used many times in 
immunohistochemistry (Mackey et al., 2007, Charifi et al., 2003, Crameri et al., 2004, 
Murphy et al., 2008) and in FACS sorting to isolate satellite cells (Webster et al., 1988, 
McKay et al., 2010), it was decided to try and characterise the CD56+ cells further. 
Historically, satellite cells have been defined by their anatomical position on the 
periphery of the muscle fibre, however, there is ongoing debate regarding which of these 
cells are the “true” muscle precursor cells (Biressi and Rando, 2010). It has been 
demonstrated that fibre type renewal is mediated by heterogeneous fast or slow/fast 
type satellite cells through the expression of myosin heavy chain (MHC) (Feldman and 
Stockdale, 1991). Quiescent satellite cells are heterogeneous on the basis of m-cadherin 
(Cornelison and Wold, 1997), CD34, and Myf5 (Beauchamp et al., 2000), and when 
activated they display different patterns of Myf5, MyoD, and Pax7 (Cooper et al., 1999, 
Zammit et al., 2004). A recent study by Kuang et al. (2007) demonstrated that quiescent 
satellite cells were heterogeneous on the basis of Pax7/Myf5, and that the pattern of 
expression determined the expression of these factors in later stages of development. 
The eventual fate of these cells (myogenesis or self-renewal) was dependent on the cell’s 
orientation under the basal laminar (Kuang et al., 2007). 
3.4.2.1 Growing CD56+ Cells 
One way to show these cells are myogenic is to grow them in cell culture. During the FACS 
sort some of the cells were sorted directly into a twenty four well plate containing 
skeletal muscle cell media (SKCM). Dead cells were gated out of the CD56+ fraction using 
DAPI (Figure 3.3C). After sorting, the plates were placed in the incubator at 37oC, with 5% 
CO2, and the media changed every two days. After the first attempt no myoblasts were 
visible on the bottom of the wells after a period of ten days. 
 It was thought this may be attributable to a lack of growth factors in the medium, so it 
was decided to use conditioned medium. In order to obtain conditioned medium control 
myoblasts were grown in SKCM for two days, after which the medium was removed, 
filtered through a 0.2µm filter and stored at 4oC until required. Again, CD56+ cells were 
FACS sorted into conditioned medium in a twenty four well plate. This approach was 
combined with attempts varying the numbers of cells sorted into each well, using ninety 
six well plates, and coating the bottom of the wells with BD BioCoatTMMatrigelTM (Becton 
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Dickinson), to both adhere the cells to the bottom of the well, and provide extra growth 
factors. However, to date it has not been possible to culture CD56+ cells. 
3.4.2.2 Immunohistochemistry 
It was decided to try and stain CD56+ cells for Pax7, a marker of satellite cells, to give a 
better indication of the characteristics of the cells collected. Pax7 marks a population of 
activated and proliferating cells, although again with heterogeneous expression (Olguin 
and Olwin, 2004). It is an early marker of proliferating cells, but becomes down regulated 
as the cells develop (Zammit et al., 2006). 
When muscle biopsies were FACS sorted, the CD56+ cells were collected in 1.5ml 
microcentrifuge tubes in a small amount of FACS Flow solution. The first step in the 
immunohistochemistry protocol was to adhere enough cells to a slide in order to perform 
staining. This was done using a cytocentrifuge. A coated cytoslide was placed on a filter 
card containing a single hole and placed in a cytoclip. The cell sample in approximately 
200µl of FACS flow liquid was pipetted into a cytofunnel, which was attached to the 
cytoclip with the opening of the funnel placed in the hole of the filter card next to the 
slide (Figure 3.4). The cytoclip was then loaded into the cytorotor, and placed in the 
cytocentrifuge. The samples were spun at 800rpm for ten minutes. The slides were left to 
air dry for at least one hour, to allow any excess liquid to evaporate. When the cells were 
put through an immunohistochemistry protocol and mounted with DAPI Vecta-shield, 
many cells were visible. However, when this was repeated with a CD56+ fraction no Pax7 
nuclei could be observed (Figure 3.5A). 
Attempts to permeabilise the cell membranes using 1% sodium citrate, with 0.1% triton 
for two minutes over ice, and fixing the cells in ice cold 100% methanol instead of PFA 
also did not yield any Pax7 positive cells (Figure 3.5B). 
In order to check if there were problems with the antibody, a muscle section was stained 
for Pax7 using both chromagens and fluorescence. While Pax7 worked well with a 
secondary antibody, ABC, and DAB (Figure 3.5C), it was not possible to see anything on 
the section that had been stained fluorescently (Figure 3.5D), suggesting it was something 
specific about the fluorescent protocol that was not working. 
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Figure 3.4 Set up of a cytospin slide. FACS sorted CD56+ cells in a small amount of liquid were 
placed in a cytofunnel in close proximity to a cytoslide, and then loaded onto a cytoclip and 
cytorotor. They were then placed in the cytocentrifuge and spun for ten minutes. The cells come 
out of solution and adhere to the slide, with excess liquid being absorbed by the filter card. 
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Figure 3.5 Images of cytospun FACS sorted cells. A. Cytospin of CD56+ onto slides resulted in many 
cells adhering; however, these cells did not stain for Pax7. B. Permeabilising the cells and fixing in 
methanol did not result in any Pax7 positive cells. C. When used with a secondary antibody and DAB 
on a muscle section Pax7 positive cells could be seen. D. But not when used on a muscle section with a 
fluorescence protocol and FITC. Blue = DAPI, Green = FITC. 
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3.4.2.3 Western Blot 
It was decided to see if any Pax7 protein could be detected by Western blot. It was 
assumed that large amounts of cells would be required to attain enough protein, so 
muscle samples were obtained from orthopaedic surgery patients undergoing operations 
to repair their anterior cruciate ligament (ACL). This resulted in 28324 CD56+ cells and 
69836 CD56- cells. These were then lysed and a Bradford assay used to determine protein 
concentrations. Despite the large numbers of cells used it was still not possible to obtain 
enough protein from either the positive or negative populations of cells to progress with 
the protocol. 
3.4.2.4 FACS Analysis of CD56+ Cells 
Recent attempts to characterise these CD56+ cells have involved fluorescently activated 
cell analysis. It could be possible to show that the CD56+ cells are also positive for Pax7. 
Due to the nuclear expression of Pax7 a permeabilisation step is required in addition to 
conjugating the antibody to a flurophor. In order to permeabilise the cells the Fix & Perm 
kit® (Invitrogen) was used, with Pax7, and Donkey IgG (BD Systems) as a secondary 
antibody. A control sample with no Pax7 and just secondary antibody was also analysed. 
With the Pax7 antibody many highly fluorescing cells were visible (Figure 3.6A). However 
there were also many fluorescing cells in the same region (Figure 3.6B) which would make 
it difficult to distinguish a true Pax7 population. Due to lack of muscle samples it has not 
been possible to optimise this method further. 
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Figure 3.6 FACS analysis of Pax7 expression. A. A muscle sample was 
dissociated, fixed, permeabilised, stained with Pax7, and had a fluorescing 
secondary antibody applied, many cells stained with Pax7. These are visible in 
the top right corner marked P2. B. When a sample of cells with only the 
secondary antibody was analysed there appeared to be fluorescing cells. These 
are visible in the bottom right corner. While there are not as many as the 
sample with the primary antibody added, they are still a considerable number. 
These will be fluorescing because of auto-fluorescence or non-specific binding 
of the secondary antibody. The vertical axis denotes numbers of cells and the 
horizontal axis is fluorescence. 
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3.4.3 Single Muscle Fibre Culture: Another Method for Isolating Satellite Cells 
Another way of collecting human satellite cells has been described which involves the 
isolation of single muscle fibres (Bonavaud et al., 2002). This paper described the use of 
samples obtained from the gluteus maximus, intercostal, and abdominal muscles after 
orthopaedic surgeries and post-mortems. A few days after isolating single fibres from 
these muscle samples, and plating in cell culture conditions, cells could be observed to 
migrate away from the fibre to proliferate. While this method strictly describes a method 
for collecting myoblasts and not satellite cells it was thought it may be useful to collect 
myoblasts very early on during the developmental process. 
A method adapted from D. Rosenblatt (Rosenblatt et al., 1995) was used for the isolation. 
Briefly, a needle muscle biopsy was obtained from a patient who had been referred to the 
Newcastle Mitochondrial Diagnostic Service. The sample was digested using collagenase 
for thirty minutes; single fibres were then detached from the muscle by gentle titration 
with wide-mouthed pipettes. The individual fibres were serially transferred through three 
Petri dishes containing DMEM for washing. They were then plated on a drop of 
MatrigelTM in a twenty four well plate with SKCM, and incubated at 37oC, 5% CO2. 
After a few days, while the fibres had adhered to the MatrigelTM many appeared dark and 
truncated, and no migrating cells were visible. It is probable that the biopsy method will 
have cut many of the fibres. When performing this technique it is important to get the 
whole fibre to avoid them hyper-contracting, it is possible this is what happened. In order 
to get the technique to work, larger samples should probably be used, possibly sourced 
from open biopsies. 
This method is advantageous in that it allows for the isolation of truly myogenic cells, the 
separation of myoblasts derived from specific muscle fibre types, and the ability to get 
cultures free from fibroblasts. However, the need for large amounts of muscle and thus 
open biopsies is a disadvantage. 
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3.4.4 D-Loop Sequencing 
After the biopsies were taken the muscle was divided up into three samples: for myoblast 
culture to be performed in the MRC Neuromuscular Biobank, molecular and histological 
analyses in the Newcastle Mitochondrial Diagnostic Service, and for FACS sorting at the 
North East Stem Cell Institute Core Facility. It was decided to sequence the D-loop of the 
samples once they had been brought together for this research project in order to ensure 
the identity of the different samples from each patient. 
The D-loop, part of the control region, is a section of mtDNA that contains an extra replica 
of the H strand. It is formed when extension of the H strand is arrested (Doda et al., 
1981). It is non-coding and contains the origin of heavy chain replication (OH), and 
promoter elements for both the light and heavy strands. While the D-loop itself is 
conserved between mammals, the nucleotide sequence and size of the region is not. 
The D-loop contains hypervariable regions and many polymorphisms. These are probably 
created due to the structure of the region, and persist due to the non-coding nature of 
the area. The variable nature of this region has led to the D-loop sequence being utilised 
in many fields of research, from authenticating remains of Tsar Nicholas of Russia, his 
wife and children (Ivanov et al., 1996), to determining the variability and origins of Sada 
goats in the Mediterranean area (Vacca et al., 2010). 
The D-loop was therefore thought a good region to use in order to confirm the identity of 
samples. The D-loop region of skeletal muscle homogenate DNA, FACS sorted CD56+ cells, 
and cultured myoblasts, was amplified using primers corresponding to regions D1 
(Forward nt.15758-nt.15777, Reverse nt.019-nt.001), D2 (Forward nt.16223-nt.16244, 
Reverse nt.129-nt.110), D3 (Forward nt.16548-nt.16569, Reverse nt.389-nt.370), and D4 
(Forward nt.323-nt.343, Reverse nt.771-nt.752) (Table 2.1). The products were then run 
on the ABI sequencer and analysed with SeqScape software. They were compared to the 
Cambridge Reference Sequence (CRS) (Anderson et al., 1981), and any differences 
recorded. Sequences are shown in the following tables, patients 1, 2, and 3 (Figure 3.7), 4 
and 5 (Figure 3.8), 6 (Figure 3.9), 7 and 8 (Figure 3.10). 
All of the patients contained polymorphisms in their D-loop, mainly in the D1, D2, and D3 
regions. Patients 2, 4, and 6 contained many differences, while 1, 3, 5, 7, and 8 contained 
fewer. 
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Figure 3.7 Differences from the Cambridge Reference Sequence (CRS). Patients 1, 2, and 3, had their D-loop sequenced and compared to the CRS. 
D1-4 refers to the region of the D-loop. Position & CRS refers to the nucleotide position in the mtDNA and the base pair that is present in the CRS. X 
denotes areas that did not sequence and the base pair is not known, C In = C insertion. 
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Figure 3.8 Differences from the Cambridge Reference Sequence (CRS). Patients 4 and 5 had their D-loop sequenced and compared to the CRS. 
D1-4 refers to the region of the D-loop. Position & CRS refers to the nucleotide position in the mtDNA and the base pair that is present in the CRS. 
X denotes areas that did not sequence and the base pair is not known, C In = C insertion. 
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Figure 3.9 Differences from the Cambridge Reference Sequence (CRS). Patient 6 had his D-loop sequenced and compared to the CRS. D1-4 refers to the 
region of the D-loop. Position & CRS refers to the nucleotide position in the mtDNA and the base pair that is present in the CRS. X denotes areas that did not 
sequence and the base pair is not known. C In = C insertion. 
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Figure 3.10 Differences from the Cambridge Reference Sequence (CRS). Patients 7 and 8 had their D-loop sequenced and 
compared to the CRS. D1-4 refers to the region of the D-loop. Position & CRS refers to the nucleotide position in the 
mtDNA and the base pair that is present in the CRS. X denotes areas that did not sequence and the base pair is not known, 
C In = C insertion. 
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3.4.5 MtDNA Deletion Break Point Analysis 
As will be discussed in chapter 4, it was necessary to have the break points for the 
patient’s mtDNA deletions in order to create qPCR protocols to determine mtDNA 
heteroplasmy levels. While many of the mtDNA deletion break points had been 
determined by other members of our lab, patient 1 had not been characterised.  
In order to do this, a sample of the patient’s muscle homogenate DNA was amplified with 
two sets of primer pairs 15F and 29R (Forward nt.7272-nt.7293, Reverse nt.14374-
nt.14356), 16F and 30R (Forward nt.7713-nt.7723, Reverse nt.14857-nt.14838) (Table 2.1) 
using a long range PCR. These primer pairs would normally result in fragment sizes of 
7063bp and 7115bp respectively. However, if a deletion is present in the mtDNA of these 
regions it would remove some of the base pairs, and smaller fragments would be 
generated. After running the PCR product on a 0.7% agarose gel at 50V for two hours 
along with a 1Kb ladder (Invitrogen) bands corresponding to fragment sizes of 3900bp 
(15F, 29R) and 3950bp (16F, 30R) were observed (Figure 3.11A). Given the fragment sizes 
that would have been generated with WT DNA (7063bp and 7115bp); this suggested the 
patient harboured an mtDNA deletion of approximately 3160bp. 
The entire PCR sample was then run on an agarose gel. The mtDNA bands excised, 
purified using the Qiagen Gel Extraction kit, and then run on the ABI 3130xI Sequencer. 
However, this fragment did not sequence, probably due to its large size, so primer pairs 
generating a smaller fragment were used. Once the primer binding site is inside the 
deletion area it will not bind and thus not elongate, and no PCR product will be 
generated. Using primers 20F and 27R (Forward nt.9607-nt.9627, Reverse nt.13453-
nt.13435) generating a 3808bp fragment, a product was observed of approximately 
600bp (Figure 3.11B). This band was gel extracted and run on the sequencer to determine 
the brake point. A 3693bp mtDNA deletion was observed between nt.9756-nt.13449, 
with a 13bp indirect repeat (5’ repeat CTCCCTTCACCAT, 3’ repeat CTCCCTCACCAT). The 5’ 
repeat was removed by the deletion. 
This breakpoint was added to that of the other patients (Table 3.3) and used to create 
mtDNA deletion specific qPCR. 
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Figure 3.11 Generating a PCR fragment for sequencing analysis. A. A sample of patient muscle 
homogenate mtDNA was amplified using primers 15F & 29R (Lane 1) and 16F & 30R (Lane 2). In WT 
mtDNA these primers would generate fragments of 7063bp and 7115bp respectively. The bands 
observed here correspond to fragments of around 3900bp, which suggests the patient harbours an 
mtDNA deletion of approximately 3160bp. B. A second set of primers was used to amplify smaller 
fragments of around 4000bp. Bands corresponding to fragment sizes of ~600bp were observed with 
primer pairs 20F & 28R (lane 1), and 20F & 27R (Lane 2), again suggesting an mtDNA deletion of 
around 3200bp. However when the primers were stepped in to 20F & 26R (lane 3) and 20F & 25R (lane 
4) no products were visible as the reverse primer was inside the deletion break point. +Lanes 5 & 6 = 
WT DNA with primers 17F&R and 20F & R respectively (giving a 600bp fragment). Lane 7 = Empty, Lane 
8 negative control (20F & 20R). 
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Figure 3.12 Electropherogram of patient 1’s break point. When run on the sequencer, a 
breakpoint at nucleotide 9756 to 13449 was observed. The coloured section defines where the 
software was able to match up the sequence to the CRS, but then the deletion resulted in the 
next sequence being unaligned and therefore in grey. The sequence in grey corresponds to that 
leading up to nucleotide 9756. The break contained an indirect 13bp repeat (Boxed). 
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Table 3.3 Molecular information on mtDNA single deletion patients. All patients 
harboured a large scale single deletion of the mtDNA in the major arc region. 
Three of the patients had the common deletion (CD). Patients 3, 5, and 6 had 
break points determined by the Newcastle Mitochondrial Diagnostic Service, 
patients 2 and 4 by Dr. J. Murphy and patients 7 and 8 by Georgia Campbell. 
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3.5 Discussion and Future Work 
The use of exercise therapy in patients with sporadically occurring mitochondrial 
myopathies is currently being investigated in many labs (Murphy et al., 2008, Jeppesen et 
al., 2009, Jeppesen et al., 2006b, Cejudo et al., 2005, Taivassalo et al., 2001). The theory 
behind the use of resistance training in myopathy patients with sporadically occurring 
mtDNA mutations relies somewhat on the characteristics of muscle satellite cells. It is 
therefore very important that we are able to examine these cells before any changes 
could occur in the population through selection. 
FACS sorting on the basis of CD56 allowed isolation of a cell population that has not been 
examined in these patients before, as previous experiments have focused on myoblasts, 
the cultured progeny of these cells. Further analysis of these cells should provide an 
indication of their mtDNA deletion heteroplasmy levels. In addition FACS sorting allowed 
isolation of cells in sufficient numbers to perform molecular studies characterising mtDNA 
deletion break points and D-loop sequencing. 
While CD56 has been shown to be a proximal marker of commitment to myogenic 
differentiation (Capkovic et al., 2008), the inability to stain the cells with Pax7 was 
disappointing. Though the lack of activity seen in muscle sections using the same 
antibody, suggests this is more of a protocol related issue rather than cell related. 
Characterisation of the cells using FACS analysis shows promise but needs further 
optimisation. 
While FACS sorting has been used to characterise satellite cells in humans (McKay et al., 
2010), many of the studies that have gone on to culture these FACS sorted cells have 
been performed in mice (Montarras et al., 2005, Pallafacchina et al., 2010). Satellite cells 
are extremely reliant on their stem cell niche. FACS sorting cells into medium in order to 
obtain a myoblast culture not only takes them away from growth factors needed to 
maintain the cells, but also away from any factors that may be necessary to activate the 
cells from their quiescent state. In addition, the passage through the FACS machine may 
damage surface markers on the cells making it difficult for them to become established in 
the wells. Further attempts to culture CD56+ cells could use a fibroblast feeder layer. 
Once CD56+ cells were isolated, the DNA was extracted and a number of experiments 
performed on the cells to characterise them. The sequencing of the D-loop of all the 
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samples from the patients allowed their identity to be confirmed when all the samples 
were brought together for this project. 
While all patients exhibited a large scale single deletion of the mtDNA, the size and 
breakpoints of these deletions varied. Three of the patients harboured the common 
deletion while others had deletions ranging from around 3500bp to 8000bp. It was 
therefore highly important to characterise the deletions before any molecular analysis 
could be performed. The breakpoint characterisation allowed for the design of deletion 
specific SYBR Green qPCR assays which are described in chapter 4. In addition it showed 
that all the deletions occurred in the major arc region of the mtDNA, allowing for the use 
of the MTND1/MTND4 qPCR assay (see section 4.3.5). 
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Chapter 4 MtDNA Deletions in Satellite Cells 
4.1 Introduction 
4.1.1 Satellite Cells and Regeneration  
Treatments for patients with mitochondrial myopathies are limited. Resistance exercise 
has long been suggested as a possible intervention for patients harbouring sporadically 
occurring mtDNA mutations (Taivassalo and Haller, 2004). It is proposed that resistance 
training can activate satellite cells which will go on to regenerate muscle, and in the 
presence of heteroplasmy, change the balance of WT to mutated mtDNA (Shoubridge et 
al., 1997). This process has been referred to as “gene shifting”. 
Postnatal muscle growth (hypertrophy) and regeneration is achieved through satellite cell 
activation. In response to stress caused by injury to the fibre, the satellite cells activate 
and re-enter the cell cycle, and in a pathway that demonstrates similarities to muscle 
embryogenesis, repair the damage. 
Quiescent satellite cells sit underneath the basal laminar and on top of the sarcolemma 
on the muscle fibre (Figure 4.1). In their quiescent state they have up-regulated genes 
that encode negative regulators of the cell cycle, including Rgs2 (regulator of G-protein 
signalling2), and Cdkn1c (cyclin-dependent kinase inhibitor 1C). They have up regulated 
myogenic inhibitory molecules, for example Bmp4 (bone morphogenic protein 4), and 
Notch molecules which are negative regulators of MyoD expression. In addition, they 
exclusively express the calcitonin receptor which further inhibits their activation (Fukada 
et al., 2007). 
The activation of satellite cells is probably initiated by a number of factors including 
hepatocyte growth factor/scatter factor (HGF/SF) (Tatsumi et al., 1998), and nitric oxide 
(Anderson et al., 2002). Mechanical stretch has been shown to stimulate both these 
factors (Tatsumi et al., 2006), suggesting a possible mechanism for contraction induced 
injury and satellite cell activation. In addition there may be a role for inflammatory cells 
that flock to the site of injury in order to phagocytose the debris (Ten Broek et al., 2010). 
Following activation, the cells become proliferating myoblasts under the control of Myf5 
and MyoD. During this process some cells become Pax7+MyoD- and return to quiescence 
in order to replenish the stem cell pool. While Pax7+MyoD+ cells become committed to a 
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muscle cell fate through differentiation (Tedesco et al., 2010). This is followed by down 
regulation of Pax7 in the myoblasts and up regulation of the myogenic regulatory factors, 
myogenin and Myf4. These myoblasts then fuse to each other to form myotubes which 
are able to fuse into the damaged fibre to repair it (Figure 1.20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Satellite cells. Satellite cells sit on the periphery of the fibre, in a “satellite” 
position. A. They lie under the basal laminar and on top of the sarcolemma. B. In transverse 
sections they can be seen in between the muscle fibres with Pax 7 staining. Brown= satellite 
cells (DAB), purple = myonuclei (haematoxylin). 
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4.1.2 Rationale for Exercise Training 
4.1.2.1 Early Investigations 
The rationale for resistance training as a potential therapeutic intervention comes from 
early experiments examining patients harbouring sporadically occurring mutations. In 
1996 Fu et al. described a male patient who presented with CPEO, ptosis, pigmentary 
retinopathy, and sensorineural hearing loss. When a muscle biopsy was performed, RRFs 
were present. Molecular analysis showed a sporadically occurring novel point mutation in 
the mt-tRNAleu(CUN) gene, causing a heteroplasmic G to A transition at conserved position 
nt.12315. The mutation was present in the muscle at 94%, but was undetectable in blood 
samples and cultured fibroblasts, suggesting that the mutation had been lost from 
dividing tissue. Interestingly, when the group cultured myoblasts from this patient no 
mtDNA point mutation was detected. It was suggested that the mutation may not be 
present in the patient’s satellite cells. 
They concluded that the mutation had accumulated in the muscle due to its post mitotic 
nature, but had been lost by random genetic drift in mitotic cells, fibroblasts and blood. 
They further suggested that this pattern may be a feature of sporadically occurring 
conditions. It was hypothesised that by activating satellite cells and incorporating them 
into mature muscle, the heteroplasmy level could be favourably changed, therefore 
improving symptoms (Fu et al., 1996). 
This study was followed a year later by another group also reporting a patient with a 
sporadically occurring point mutation (Weber et al., 1997). This patient presented in her 
mid-thirties with joint pains, progressive proximal weakness, and mild ptosis. Biopsy 
analysis demonstrated RRFs, and COX negative fibres. Molecular investigations 
demonstrated an A to G transition at a conserved position (nt.12320), in the mt-
tRNALeu(CUN) gene. The patient had undergone a number of muscle biopsies and harboured 
the mutation at high levels in this tissue. Over a twelve year period her heteroplasmy 
level had risen from 69% to 90%. In agreement with Fu et al. (1996), they also could not 
detect the mutation in fibroblasts or blood. In addition, myoblasts grown from one of the 
biopsies did not harbour the mutation, again raising the possibility that satellite cells 
contain little or no mutation. 
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The previous two papers described no mutation in satellite cells, fibroblasts and blood 
from patients harbouring sporadically occurring mtDNA point mutations. However, other 
papers have reported lower levels of deletions in fibroblasts, myoblasts and blood cells 
from patients with KSS (Moraes et al., 1989a, Moraes et al., 1989b). While deletions often 
occur sporadically (Chinnery et al., 2004) these papers do not state if that was the case 
here. 
These findings opened up the possibility of changing the amount of WT to mutated 
mtDNA in the muscles of patients, in a process termed “gene shifting”. It was suggested 
that this could be performed through the stimulation and incorporation of satellite cells 
that contain none or very little of the disease causing defect. This theory was tested by 
two groups in 1997. 
4.1.2.2 Testing the Hypothesis 
The first group (Clark et al., 1997) described the use of bupivicaine hydrochloride to 
induce muscle necrosis in the left vastus lateralis of their previously described patient 
(Weber et al., 1997), in the hope of “gene shifting”. Bupivicaine disrupts calcium 
homeostasis and perturbs the plasmalemma membrane, eventually leading to fibre 
necrosis. But muscle satellite cells are resistant to this effect. They waited three weeks to 
allow for satellite cell regeneration of the damaged area, and then removed a sample of 
the previously injected muscle. While the pre-intervention muscle biopsy contained 
approximately 75% COX negative fibres, the follow up biopsy not only showed evidence 
of muscle regeneration, but many of these regenerating fibres were COX positive. Single 
fibre PCR analysis showed these regenerating COX positive fibres to have little or no 
mutation. 
This study was followed a few months later (Shoubridge et al., 1997) again by a group 
investigating the effects of instigating muscle regeneration on a previously reported 
patient (Fu et al., 1996). This time muscle necrosis was initiated by a muscle biopsy of the 
right biceps. Three weeks later the same site was biopsied again. In regenerating fibres, 
determined by NCam reactivity, mutant mtDNA was undetectable. It was highlighted 
however, that the assay used to determine mtDNA mutation load had a sensitivity of 
greater than one percent, leaving open the possibility that the mutations persisted at 
levels lower than this. 
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4.1.3 Possibilities for the Absence of Sporadic Mutations 
There are a number of reasons why sporadically occurring mtDNA mutations may not be 
present in satellite cells of affected patients. 
These are sporadically occurring mutations and it is possible that they developed after the 
satellite cells formed. However, the finding of a sporadically occurring mtDNA deletion in 
both brothers of a set of identical twins (Blakely et al., 2004) suggests deletions are 
probably present in the zygote. In addition research has suggested that around 50% of 
oocytes contain mtDNA with the common deletion, with 0.01% to 0.1% of total mtDNA 
examined harbouring this 4977bp deletion (Chen et al., 1995). This suggests the 
mutations did not arise at a later stage of development. 
While the mutations were probably present at the beginning of embryogenesis, it is 
possible that the mutations segregated to the muscle but not the satellite cells. However, 
the common dermomyotome origin of limb skeletal muscle and satellite cells (Gros et al., 
2005), coupled with reports demonstrating that single deletions segregate to many 
tissues during development (Hurko et al., 1990, Marzuki et al., 1997, Brockington et al., 
1995, Pistilli et al., 2003) suggest this is probably not the case. 
The above papers did however report lower amounts of mtDNA deletions in mitotic 
tissue, suggesting that the mutations had originally been present in all tissue but then lost 
from mitotic cells. While satellite cells do have the ability to divide, they are mitotically 
quiescent until activated. It is doubtful that they would have undergone enough divisions 
in the process of repairing muscle and renewing the satellite cell pool to have lost the 
mutation. Although, it is possible that the myopathic nature of mitochondrial disease 
could have resulted in more muscle regeneration in these patients and thus more satellite 
cell divisions. In addition, while we know satellite cells themselves are quiescent, the 
status of mtDNA replication in the cells is not known, so it is possible that some selection 
may be acting at the mtDNA or mitochondrial level. 
An alternative explanation for the absence of mtDNA mutations in myoblasts from 
patients with sporadically occurring mitochondrial diseases could be that the mutations 
were present in the satellite cells but were lost through selection before the harvesting of 
the myoblasts. 
Chapter 4  MtDNA Deletions in Satellite Cells   
127 
  
4.1.4 Inducing Muscle Regeneration 
While experiments demonstrating the feasibility of “gene shifting” were very successful, 
the methods employed to initiate muscle necrosis are not workable in a clinical setting 
due to their invasive nature. For this reason, resistance exercise performed in a way to 
induce muscle hypertrophy has been suggested as an alternative (Shoubridge et al., 
1997). 
Muscle can contract in a number of ways. Concentric muscle contractions are when the 
muscle shortens while active and eccentric contractions involve the muscle lengthening 
while being active (Figure 4.2). For example, during a bicep curl the bicep muscle would 
be contracting concentrically when being raised or brought closer to the shoulder, and 
when being lowered the bicep would be contracting eccentrically  
It has been shown that a single bout of eccentric exercise is sufficient to elicit a significant 
satellite cell response in males (Dreyer et al., 2006, Crameri et al., 2004), although the 
exact mechanism by which this happens is not fully known. It is thought that satellite cells 
may be activated by exercise alone, through ultrastructural damage, the release of 
inflammatory substances or via exercise-induced release of growth factors (Kadi et al., 
2005). 
In healthy subjects, eccentric muscle contractions induce more pain, soreness, 
morphological abnormalities, and sarcomere disruption than concentric contractions 
(Newham et al., 1983). The appearance of serum CK twenty four hours after eccentric 
exercise suggests that there has been a breakdown in the cell membrane surrounding the 
muscle fibre (Friden and Lieber, 2001). It is though this damage will activate satellite cells 
to repair the muscle and hopefully incorporate mitochondria containing WT mtDNA. 
It is possible that damage may not be essential to stimulate a satellite cell response. A 
recent study demonstrated that muscle injury (determined by serum CK) was not 
required to induce hypertrophy in subjects undergoing an eccentric exercise program. 
However, since the study was not conducted alongside muscle biopsies it is difficult to 
ascertain if any micro-damaged occurred in the muscle that would have activated satellite 
cells but not resulted in the release of CK (Flann et al., 2011). The myonuclear domain 
hypothesis suggests that after repeated bouts of resistance training the muscle fibre area 
increases. The up-regulation of myonuclei transcriptional activity can initially compensate 
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for this, but further hypertrophy requires the activation and incorporation of satellite 
cells, which occurs independently of muscle damage (Kadi et al., 2005). 
 
 
 
 
 
 
 
 
 
 
4.1.4.1 Resistance Training in Mitochondrial Myopathies 
One of the earliest studies examining the effects of resistance training in a patient with a 
sporadically occurring mutation, showed a decrease in COX negative muscle fibres and an 
increase in WT mtDNA, in muscle exercised both concentrically and eccentrically 
(Taivassalo et al., 1999). A more recent study involving patients with sporadically 
occurring single mtDNA deletions also found a reduction in COX negative fibres coinciding 
with an increase in COX intermediate fibres. However, there was no significant change in 
muscle heteroplasmy level (Murphy et al., 2008). It may be possible that the protocol 
performed was not of sufficient intensity to elicit enough damage and satellite cell 
incorporation to “gene shift”. 
 
 
Figure 4.2 Muscle contraction. When the bicep muscle lengthens while holding a 
weight it is contracting eccentrically. This type of contraction is more likely to 
damage the muscle fibres. When the bicep shortens while lifting a weight, for 
example during a bicep curl, it is contracting concentrically. 
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4.2 Aims 
Studies suggesting absent or low levels of mutant mtDNA in the muscle stem cells of 
patients harbouring sporadically occurring mtDNA mutations have involved culturing 
satellite cells and then examining their progeny for the genetic defect. This lapse in time 
could allow for a period of selection to act on the cells and for mutated mtDNA to 
disappear completely or reduce to low levels. Studies showing the feasibility of gene 
shifting (Shoubridge et al., 1997, Clark et al., 1997) have also looked at muscle 
characteristics after a period of regeneration, again allowing for selection to act on the 
developing cells. 
The aims of this chapter were to look for mtDNA deletions in the satellite cells of patients 
before any selection could occur. In order to do this a number of mtDNA deletion specific 
SYBR Green qPCR assays were designed and optimised. This chapter describes in detail 
the optimisation of one of these assays and explains the development of two other SYBR 
Green assays. It was hypothesised before starting this work that there would be very little 
or no mutation in the satellite cells of these patients. 
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4.3 Methods Optimisation and Results 
While it would be possible to detect mtDNA deletions using a traditional PCR assay, 
followed by running the products on an agarose gel, this method has limitations. 
Traditional PCR can determine if a product is present or not, it is an end point assay, and 
cannot give any indication of how much product is present. The use of a real time PCR 
(qPCR) method allows for DNA detection during the exponential phase of the PCR 
reaction. The amount of DNA present in this phase of the reaction is proportional to the 
amount of starting DNA. The value obtained for the assay is a cycle threshold (Ct) value, 
which is the point when the fluorescence level crosses a threshold value during the 
exponential amplification of DNA (Figure 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Real time PCR (qPCR). Traditional PCR visualizes DNA at an endpoint, or at 
the plateau phase of amplification, it cannot give an indication as to how much DNA is 
present. Real Time PCR measures fluorescence generated by a fluorescent dye during 
the exponential phase of a PCR reaction. It results in a cycle threshold (Ct) value, 
which is the number of PCR cycles needed before the fluorescence crosses a threshold 
value. 
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4.3.1 SYBR Green Assay 
Due to previous reports suggesting little or no sporadically occurring mtDNA mutation in 
satellite cells (Fu et al., 1996, Weber et al., 1997), it was decided to use an extremely 
sensitive qPCR method. SYBR Green is a fluorescent dye that binds to the minor groove of 
all double-stranded DNA formed during a PCR reaction, for this reason it is extremely 
sensitive. When bound to double stranded DNA the intensity of its fluorescence increases 
(Figure 4.4). As more double stranded products are created the SYBR Green signal will 
increase. Due to its sensitivity, it is possible to detect single mtDNA deletions below 1%. In 
addition it allows for the design of assays specific to each mtDNA deletion. Its sensitivity 
and ability to work at levels below 1% made it an advantageous method to use. However, 
because of its sensitivity the assay requires a well optimised reaction. Two mtDNA 
deletion specific qPCR assays have been designed and optimised for this study and a 
further assay for patient 3 was re-optimised. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 SYBR Green. SYBR Green is a fluorescent dye that binds to double 
stranded DNA. The signal generated is proportional to the amount of DNA 
present in the reaction and can be quantified using qPCR instruments. 
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4.3.2 Patient 3 
Patient 3 had previously been reported in our lab (Blakely et al., 2004). He presented with 
bilateral ptosis, and a mild proximal myopathy. A Southern blot analysis of his muscle 
showed a large scale single deletion of 4115bp between nt.11262 and nt.15375. A SYBR 
Green assay was optimised and revealed the deletion was present at 66% in his muscle 
homogenate. Interestingly his identical twin also had the same deletion but at 0.016%. In 
order to investigate the CD56+cells isolated in chapter 3 from this patient it was decided 
to use the previously optimised SYBR Green assay (Blakely et al., 2004). 
4.3.2.1 Generating Template DNA 
SYBR Green binds to all double stranded DNA, so it was necessary to set up two reactions, 
one to amplify WT mtDNA, and another to amplify delete mtDNA. In order to optimise 
these two reactions template DNA was generated. Two pairs of primers were chosen to 
amplify a 600bp fragment of either WT mtDNA (Forward nt.10958-nt.11004, Reverse 
nt.11605-nt.11586) or mtDNA containing a deletion (Forward nt.10985-nt.11004, Reverse 
nt.15681-nt.15661) (Figure 4.5A & B). The entire PCR sample was run on a 1% agarose gel 
(Figure 4.5C), the bands excised and the PCR products purified using the Qiagen Gel 
Extraction Kit. The amount of DNA in the sample was then determined using the 
NanoDrop® Spectrophotometer. The WT mtDNA was 25.4ng/µl, and the delete mtDNA 
was 10.1ng/µl. 
The template DNA was then serially diluted in dH2O to give dilutions of 1:10, 1:100, up to 
1:10,000. This was done in order to create a standard curve of DNA which could be used 
to optimise the WT and delete mtDNA reactions. 
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Figure 4.5 Generating template DNA. Primer pairs (blue) were chosen to amplify an approximately 
600bp region of either WT (A) or delete (B) mtDNA. This was to generate template mtDNA that could be 
used to optimise the SYBR Green assay. Primers chosen to anneal to regions within the breakpoints (red) 
of the deletion will not amplify delete mtDNA and will therefore give a 600bp fragment of WT mtDNA, 
while primers chosen to anneal to either side of the breakpoint will only amplify deleted mtDNA due to 
the extension time and PCR conditions, resulting in a 600bp fragment that incorporates the mtDNA 
deletion. Green indicates the primers used for the final SYBR Green assay when analysing the patient’s 
samples. These reactions were set up in parallel to amplify WT (A) and delete (B) mtDNA. C. Reaction 
products were run on a 1% agarose gel showing the generated fragments were approximately 600bp. 
The products were then gel extracted and used as template mtDNA on which to optimise the final 
reactions. Lanes 1, 4, and 7, contained primers to amplify delete mtDNA and a sample of patient 3’s 
muscle homogenate. Lane 10 contained primers to amplify WT mtDNA and patient 3’s muscle 
homogenate. Lanes 2, 5, 8 and 11 contained WT control DNA, and lanes 3, 6, and 9 contained water. 
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4.3.2.2 Optimising the Template DNA Reactions 
WT and delete reactions were set up as previously described (Blakely et al., 2004). Two 
master mixes were created, one with primers to amplify delete mtDNA (Forward 
nt.11155-nt.11173, Reverse nt.15384-nt.15366) and one with primers to amplify WT 
mtDNA (Forward nt.11155-nt.11173, Reverse nt.11287-nt.11267) (Figure 4.5A & B), all 
primers were at 125pmol. In addition, the master mix contained MgCl2 optimised to 3mM 
for the WT reaction, and to 4mM for the delete reaction. All experiments were set up in 
25µl volumes in LightCycler® Capillaries (Roche), to which 1µl of sample DNA was added. 
They were performed on a Lightcycler® (Roche) using LightCycler® DNA Master SYBR 
Green I (Roche). The cycling conditions were an initial denaturation step (95oC for 10 
minutes), then forty five cycles of amplification consisting of a denaturation step (95oC for 
10 seconds), annealing phase (64oC for 5 seconds) and extension phase (72oC for 10 
seconds). A fluorescence acquisition step was included at the end of each extension 
phase. The reaction ended with a melt curve analysis of a rise to 95oC, followed by an 
annealing step of 65oC for fifteen seconds, and then a slow increase to 95oC 
(0.1oC/second) with a continuous acquisition of fluorescence levels. 
When performed under these conditions with template DNA the WT reaction produced 
products that were all of very similar Ct values (Table 4.1). The melt curve analysis 
suggested this was because the reaction had resulted in all the Ct values being generated 
because of primer-dimer (Figure 4.6A). The results for the delete mtDNA reaction showed 
a similar pattern. While the first three concentrations of template DNA (1:100, 1:1000, 
and 1:10,000) produced values attributable to products (Table 4.1), the remaining 
dilutions all resulted in primer-dimer (Figure 4.6B). With every ten fold dilution an 
approximately 3.3 Ct value increase would normally be expected. 
It was decided to focus solely on optimising the WT reaction. Further attempts involved 
adjusting the annealing temperature, varying primer and MgCl2 concentrations, and 
adding more sample DNA, but primer-dimer persisted. 
It was decided to move completely away from the cycling conditions used by Blakeley et 
al. (2004), and adjust the conditions to those given by the company supplying the 
LightCycler® DNA Master SYBR Green I (Roche). These were an initial denaturation step 
(95oC for 30 seconds), then forty five cycles of amplification consisting of a denaturation 
step (an increase to 95oC), annealing phase (58oC for 5 seconds) and extension phase 
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(72oC for 5 seconds). But again no products were visible and further attempts varying 
reagent and sample concentrations, and performing temperature gradient checks for 
primer annealing temperatures were unsuccessful. 
At this point it was decided to change the SYBR Green to Platinum®SYBR®Green qPCR 
SuperMix-UDG (Invitrogen). The master mix consisted of Platinum®SYBR®Green qPCR 
SuperMix-UDG (Invitrogen), MgCl2 at 3mM, and primers at 125pmol. The cycling 
conditions were changed back to those of Blakeley et al. (2004), except with the 
annealing temperature set at 58oC. 
An initial attempt looked promising with peaks being observed for both dilutions run, and 
the melt curve showed no primer-dimer (Figure 4.7A). However, both negative samples 
showed small product peaks, suggesting contamination. This run was repeated with fresh 
reagents and fresh primers from stock solutions. This time there was no primer-dimer and 
no contamination (Figure 4.7B). In addition, as can be seen from the Ct values, the 1:10 
and 1:100 dilutions contained large quantities of DNA. From this stage onwards, all 
reagents, dH2O and primers were aliquoted and used fresh each time.  
It was then possible to perform a run with the WT mtDNA dilution series in order to 
construct a concentration graph for the WT reaction. This would give an indication as to 
how efficient the reaction was (Figure 4.8A). The Ct values stretched to above thirty 
which meant the assay was able to detect very low amounts of DNA, and the x value for 
the line was close to 3.3 (3.43) demonstrating a good efficiency. The efficiency of the 
reaction can be determined by the slope of the line of DNA concentration plotted against 
Ct values. It was decided to progress to optimising the reaction for the delete mtDNA. 
The delete mtDNA template DNA was re-diluted down to 1 in 1011. The concentration of 
MgCl2 and primers were as they were for the WT reaction, as were the cycle conditions 
with the annealing temperature at 58oC. These conditions produced a standard curve that 
extended above a Ct of thirty and had an x value (3.46) close to that of the WT (3.43) 
reaction (Figure 4.8B). 
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Table 4.1 Ct values for template DNA optimisation. An initial run attempting to 
optimise WT and delete mtDNA reactions resulted in many of the dilution series 
having similar Ct values, including the negative (NTC) reactions.  
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Figure 4.6 Melt curve analysis. A. The WT reaction resulted in only one 
product peak at around 95
o
C for the 1:100 dilution, although this 
sample contained a large primer-dimer peak at 78
o
C. This suggests that 
the Ct values obtained for the WT reaction were created by the primers 
annealing to each other and not to the sample DNA in the reaction 
mixture. B. A few more product peaks were visible for the delete 
reaction, but again there were primer-dimer peaks. Horizontal axis 
denotes temperature, and shows at what temperature the products 
melted. The horizontal axis denotes fluorescence. 
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Figure 4.7 Melt curves. A change in SYBR Green supplier appeared to have reduced 
problems with primer-dimer. A. A first run showed no primer-dimer for the two 
dilutions tested, but a small amount of contamination in the NTC. B. Fresh reagents 
removed the contaminated NTC and primer-dimer. 
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Figure 4.8 Efficiency curves for WT and delete mtDNA reactions. A. A dilution series of WT mtDNA 
plotted against Ct values gave a good efficiency of 3.4. B. A dilution series of delete mtDNA plotted 
against Ct values also gave an efficiency of 3.4. 
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4.3.2.3 Optimising a Percentage Deletion Curve 
Once the individual reactions had been optimised for WT and delete mtDNA it was 
necessary to create a deletion curve for this patient. By plotting the amount of delete 
mtDNA against Ct values it would be possible to create a graph which could be used to 
determine the heteroplasmy level of a sample by using the Ct value that sample 
generated. 
This patient had previously been shown to harbour the deletion at 66% in his muscle 
homogenate. A sample of his homogenate mtDNA was obtained from the Newcastle 
Mitochondrial Diagnostic Service and serially diluted down from 66% to 0.0066% with WT 
mtDNA to create a percentage deletion curve. These standards were then diluted to 
1:100,000 and WT and delete mtDNA reactions run in parallel. The percentage of delete 
mtDNA in the sample was then plotted against the difference between Ct values for WT 
and delete mtDNA. An equation of a line of best fit for the data was generated. By re-
arranging this equation it was possible to insert Ct values obtained from an unknown 
sample and determine the heteroplasmy level. 
4.3.2.4 Sample Runs 
A sample of CD56+ cells and muscle homogenate DNA from this patient’s first biopsy 
were run with primers and reaction conditions to amplify up WT and delete mtDNA in 
separate reactions. These were set up in duplicate along with deletion standards in order 
to create a percentage deletion curve. Controls for the assay were a sample of this 
patient’s blood (which should not contain a deletion), and a sample of muscle 
homogenate DNA from a patient harbouring the m.3243 A>G mutation. This reaction 
gave a 60% deletion in the CD56+ cells (Figure 4.9). The muscle homogenate sample was 
35%, which is perhaps a bit low given previous work published on this patient (Blakely et 
al., 2004). However, the Ct values for the muscle homogenate sample lay far from the 
range of the standard curve which could account for this discrepancy. Both the blood and 
the WT DNA sample came out as 0%. Repeats of this assay showed some variation but the 
CD56+ cells were averaged out at 51%, and the muscle homogenate at 69%. This assay 
was later performed on the second biopsy samples and the CD56+ cells had a deletion 
level of 69% (Table 4.3). 
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Figure 4.9 Deletion curve and sample runs. Samples of Patient 3’s CD56+, blood, and muscle 
homogenate (SKM) were run alongside deletion standards, WT mtDNA and a NTC. The Ct values for the 
percentage deletion standards were plotted against percentage deletion to construct a curve. The 
equation of the line was generated from the line of best fit. This was re-arranged (x=[Ct(Del-
WT)+2.9149]/(-4.83)) to provide an equation into which the Ct values for the samples could be inserted. 
The CD56+ cells were run in duplicate and averaged out. NTC=no template control. 1
st
 refers to first 
biopsy. 
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4.3.3 Patients 2 & 4 
As previously described in chapter 3, patients 2 and 4 harboured the “common deletion” 
(nt.8469-nt.13447).Therefore it was necessary to develop an mtDNA common deletion 
specific qPCR assay. 
4.3.3.1 Generating Template DNA 
Primers were chosen to amplify both WT (Forward nt.8196-nt.8215, Reverse nt.8740-
nt.8720) and delete (Forward nt.8196-nt.8215, Reverse nt.13859-nt.13839) mtDNA giving 
an approximately 600bp fragment (Figure 4.10). The samples were run on a 1% agarose 
gel, the bands excised and the products purified using the Qiagen Gel Extraction Kit. The 
amount of DNA in the sample was then determined using the NanoDrop® 
Spectrophotometer. The WT mtDNA concentration was 11.7ng/µl, and the delete mtDNA 
concentration was 13.2ng/µl. 
4.3.3.2 Optimising Template DNA 
Primers were designed using Primer3 (v.0.4.0) (Rozen and Skaletsky, 2000), that would 
amplify up an approximately 95bp region, with either WT or delete mtDNA (Figure 4.10). 
WT and delete mtDNA reactions were then optimised for primer and MgCl2 
concentration, and annealing temperature, until the reactions showed similar efficiency. 
Two master mixes were created, one with primers to amplify WT mtDNA (Forward 
nt.8430-nt.8449, Reverse nt.8524-nt.8505), and the other to amplify delete mtDNA 
(Forward nt.8419-nt.8438, Reverse nt.13511-nt.13493). Primers for all reactions were at 
125pmol and the MgCl2 concentration for the WT reaction was 3mM and for the delete 
reaction 4mM. All experiments were set up in 25µl volumes in LightCycler® Capillaries 
(Roche), with 1µl of sample DNA added. They were performed on a Lightcycler® (Roche) 
using Platinum®SYBR®Green qPCR SuperMix-UDG (Invitrogen). The cycling conditions 
were an initial denaturation step (95oC for 10 minutes), forty five cycles of amplification 
(95oC for 10 seconds, 52.3oC for 5 seconds, 72oC for 10 seconds) with an acquisition step 
at the end of each cycle, followed by a melt curve analysis (increase to 95oC, 65oC 15 
seconds, increase to 95oC (0.1oC/second)), with continuous acquisition. 
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4.3.3.3 Percentage Deletion Curve 
MtDNA containing the common deletion at a heteroplasmy level of 75% was obtained 
from the Newcastle Mitochondrial Diagnostic Service, along with a sample of WT DNA 
from a patient harbouring the m.3243A>G mutation. Both samples were diluted in dH2O 
so they were at similar concentrations (WT 33.6ng/µl, Delete 36.6ng/µl). The delete 
mtDNA was then serially diluted down with the WT mtDNA to give a set of deletion 
standards (75%, to 0.0075%). This was diluted to 1:1000 and run at the same time as the 
samples from patients 2 and 4. 
4.3.3.4 Sample Runs 
Samples of CD56+ cells from two biopsies from Patient 2 were run alongside the deletion 
standard curve, along with a sample of WT mtDNA. The two samples of CD56+ cells from 
this patient contained mtDNA deletion levels very similar to each other, with the first 
biopsy CD56+ cells containing 59% heteroplasmy and the second biopsy 57% 
heteroplasmy, the WT DNA was 0% (Table 4.2). A later run showed the muscle 
homogenate sample to be considerably higher at 89%. 
When samples of CD56+ cells from patient 4 were run with this assay the cells from the 
first biopsy contained 48% delete mtDNA and the cells from his second biopsy had a 46% 
heteroplasmy level. The muscle homogenate sample harboured the common deletion at 
37% (Table 4.3). Again the samples of CD56+ cells from the two biopsies were fairly 
similar, with a slight difference between these samples and the muscle homogenate DNA. 
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Figure 4.10 Generating template DNA. Primer pairs (blue) were chosen to amplify an 
approximately 600bp region of either WT mtDNA (A) or delete (B) mtDNA. This was to generate 
template mtDNA which could then be used to optimise the SYBR Green assay involving the 
reaction primers (green). Primers chosen to anneal to regions within the breakpoints (red) of the 
deletion will only amplify WT mtDNA and not mtDNA harbouring a deletion, because the reverse 
primer will have nothing to bind to. Primers chosen to anneal to either side of the breakpoint will 
only amplify deleted mtDNA. This is because the size of fragment between the two primers in WT 
mtDNA will not amplify due to the extension time and PCR conditions not being capable of 
amplifying such a large fragment. 
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Table 4.2 Sample runs. CD56+ cells from patient 2’s first and second biopsy were run alongside a set of 
delete mtDNA standards which were used to generate a curve with an equation for the line of best fit. 
This equation was then re-arranged (x= [Ct (Del-WT) +0.8506]/ (-4.029)), to make X the subject. The 
values for Ct(Del-WT) for the samples were then inserted into the equation in order to determine the 
heteroplasmy level for the cells. WT DNA is from a m.3243A>G patient that does not contain a deletion. 
NTC = No template control. 1
st
 and 2
nd
 refers to first and second biopsies. 
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4.3.4 Patient 5 
This patient had previously been investigated by the Newcastle Mitochondrial Diagnostic 
Service. A Southern blot revealed that he harboured a single deletion at 9% in his muscle 
homogenate. Break point analysis showed it was a 7959bp (nt.7845-nt.15440) deletion. 
Again a SYBR Green assay needed to be designed and optimised to investigate this 
patient. Previous to the start of this optimisation an ABI StepOnePlus Real Time Detection 
System became available for use. It was decided to optimise the assay on this machine as 
it allowed for the use of ninety six well plates, thus enabling the samples to be run in 
triplicate. In addition it contained settings for a VeriFlexTM step which allowed different 
annealing temperatures to be used on the same run, which became important for this 
particular assay. 
4.3.4.1 Generating Template DNA 
Primers were chosen to amplify both WT (Forward nt.7713-nt.7723, Reverse nt.8301-
nt.8283) and delete (Forward nt.7713-nt.7723, Reverse nt.15896-nt.15877) mtDNA giving 
approximately 580bp fragments (Figure 4.11). The samples were run on a 1% agarose gel, 
the bands excised and the products purified using a Qiagen Gel Extraction Kit. The 
amount of DNA in the sample was then determined using the NanoDrop® 
Spectrophotometer. The delete mtDNA concentration was 8.7ng/µl, and the WT mtDNA 
concentration was 14.6ng/µl. The WT and delete mtDNA templates were then diluted in 
dH2O from 1:10 to 1:10
12. 
4.3.4.2 Optimising Template DNA 
Primers were designed using Primer3 (v.0.4.0) that would amplify an approximately 60bp 
region of either WT (Forward nt.7816-nt.7834, Reverse nt.7881-nt.7863) or delete mtDNA 
(Forward nt.7816-nt.7834, Reverse nt.15445-nt.15463) (Figure 4.11). Reactions for WT 
and delete mtDNA were then optimised for primer and MgCl2 concentrations and 
annealing temperature, until the reactions showed similar efficiency. 
The WT master mix contained MgCl2 at 4mM, the forward primer (nt.7816-nt.7834) at 
75pmol and the reverse primer (nt.7881-nt.7863) at 100pmol; the annealing temperature 
was 61oC. The delete mtDNA master mix contained MgCl2 at 3mM, the forward primer 
(nt.7816-nt.7843) at 100pmol, and the reverse primer (nt.15445-nt.15463) at 75pmol; the 
annealing temperature was 56oC. All experiments were carried out in a 25µl volume on an 
ABI StepOnePlus Real Time Detection System using Platinum®SYBR®Green qPCR 
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SuperMix-UDG (Invitrogen). The use of this Real Time machine allowed a VeriFlexTM step 
whereby different regions of the plate could be taken to different temperatures during 
the run. The cycling conditions were an initial denaturation step (95oC for 10 minutes), 
forty cycles of amplification (95oC for 15 seconds, annealing temperature for 1 minute) 
with an acquisition step at the end of each cycle, followed by a melt curve analysis (95oC 
for 15 seconds, 60oC for 1 minute, increase to 95oC 0.3oC/15 seconds), with continuous 
acquisition. 
 
 
 
 
Figure 4.11 Generating template mtDNA. Template primer pairs (blue) were chosen to amplify an 
approximately 580bp region of either WT (A) or delete (B) mtDNA. Primers chosen to anneal to regions 
within the breakpoints (red) of the deletion will not amplify delete mtDNA, while primers chosen to 
anneal to either side of the breakpoint will only amplify deleted mtDNA due to the extension time and 
PCR conditions. For the WT and Delete qPCR reactions primers (green) were used to amplify up a ~60bp 
product. 
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4.3.4.3 Percentage Deletion Curve 
This patient harboured the deletion at 9%, so rather than diluting down a sample of his 
homogenate DNA, the WT and delete mtDNA templates were mixed to provide a deletion 
standard curve. Delete template mtDNA of 100% was diluted down using WT mtDNA to 
give standards at 75%, 50%, 25%, 12.5%, 6%, 3%, and 1.5%. These standards were then 
diluted to 1/1000 and run alongside samples from this patient.  
4.3.4.4 Sample Runs 
When CD56+ cells from this patient were run alongside the deletion curve his cells from 
his first biopsy contained a 0.6% deletion level, and a sample of his muscle homogenate 
had 10%. Later runs of this assay showed his second biopsy cells to have a 1.3% deletion 
level and his third biopsy cells to have 3.6% delete mtDNA (Table 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3 SYBR Green results. Three SYBR Green assays were optimised to 
examine mtDNA deletion levels in samples of CD56+ cells and muscle 
homogenate samples from four patients. Patient 5 had all three biopsy 
samples analyzed using his specific SYBR Green assay while the other three 
patients had two of their biopsies analyzed. SKM = skeletal muscle 
homogenate DNA. 
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4.3.5 MTND1/MTND4 TaqMan® qPCR 
Initially it was hypothesised that the CD56+ cells would contain little or no mtDNA 
deletion. Therefore it was decided to develop SYBR Green qPCRs in order to have 
complete confidence that any deletion, no matter how low the heteroplasmy level, would 
be observed. SYBR Green qPCR results suggested that not only were deletions present 
(Table 4.3), but that they were present at levels that could be determined using a 
TaqMan® qPCR method. 
TaqMan® qPCR assays rely on two principles, Fluorescent Resonance Energy Transfer 
(FRET) and the 5’nuclease activity of the Taq polymerase. FRET occurs when a high energy 
dye (reporter) is in close proximity to a low energy dye (quencher).There is a resultant 
transfer of energy from the high energy molecule to the low energy molecule. Once the 
probe has bound to the DNA, the 5’nuclease activity of the Taq polymerase allows the 
reporter to be cleaved from the quencher during primer extension. Once the reporter has 
separated from the quencher its fluorescence increases (Figure 4.12). 
The MTND1/MTDN4 qPCR assay compares the ratio of the MTND1 and MTND4 regions of 
the mitochondrial genome. Single deletions often occur in the major arc of the mtDNA 
and take out the ND4 gene, but not the ND1 gene. By designing probes that bind to these 
regions it is possible to detect levels of mtDNA deletions, using a ΔCt calculation (He et 
al., 2002). By assigning different fluorescent dyes to the probes it is possible to multiplex 
the assay and improve reliability (Krishnan et al., 2007) (Figure 4.13). The use of probes 
designed for particular regions of the genome means this assay is a great deal more 
specific and consistent than SYBR Green qPCR. However, it is not as sensitive as SYBR 
Green, and cannot accurately detect mtDNA deletions levels below about 30%. 
It was decided to test all the CD56+ samples from our patients using this assay. In 
addition, a sample of the patient’s muscle homogenate DNA from the first biopsy was 
analysed. The samples were run with standards of known deletion levels and a no 
template control (NTC). This assay was not used on patient 5 as his levels were known to 
be below 30%, the threshold for detection. Again, all patients examined had single 
deletions at high levels in their CD56+ cells (Table 4.4). The universal nature of this qPCR 
method allows it to be used for all patients who harbour single mtDNA deletions in the 
major arc, which removes the need for patient specific assays. 
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Figure 4.12 Principles of the TaqMan® probe based assay. This assay uses the 
5’nuclease activity of the Taq polymerase (orange) to cleave the reporter (red) 
fluorescent tag from the quencher (blue) molecule. 
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Figure 4.13 Basis of MTND1/MTND4 assay. Single mtDNA deletions mainly occur in the major arc 
(black line) and often take out the ND4 region of the genome. By designing probes that anneal to 
this region (green star) and the ND1 region (red star) and comparing the amounts of ND1 and ND4 
probe generated fluorescence, it is possible to determine the mtDNA deletion level. 
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Table 4.4 MTND1/MTDN4 results table. CD56+cells and skeletal muscle 
homogenate (SKM) samples were analysed on the MTND1/MTND4 qPCR 
assay. The SKM samples were from the first biopsy the patients underwent, 
before any exercise intervention. 
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4.3.6 Heteroplasmy Levels in CD56+ Cells and Muscle Homogenate Samples 
The MTND1/MTND4 qPCR results were combined with the SYBR Green qPCR results for 
patient 5. All patients examined harboured deletions in their CD56+ cells and in their 
muscle homogenate (Table 4.5). The mean heteroplasmy level was 45.1% ±23.4% for the 
CD56+ cells (n=17), and 48.3% ± 17.6% for the first biopsy muscle homogenate samples 
(n=8) (Figure 4.14A). Both cell types showed a wide standard deviation, partly attributable 
to the results from patient 5. A test of normality in Minitab (Anderson-Darling Test) 
showed the data to be normally distributed. While there was a slightly lower amount of 
delete mtDNA in the CD56+ cells, a 2 sample t-test revealed this was not a significant 
difference (P=0.712). 
4.3.7 Effects of Six Months Resistance Training 
While it was not possible to obtain results for all three biopsies from all eight patients 
enrolled on the exercise trial, the first two biopsies were available from six of the 
patients. These two biopsies were taken before and after six months of resistance 
training. The mean heteroplasmy level for the CD56+ cells before resistance training was 
47.6% ± 26.6%, and after resistance training it was 45% ± 25.1%  (n=6) (Figure 4.14B). 
While there was a slight decrease after resistance training a paired t-test showed this was 
not significant (P=0.290). 
4.3.8 SYBR Green and MTND1/MTND4 qPCR 
Three of the patients had their heteroplasmy levels determined using both a SYBR Green 
qPCR and a TaqMan® qPCR. The mean heteroplasmy level with SYBR Green was 58.6% ± 
15.4% and with TaqMan® 58.5% ± 14.7% (n=9) (Figure 4.14C). The levels of heteroplasmy 
obtained from the SYBR Green assay were not significantly different to those obtained 
with the TaqMan® based assay (paired t-test P=0.984). 
 
 
 
 
 
 
Chapter 4  MtDNA Deletions in Satellite Cells   
154 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5 QPCR results. MTND1/MTND4 qPCR results for all patients were 
combined with the SYBR Green qPCR results from patient 5. When 
compared to the heteroplasmy level in the skeletal muscle homogenate 
there was no significant difference between the amounts of deletion in the 
CD56+ cells and the skeletal muscle. 
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Figure 4.14 Heteroplasmy levels. A. There was a slightly higher level of mtDNA deletion in 
the muscle homogenate samples when compared to the CD56+ cells, but this was not 
significant. B. A slight decrease in delete mtDNA was observed after six months of resistance 
training in the CD56+ cells, again this was not significant. C. There was no difference 
observed in heteroplasmy levels obtained with SYBR Green qPCR and TaqMan®
 
qPCR. Lines 
indicate standard deviation. 
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4.3.9 Long Range PCR 
MtDNA deletions have been shown to be present in the CD56+ cells of patients 
harbouring sporadically occurring mutations using two different qPCR methods. In order 
to confirm this finding it was decided to use a non-qPCR method to demonstrate the 
mtDNA deletion. Consequently, a long range PCR was performed. A traditional PCR is able 
to generate a fragment of up to 1kbp, while long range PCR is able to amplify a much 
larger region. If a band is visible on the agarose gel that is shorter than the fragment that 
would be generated with the primers and Wt DNA, then it suggests that some of the DNA 
is missing and the mtDNA harbours a deletion. 
CD56+ cells from patient 1 were amplified with primers (Forward nt.6863-nt.6882, 
Reverse nt.14857-nt.14838) designed to generate a 7956bp fragment. PCR products were 
diluted 1:50 and 1:100, before undergoing a second round of amplification with primers 
(Forward nt.7272-nt.7293 and Reverse nt.14374-nt.14356) to give a 7063bp fragment 
(Figure 4.15A). Bands could be observed corresponding to a fragment of ~3500bp 
indicating a deletion size of 3563bp, which closely matches the deletion size for this 
patient of 3693bp. 
CD56+ cells from patient 6 were amplified with primers (Forward nt.5855-nt.5875, 
Reverse nt.129-nt.110) designed to generate a 10774bp fragment. PCR products were 
diluted to 1:50, 1:100, and 1:150, and underwent a second round of long range PCR with 
primers (Forward nt.6863-nt.6882, Reverse nt.1589-nt.15877) designed to amplify an 
8995bp fragment. Bands could be observed at 1000bp (Figure 4.15), which corresponds 
to an approximately 7995bp deletion which closely matches this patient’s deletion size of 
8039bp. 
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Figure 4.15 Second round long range gels showing mtDNA deletions in CD56+ cells. A. Patient 
1’s CD56+ cells underwent two rounds of long range PCR. Lanes 1 and 2 are CD56+ cells with 
primers designed to generate a 7063bp fragment. Bands can be observed at 3500bp suggesting a 
~3563bp deletion. Lane 3 is WT mtDNA and therefore a band can be observed at ~7000bp. Lane 1 
was diluted 1:50 and lane 2 was diluted 1:100 before this second round of long range PCR. B. 
Patient 6’s CD56+ cells underwent two rounds of long range PCR. Lanes 1-4 have primers 
designed to generate a 8995bp fragment, bands have been generated corresponding to a 1000bp 
fragment, suggesting this patient harbours a mtDNA deletion of ~7995bp. Lane 1 is a sample of 
this patient’s muscle homogenate DNA diluted 1:200, while lanes 2-4 are CD56+ cells diluted 1:50, 
1:100, and 1:150 respectively, before undergoing the second round of amplification. 
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4.4 Discussion 
The aim of this chapter was to develop mutation specific SYBR Green qPCR assays to look 
for mtDNA deletions in CD56+ cells from patients harbouring a sporadically occurring 
single mtDNA deletion. It was hypothesised before this research that there would be little 
or no mutation in these cells and an extremely sensitive qPCR method was therefore 
employed to investigate this theory. Two mtDNA deletion specific SYBR Green qPCR 
assays were designed and optimised, and a further assay was re-optimised for this 
research.  
MtDNA deletions have been demonstrated in the satellite cells of patients harbouring 
sporadically occurring single mtDNA mutations. This has been carried out using two qPCR 
methods; mtDNA deletion specific SYBR Green assays and a TaqMan® based assay. In 
addition, for patients 1 and 6, long range PCR gels revealed bands corresponding to the 
presence of a single deletion of the size previously determined (Table 3.3). The levels of 
mtDNA deletions in the CD56+ cells did not differ from those present in the skeletal 
muscle homogenate samples. The similar levels in CD56+ cells and muscle homogenate 
samples further suggests that there is not a sub population of cells in the CD56+ fraction 
that contains only WT mtDNA. If there was a more “stem cell like” sub population in the 
CD56+ fraction that had no mutation, then the heteroplasmy level of the CD56+ cells 
would be much lower than the homogenate sample. 
These findings were somewhat surprising given previous investigations demonstrating the 
lack of mutations in myoblasts of patients with sporadically occurring mutations (Fu et al., 
1996, Weber et al., 1997). In addition, mtDNA deletions have been reported to be absent 
from patients with CPEO in dividing cells, for example blood, fibroblasts (Moraes et al., 
1989a), oral mucosa (Bau and Zierz, 2005), and bone marrow (Marzuki et al., 1997). While 
CPEO can be multi-systemic, this is not the norm and it may be that the segregation 
observed in CPEO is responsible for its milder phenotype (Bau and Zierz, 2005). 
However, this is not the case in patients with KSS caused by sporadically occurring single 
mtDNA deletions. KSS is a multi-system disorder where clinical features often present 
before the age of twenty and can include pigmentary retinopathy, cerebella ataxia, 
proximal myopathy and cardiomyopathy (Pistilli et al., 2003). In contrast to CPEO, mtDNA 
single deletions have been reported to be present in dividing cells for example myoblasts 
(Collombert et al., 1997, Bonod-Bidaud et al., 1999), fibroblasts (Larsson et al., 1990) and 
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leukocytes (Moraes et al., 1989a). However, these levels are lower than those observed in 
skeletal muscle. While none of the patients examined in this study demonstrated a KSS 
phenotype, it could be hypothesised that KSS patients would also be expected to harbour 
mtDNA deletions in their satellite cells if they were examined. 
4.4.1 Sporadically Occurring MtDNA Deletions in Satellite Cells 
While these findings were unanticipated, a closer examination of the nature of satellite 
cells suggests they may not be all that unexpected. 
The presence of a mtDNA deletion in both brothers of a set of identical twins (Blakely et 
al., 2004), and the presence of mtDNA deletions in oocytes suggests that the sporadic 
mutation arises early in development (Chen et al., 1995). Possibly in the oocytes of the 
grandmother, followed by segregation into the oocytes of the mother of the affected 
individual (Chinnery et al., 2004). Interestingly, a recent report suggests that the 
occurrence of sporadic mtDNA deletions in the grandmothers is not attributable to age 
(Elson et al., 2010). 
Given that the mutation will have been present during embryogenesis and that satellite 
cells and skeletal muscle have the same embryological origins (Gros et al., 2005), it is 
probable that the mutation will have segregated to the satellite cells in the same way that 
it segregated to the muscle. 
The presence of mutations at levels similar to the muscle homogenate are intriguing given 
the assumption that clonal expansion has occurred in the post mitotic muscle fibres. 
Satellite cells are quiescent, so at what point has clonal expansion acted upon these cells? 
The mutation has either been laid down at that level during embryogenesis, or has 
clonally expanded during a very short period of time within the cells while they have been 
repairing the muscle. While it would initially seem unlikely that the cells have undergone 
enough divisions for clonal expansion to occur, the low mtDNA copy number in these cells 
(see section 6.4.1) could mean that clonal expansion requires fewer divisions in which to 
take place. It is also possible that the mutation was laid down at similar levels in both the 
satellite cells and muscle cells. A small increase in the mutation level in muscle fibres 
could have resulted in the muscle cells passing the threshold level. 
These experiments have been performed on muscle homogenate samples; they do not 
take into account differences that could exist between individual cells. For example, at 
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birth the mutation may be present at 50% in the muscle homogenate, clonal expansion 
could result in some muscle cells increasing above this level and some cells decreasing, 
but a heteroplasmy level of 50% would still be maintained. 
Satellite cells are quiescent until they activate, and while it is currently not known if there 
is any mtDNA turnover in quiescent satellite cells there has obviously not been enough to 
allow an opportunity for negative selection. While it is probable that these satellite cells 
will have been activated at some point in order to repair muscle before returning to 
quiescence, again this will not have occurred enough times to allow for selection. 
While previous reports suggesting sporadic mutations are not present in the satellite cells 
of patients harbouring mtDNA mutations, may have been somewhat premature (Fu et al., 
1996, Weber et al., 1997, Clark et al., 1997, Shoubridge et al., 1997), the experimental 
results they obtained can still be explained in light of the current findings. 
4.4.2 Explanation of Previous Findings 
The original papers (Weber et al., 1997, Fu et al., 1996) based their hypothesis on what 
they found in cultured myoblasts; this would have allowed for a period of selection to act 
on the cells. Papers testing the theory of “gene shifting” (Shoubridge et al., 1997, Clark et 
al., 1997) examined regenerated muscle fibres, again allowing for selection to occur 
during muscle regeneration. 
During the process of myoblast culture or muscle regeneration the mtDNA deletions 
could have been lost. An mtDNA deletion would be deleterious at both the mitochondrial 
and the cellular level and could therefore affect the ability of the myoblasts to proliferate. 
After cell division if there was segregation of WT and delete mtDNA into daughter cells, 
any cells that inherited large amounts of delete mtDNA may die. 
In addition it has been shown that clonal cultures of both fibroblasts and myoblasts 
containing mtDNA deletions may grow slower (Moraes et al., 1989b). It is possible that 
this occurred in these instances and resulted in very diluted samples of delete mtDNA. 
Furthermore, it is possible that satellite cells containing mutations may not activate. After 
activation there is a period of intense up-regulation of transcription and replication within 
satellite cells. Cells with impaired OXPHOS may not be able to survive this process. 
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It will be necessary to investigate the myoblasts of these patients to determine what 
happened to these mutations as the satellite cells started to proliferate and differentiate 
into myotubes. 
4.4.3 Stem Cells and MtDNA Mutations 
Other investigations examining mtDNA mutations in stem cells have mainly focused on 
colon tissue and blood stem cells. 
Howell et al. (2000) examined levels of the m.3460A>G LHON mutation in blood samples 
from a family with the disease and saw a decrease of approximately 1% per year (over 5-6 
years) in the mutation. The levels of a silent polymorphism did not change. They 
hypothesised this decrease was attributable to the presence of homoplasmic mutant and 
homoplasmic WT blood stem cells. They suggested the homoplasmic mutant stem cells 
may produce fewer white blood cells and platelets over time, or that the stem cells may 
be heteroplasmic and selection acted to favour proliferation of mitochondria with lower 
levels of mutations (Howell et al., 2000). Computer simulations have demonstrated the 
loss of the m.3243A>G mutation in blood may also be caused by selection at the stem cell 
level (Rajasimha et al., 2008). 
MtDNA point mutations have been reported in the stem cells of colonic crypts, (Taylor et 
al., 2003, Greaves et al., 2010a), although not from patients presenting with a 
mitochondrial disease. In contrast to blood, these mutations were maintained in the stem 
cell population, and the developing cells. This could be attributable to the position of the 
colonic crypt stem cell in a tight niche not allowing for selection. 
4.4.4 Effects of Six Months Resistance Training 
Six months of resistance training had no effect on the levels of mtDNA mutations in the 
satellite cells of these patients. Due to the high intensity of the resistance training being 
performed it is reasonable to expect that there will have been some regeneration 
occurring in the muscle. This will have involved activation of satellite cells and the 
renewal of the stem cell pool. The absence of any change in heteroplasmy level suggests 
that the degree of damage induced was not sufficient to induce enough satellite cell 
divisions and renewal to allow for the loss of the mutation. 
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4.4.5 SYBR Green and TaqMan® qPCR 
While initial attempts to optimise a SYBR Green assay for patient 3 were frustrating, 
changing the supplier of the reagent was an advantageous step. Both reagents contained 
Taq DNA Polymerase, dNTP mix (with dUTP instead of dTTP), SYBR Green I dye, MgCl2 and 
a reaction buffer (contents not stated). It can only be assumed these two reagents 
differed in their reaction buffers or the concentration of contents. This would account for 
the highly varied results with the two reagents. 
Two qPCR methods have been used to quantify mtDNA deletions in muscle stem cells and 
muscle homogenate samples from patients. Once it was realised that deletions were 
present in enough quantities to quantify with the MTND1/MTND4 assay, the samples 
were re-analysed using this technique. 
SYBR Green has been used to quantify both mtDNA point mutations (Bai et al., 2004) and 
deletions (Blakely et al., 2004, Fuke et al., 2008). The results obtained using the SYBR 
Green and TaqMan® assays were not significantly different from each other. This is in 
agreement with other studies examining mtDNA deletions in brain tissue, where results 
obtained with the two techniques showed minimal differences (Sabunciyan et al., 2007). 
While the TaqMan® based assays are more consistent and specific for deletions, the 
ability to use SYBR Green on small DNA concentrations and to quantify low level mtDNA 
deletions does make it valuable in these situations. If the levels of mtDNA deletions are 
above 30%, the ability to multiplex the MTND1/MTND4 qPCR allows for more samples 
and runs in triplicate. Coupled with the ability to compare results between runs, this does 
make the MTND1/MTND4 qPCR technique superior. 
 
 
 
 
 
 
Chapter 4  MtDNA Deletions in Satellite Cells   
163 
  
4.5 Conclusions  
MtDNA deletions are present in the satellite cells of patients harbouring sporadically 
occurring large scale single mtDNA deletions, at levels comparable to muscle homogenate 
samples.  
This is probably due to the mutation being present in the oocyte and then not being lost 
as the tissue develops prenatally and regenerates postnatally. The mutation was either 
present at current levels at birth or has clonally expanded during short periods of division 
that have occurred during muscle regeneration. 
These results do not contradict earlier findings of little or no mtDNA mutations in the 
myoblasts of patients harbouring sporadically occurring mutations. 
Findings of mutation in the satellite cells of patients with sporadically occurring 
conditions may have initially been worrying considering current attempts at “gene 
shifting”. However, the probable loss of the mutation as the cells develop into myoblasts 
to eventually repair the muscle means that “gene shifting” is still a viable option for these 
patients. 
It will be necessary to grow myoblasts from these biopsies in order to determine what 
happens to the mtDNA deletions as new muscle cells develop. 
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Chapter 5 MtDNA Deletions and Myoblasts 
5.1 Introduction 
Sporadically occurring single mtDNA deletions have been demonstrated in the satellite 
cells of patients with mitochondrial myopathies. While this was initially surprising given 
previous reports, it did not contradict those findings or rule out the possibility of “gene 
shifting” in patients with mitochondrial myopathies caused by sporadic mutations. 
The initial experiments reporting no mutations in myoblasts from patients with sporadic 
mutations examined cultured myoblasts, and experiments demonstrating the feasibility 
of “gene shifting” examined muscle after a period of intense regeneration (Weber et al., 
1997, Fu et al., 1996, Clark et al., 1997, Shoubridge et al., 1997). It is therefore possible 
and probable that the mutation was lost from myoblasts in vitro during cell culture or in 
vivo during muscle regeneration. 
5.1.1 Selection 
There are a number of time points and a number of different mechanisms that could 
account for loss of these mutations. This could have occurred in the satellite cells and/or 
in the myoblasts. 
Satellite cell activation could have been impaired, with cells harbouring mutations being 
unable to activate. Alternatively if satellite cells are heteroplasmic on the basis of mtDNA 
deletions, then the resultant myoblasts may maintain or lose the mutation depending on 
which particular stem cells were activated. 
Selection could have happened during myoblast proliferation. This could occur at the 
mitochondrial level, with mitochondria containing high levels of mutation being signalled 
out for degradation by mitophagy (Twig et al., 2008, Alemi et al., 2007). Alternatively it 
could happen at the cellular level, where myoblasts with large amounts of deletions and 
thus impaired OXPHOS die, or are unable to replicate as quickly as WT myoblasts. The 
differentiation of myoblasts to myotubes may also be impaired in respiratory chain 
deficient cells. 
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5.1.1.1 Myoblasts, Myotubes, and Mitochondrial Biogenesis 
Quiescent satellite cells have low, if any, transcriptional activity, with most cells in the G0 
phase of the cell cycle, a stage characterised by resting. After activation, the myoblasts 
are proliferating rapidly, and these early stages coincide with an increase in the 
contribution of glycolysis for energy production (Barani et al., 2003). As myogenesis 
proceeds it is accompanied by both an increase in mtDNA copy number and 
mitochondrial protein synthesis, with increases in PGC1α and TFAM (a mitochondrial 
transcription factor) being observed (Barbieri et al., 2011). 
Early experiments have demonstrated the importance of mitochondrial function in 
myogenesis in vitro through the use of a DNA intercalating dye, ethidium bromide (EtBr). 
EtBr inhibits mtDNA synthesis and reduces copy number. Adding EtBr to myoblasts 
reversibly inhibits their differentiation into myotubes, but does not prevent their 
proliferation. Not only is differentiation impaired by a decrease in mtDNA but a successful 
differentiation is accompanied by an increase in mtDNA and mitochondrial biogenesis 
(Brunk and Yaffe, 1976, Herzberg et al., 1993). This increase in biogenesis coincides with a 
shift in energy metabolism from primarily glycolytic to mainly oxidative (Leary et al., 
1998). Although other research suggests this shift to OXPHOS occurs later, as the 
myotubes are maturing (Webster et al., 1990). 
The prevention of myotube formation by inhibition of mitochondrial protein synthesis is 
both morphological and biochemical and is thought to be attributable to a reduction in 
mitochondrial translation rather that transcription (Hamai et al., 1997). Inhibition of 
mitochondrial translation by chloramphenicol down-regulates protein and mRNA levels of 
myogenin, which has an important role in myoblast differentiation into myotubes. This 
also suggests a role for mitochondrial cell signalling during myogenesis (Rochard et al., 
2000). 
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5.1.1.2 Muscle Regeneration and Mitochondrial Biogenesis 
Much of the early work highlighting the importance of mitochondrial biogenesis and 
function during the proliferation of myoblasts and their differentiation into myotubes 
involved cell culture. More recent experiments have used in vivo models of regeneration 
to determine the importance of mitochondrial biogenesis. 
By injecting rats with 0.75% bupivicaine to necrose the tibialis anterior (TA) muscle, 
Duguez et al. (2001) demonstrated that muscle regeneration could be split into two 
overlapping time periods. Days three to fourteen were characterised by satellite cell 
activation and myoblast proliferation, followed by a period of myoblast differentiation 
into myotubes from days five to thirty five. The initiation of skeletal muscle regeneration 
was accompanied by an increase in mitochondrial biogenesis. At the point of myoblast 
differentiation (days 5-10) there was a large increase in biogenesis, possibly mediated by 
PGC-1 and TFAM (Duguez et al., 2001). 
These findings not only highlight the importance of mitochondrial function during the 
process of muscle regeneration, but also suggest a method whereby mutations could be 
lost from myoblasts in culture, or during muscle regeneration. In the period leading up to 
differentiation of myoblasts any cells with high levels of mutation may not be able to 
cope with the switch from a glycolytic state to a one in which OXPHOS is required to 
generate energy. This increase in demand on the OXPHOS pathway may result in impaired 
cells either dying or being outnumbered by WT cells. 
There are therefore many time points when selection could have occurred in these cells. 
In order to determine when the mutation is lost it will be necessary to grow and 
differentiate myoblasts and examine the levels of any deletions present as the cells 
develop. 
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5.2 Aims 
The aims of this chapter were to culture myoblasts from patients harbouring sporadically 
occurring single mtDNA deletions in both their muscle homogenate samples and their 
satellite cells. This was to determine what happens to any mutations present as the cells 
head towards, and differentiate into, myotubes. It was hoped this would identify the step 
of muscle regeneration where selection is acting on the developing muscle cells enabling 
mutations to be lost. Given the likelihood there would be very little or no mutations in 
these proliferating myoblasts it was necessary to use sensitive SYBR Green assays to have 
confidence in any results which suggested there was less than 30% delete mtDNA. 
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5.3 Methods 
5.3.1 Myoblast Culture 
At the time of biopsy, a small sample of muscle was transferred to the MRC Centre for 
Neuromuscular Diseases Biobank, where myoblast cultures were set up by the biobank 
technician Mojgan Reza. After around two weeks the cells were trypsinised and placed in 
a T25 flask and transferred from the biobank to the Mitochondrial Research Group. 
Once the cells were confluent they were transferred to a T75 flask. At this point some 
medium was taken for mycoplasma testing. Cells were cultured in SKCM, with the 
medium changed every two days. When cells were at 85% confluence they were 
passaged. Additionally, some myoblasts were frozen for storage and a pellet was also 
harvested for mtDNA analysis, the remainder were transferred into a fresh T75 flask. 
Myoblasts were grown for around seven passages and then differentiated into myotubes 
as described in section 2.2.7.4. It was, however, difficult to culture some cell lines up to 
passage seven, as the cells started to develop a strange morphology and die. 
Unfortunately it was not possible to obtain myoblasts for all of the biopsies performed. 
The patients undergoing this trial have a myopathy, and in some cases this is 
accompanied by severe muscle wasting, so it was occasionally difficult for a large enough 
sample to be collected for all the studies that required tissue. 
5.3.1.1 Desmin Staining 
Samples of patient myoblasts were grown on cover slips and then stained for desmin to 
ensure they were myoblasts and not fibroblasts. Cells were labelled with monoclonal 
mouse anti-human desmin (DAKO) and then with Alexa Fluor® -488 goat anti-mouse 
(FITC) secondary antibody, and mounted with VECTASHIELD® Mounting Medium with 
DAPI. Counts were performed at x20 magnification on an Axiovert 200M (Zeis), using 
AxioVision Release 4.6.3 software (Zeiss). The bottom middle edge of the cover slip was 
assigned as 0,0 and the same set of twelve coordinates were visited on each cover slip. All 
nuclei (DAPI) and desmin positive cells (FITC) in the field of view were counted. 
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5.3.2 Molecular Studies 
Myoblast pellets had the supernatant discarded and were stored at -20oC until DNA could 
be extracted. This was carried out using the Qiagen DNeasy Blood & Tissue Kit, with the 
final elution step being performed in water. The samples were stored at -20oC until qPCR 
analysis. 
5.3.2.1 QPCR Assays 
The MTND1/MTND4 assay was performed on all samples of myoblasts to determine 
heteroplasmy levels. Where these levels were below 30% the relevant SYBR Green assay 
was used to determine the amount of delete mtDNA. In addition a sample of blood DNA 
was available for patients 2 and 3, and a urine sample was available from patient 2. 
5.3.2.2 Patient 6 
In order to determine the heteroplasmy level, if any, in the myoblasts from patient 6, an 
mtDNA deletion specific SYBR Green assay needed to be optimised. This patient was first 
biopsied after it had been shown that deletions were present in satellite cells at levels 
that could be determined using the MTND1/MTND4 qPCR method. It was therefore not 
necessary to develop a SYBR Green assay for his satellite cells, but use of the 
MTND1/MTND4 qPCR on his myoblasts showed them to be below 30%, so it became 
necessary to develop an mtDNA deletion specific SYBR Green qPCR. 
In order to generate template DNA, primers were chosen to amplify either WT (Forward 
nt.7349-nt.7369, Reverse nt.8009-nt.7990), or delete (Forward nt.7349-nt.7369, Reverse 
nt.16067-nt.16048) mtDNA, giving an approximately 600bp fragment (Figure 5.1). These 
were used to optimise the WT and delete mtDNA reactions. Reaction primers were 
designed using Primer3 (v.0.4.0) that would amplify an approximately 100bp reaction 
product of WT (Forward nt.7592-nt7610, Reverse nt.7680-nt7660) or delete (Forward 
nt.7592-nt7610, Reverse nt.15717-n.t15735) mtDNA. 
Primers for the WT reaction were at 125pmol, and for the delete reaction the forward 
primer was at 125pmol with the reverse primer at 100pmol. MgCl2 was at 3mM and the 
annealing temperature for the WT reaction was 56oC and for the delete reaction was 
55oC. All reactions were carried out in 25µl volumes on an ABI StepOnePlus Real Time 
Detection System using Platinum® SYBR® Green qPCR SuperMix-UDG (Invitrogen), with 
1µl of sample DNA added. The cycling conditions were an initial denaturation step (95oC 
for 10 minutes), forty cycles of amplification (95oC for 15 seconds, annealing temperature 
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for 1 minute) with an acquisition step at the end of each cycle, followed by a melt curve 
analysis (95oC for 15 seconds, 60oC for 1 minute, increase to 95oC (0.3oC/15 seconds)), 
with continuous acquisition. 
Delete template mtDNA from this patient was diluted using WT mtDNA to give standards 
of 75%, 50%, 25%, 12.5%, 6%, 3% and 1.5%. These were diluted to 1/5000 and analysed 
with samples of this patient’s myoblasts. 
 
 
 
 
 
Figure 5.1 Patient 6 SYBR Green assay. Template primer pairs (blue) were chosen to amplify an 
approximately 600bp region of either WT (A) or delete (B) mtDNA. Primers chosen to anneal to 
regions within the breakpoints (red) of the deletion will not amplify delete mtDNA, while primers 
chosen to anneal to either side of the breakpoint will only amplify deleted mtDNA due to the 
extension time and PCR conditions. For the WT and delete qPCR reactions primers (green) were 
used to amplify up an approximately 100bp product. 
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5.4 Results 
5.4.1 Desmin Staining 
Desmin staining was performed on seven out of the nine myoblast cell lines available 
(Figure 5.2). The percentage of desmin positive cells ranged from 69% to 98% (mean 86% 
±11%) (Table 5.1). A few of the cell lines with lower desmin staining may have contained 
some fibroblast contamination. Given that fibroblasts from patients with sporadically 
occurring mutations do not normally harbour the mutation, it is possible that fibroblasts 
present in the cultures could have reduced any heteroplasmy levels observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Desmin staining. Desmin staining was performed on 
the myoblast cell lines to determine the percentage of 
myoblasts and fibroblasts in the cultures. The top image shows 
desmin visualized with FITC (green), while the bottom image is 
without the primary antibody. Nuclei were visualized with 
DAPI. Scale bar is 100µm. 
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Table 5.1 Table of myoblast purity. Myoblasts were grown on cover slips 
and then stained for desmin to determine the amount of myoblasts present 
in the culture. The desmin positive cells and nuclei were then counted in 
order to provide a percentage. 
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5.4.2 MtDNA Heteroplasmy Levels 
The MTND1/MTND4 qPCR was used to determine heteroplasmy levels within myoblasts. 
Samples of myoblasts were available for seven out of eight patients enrolled on the 
exercise trial, and for three of these patients myoblasts were available from more than 
one of their biopsies. There was considerable variation between patients regarding 
results, as well as one patient displaying marked differences between biopsies. 
In all MTND1/MTND4 qPCRs four controls were run; three samples of mtDNA harbouring 
known deletion levels (37%, 67%, 87%), and a blood sample. In order for a run to be 
classed as successful the blood sample needed to be 0%, and the three known deletion 
samples had to be within 10% of their true value. In addition, patient samples were run in 
triplicate with Ct values only being used if they were within one Ct of each other. 
5.4.2.1 Patient 2 
Myoblasts from patient 2’s first and second biopsies were available for analysis. This 
included first biopsy myoblasts from passages four to seven, with a sample of myotubes 
differentiated at passage eight. From his second biopsy, myoblasts from passages three to 
six were available along with a sample of myotubes differentiated at passage seven. 
When the MTND1/MTND4 assay was performed on samples from patient 2’s first biopsy, 
mtDNA deletions were present in his myoblasts at 38%, 30%, 33%, 26% (passages 4-7), 
which reduced to 24% in his myotubes (analysed with SYBR Green) (Figure 5.3A). Due to 
the surprising nature of these findings the MTND1/MTND4 assay was performed a further 
two times (Table 5.2A). These results were all within 10% of the first run, and therefore 
they were averaged (Table 5.3). 
His second biopsy harboured a deletion of around 80% (Table 5.3) in the myoblasts; this 
level was maintained in the myotubes (Figure 5.3A). These samples were run four times, 
and each set of results were within 6% of all other runs (Table 5.2A), and have also been 
given as averages (Table 5.3). 
When samples of this patient’s urine and blood were run on the same assay the results 
suggested they were less than 30%. When they were analysed on the “common deletion” 
SYBR Green assay developed in chapter 4 they were shown to harbour no mtDNA 
deletion (Table 5.3). 
 
Chapter 5  MtDNA Deletions and Myoblasts     
174 
  
5.4.2.2 Patient 3 
Myoblasts from patient 3’s second and third biopsies were available for analysis. Second 
biopsy cells from passages one to five, with myotubes differentiated at passage five were 
examined, along with myoblasts from his third biopsy passages one to six, and myotubes 
differentiated at passage seven. 
Patient 3 was shown using the SYBR Green assay developed in chapter 4 to harbour an 
mtDNA deletion at 1% in this first set of myoblasts at passage one, but this was 
undetectable in all remaining passages. The myoblasts from his third biopsy, however, 
were shown using the MTND1/MTND4 qPCR to have a deletion of around 70%, this 
gradually decreased until it was 0% in his myotubes (Figure 5.3B). These samples were 
run a second time, and apart from one value at passage two, were all within 10% of the 
first run (Table 5.2B) so heteroplasmy levels were averaged out (Table 5.3). 
It was decided to re-grow this patient’s myoblasts from passage two and repeat the 
analysis to determine if the same pattern would be observed. Again the deletion was 
present, although it appeared to be at a slightly lower level this time (around 55%) and 
reduced to 13% on differentiation to myotubes (SYBR Green qPCR) (Figure 5.3B). When a 
sample of blood DNA from this patient was analysed using his deletion specific SYBR 
Green assay it was shown that there was no mtDNA deletion present (Table 5.3). 
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Table 5.2 Heteroplasmy levels of myoblasts from patients 2 and 3. Because of the surprising 
nature of the results demonstrating single mtDNA deletions in myoblasts of these patients, the 
samples were re-analysed. A. Patient 2 had his 1
st
 biopsy samples run three times and his 
second biopsy samples run four times. B. Patient 3 also demonstrated a deletion in his 
myoblasts from his third biopsy, so again this assay was repeated. There was a good general 
agreement between runs. 
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5.4.2.3 Patient 4 
Patient 4 had myoblasts available from passages one to three, obtained from his second 
biopsy. Myotubes differentiated at passage three were also available. An initial run using 
the MTND1/MTND4 qPCR revealed levels of mtDNA deletions, if present, were less than 
30%. So these samples were analysed using the “common deletion” SYBR Green assay 
developed in chapter 4. Using this assay, it was shown that there was no mtDNA deletion 
present in any of his myoblasts or myotubes (Table 5.3). 
5.4.2.4 Patient 5 
Myoblasts from this patient’s first biopsy, passages one to seven, and myotubes 
differentiated at passage eight were available for analysis. An initial run using the 
MTND1/MTND4 qPCR showed levels of mtDNA deletions, if present, were less than 30%. 
So these samples were analysed using his deletion specific SYBR Green assay developed in 
chapter 4. This assay suggested there were tiny amounts of delete mtDNA in his 
myoblasts (0.01%), although in some of the passages this was undetectable (Table 5.3). 
5.4.2.5 Patient 6 
Myoblasts from patient 6’s first biopsy were available for analysis, these were from 
passages three to seven, and myotubes differentiated at passage eight. An initial run 
using the MTND1/MTND4 qPCR showed levels of mtDNA deletions, if present, were less 
than 30%. A SYBR Green assay was developed for him in order to determine if there was 
any delete mtDNA in these samples. Use of his deletion specific qPCR assay showed there 
was no mtDNA deletion in either his myoblasts or myotubes (Table 5.3). 
5.4.2.6 Patients 7 & 8 
Patients 7 and 8 began the exercise trial late on during this research. While it was possible 
to grow the myoblasts from these patients it was not possible to analyse their myoblasts 
using a SYBR Green assay. The MTND1/MTND4 assay suggests they both have less than 
30% delete mtDNA in their myoblasts (Table 5.3), though this could be any amount 
between 0-30%. 
  
  
Table 5.3 Heteroplasmy levels for myoblasts and myotubes. Heteroplasmy levels were determined using either the MTND1/MTND4 qPCR or a deletion specific 
SYBR Green assay. Myoblasts were not available for patient 1, and only available for some of the biopsies of other patients. Where levels are given as <30%, the 
MTND1/MTND4 assay has shown these cells have less than 30% delete mtDNA but it has not been possible to run these samples on a SYBR Green assay, so it is 
not possible to say if they have any mutation or not. Myob = myoblasts, P = passage number, MyoT = Myotubes, SKM = skeletal muscle homogenate levels (as 
determined in chapter 4). 
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Figure 5.3 Changes in heteroplasmy over time. A. Patient 2 maintained the mutation at around 
30% in his myoblasts from his first biopsy, with a slight decrease as the cells differentiated. In his 
second biopsy the mutation was maintained at around 80%, this did not change as the cells 
differentiated. B. Patient 3 lost the mutation in his second biopsy, but maintained it during his 
third biopsy, although a decrease was again observed as the cells headed towards 
differentiation. The same pattern was observed when this cell line was grown again. The last 
data points on the line correspond to levels in the differentiated myotubes. 
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5.4.3 Pyruvate and Uridine Supplementation 
The cell medium myoblasts are grown in contains FCS, L-glutamine, and after the addition 
of the supplemental mix provided by the manufacturer, also contains fetuin, basic 
fibroblast growth factor, epidermal growth factor, insulin and dexamethasone. However, 
it has been shown that cells with an OXPHOS impairment may divide slower or not at all 
in culture, and are often dependent on pyruvate and uridine for growth because of the 
absence of a functional respiratory chain (King and Attardi, 1989). Supplementing the 
medium with pyruvate and uridine avoids selection occurring against respiratory deficient 
cells. 
To determine if the lack of pyruvate and uridine in the medium could have had a negative 
selection pressure on the myoblasts some of the cells were re-grown with pyruvate and 
uridine added to the medium. 
Patients 2 and 3 had originally maintained the mutation in their myoblasts. After growing 
in supplemented medium, patient 2 still harboured the mutation (Table 5.4). This was at a 
similar level to when the cells were grown without supplementation (Figure 5.4A). Again, 
patient 3 maintained the mutation in his myoblasts when grown in supplemented 
medium (Table 5.4). It was shown that when the cells were grown without 
supplementation there was a decrease in the heteroplasmy levels. When they were 
grown with supplementation there was a slight increase in the heteroplasmy levels 
(Figure 5.4B). 
All patients who had lost the mutation first time around had MTND1/MTND4 results 
suggesting the levels were still below 30% (Table 5.4). While we can hypothesise that this 
will have been 0%, this would need to be demonstrated with the relevant SYBR Green 
assay to confirm. 
Cells grown with supplementation were grown at a later time point than those grown 
without. While they originated from the same flask of cells they will have undergone 
freezing and thawing. It is possible that this accounts for the differences in starting 
heteroplasmy levels at passage four for patient 3. In addition, this was a single 
experiment and in order to draw any firm conclusions about the effects of 
supplementation on heteroplasmy levels it should be repeated. 
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Table 5.4 Myoblast heteroplasmy levels after supplementation. Some of the myoblasts were re-
grown in medium supplemented with pyruvate and uridine, allowing for proliferation of respiratory 
chain impaired cells. The two patients who had previously maintained the mutation continued to do 
so, while the two patients who lost the mutation still contained levels below 30%. Heteroplasmy 
levels were determined using the MTND1/MTND4 qPCR on a single run. 
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Figure 5.4 Graphs showing changes in heteroplasmy. A Patient 2 maintained the levels of 
heteroplasmy in his myoblasts both with and without supplementation at similar levels. B. Patient 
3 maintained the mutation in myoblasts grown with and without supplementation. Although, the 
cell line that was grown with supplementation had a slightly lower starting level and rose slightly, 
while the myoblasts that were grown without supplementation started higher, but this was 
followed by a reduction. 
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5.4.4 Functional Consequences 
Having demonstrated that some sporadically occurring mtDNA deletions could be 
maintained in myoblasts it was decided to see if these mutations had a functional 
consequence on the cells. In order to do this COX histochemistry was performed. 
A series of optimisations ranging from forty five minutes to three hours were performed 
to determine incubation times for the COX reagent. Optimal staining was achieved with a 
two and a quarter hour incubation time, at 37oC. 
Myoblasts from one patient who maintained his mtDNA deletion (patient 3) and from two 
patients who lost their mutations (patients 5 and 6), together with a control cell line, 
were grown on cover slips and then incubated in COX medium for two and a quarter 
hours. 
Images were taken on a Zeiss Axioplan 2 microscope, and converted to greyscale (Figure 
5.5); densometric analysis was performed using AxioVision 4.8.1 software. This gave a 
value between 0-250 which was an indication of density of staining per unit area, with 1 
being the most intense and 250 being the least. Three cover slips were counted for each 
patient and on each cover slip three areas were counted. Analysis was performed at x20 
magnification and all myoblasts visible on the screen were analysed. Values were 
subtracted from 250 in order to give a scale in which the most densely stained cells had 
the highest numerical values. 
Patient 3 had a mean intensity of staining of 70.96 ± 4.7, patient 5 was 76.10 ± 12.2, and 
patient 6 was 74.62 ± 6.4, while the control myoblasts had a mean of 90.08 ± 14.1. 
Patient 3 who harboured the mtDNA deletion in his myoblasts appeared to have weaker 
staining than both the other two patients and the control cell line. However, it would be 
necessary to repeat this experiment with more controls before any firm conclusions can 
be drawn. 
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Figure 5.5 COX staining on cultured myoblasts. Myoblasts from patients 3 (A), 5 (B) and 6 (C) were grown 
on cover slips along with a sample of control myoblasts (D). Images were taken and converted to grey 
scale in order for densitometric analysis to determine how intensely the COX had stained. 
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5.4.5 Testing for an MtDNA Duplication 
Given the surprising nature of the results demonstrating the presence of mtDNA 
deletions in myoblasts of some of our patients, it was decided to examine the possibility 
that the mutations could in fact be mtDNA duplications. It is thought that mtDNA 
duplications allow the presence of mtDNA rearrangements in dividing tissues (e.g. blood), 
which would otherwise eliminate deletions (Poulton and Holt, 1994). 
5.4.5.1 Southern Blot 
To test for an mtDNA duplication, a sample of patient 2’s myoblasts, and a sample of WT 
mtDNA were cut using the restriction endonucleases BamHI and SnaBI. The samples were 
electrophoresed on a 0.7% agarose gel for twenty one hours at 30V and then transferred 
to a hybridisation membrane by Southern blot. An area corresponding to the D-loop was 
probed using 32P. Images of the DNA bands were taken using a phosphoimager. 
BamH1 cuts once in the mtDNA at position nt.14257 to give a linear 16.5Kb molecule 
(Figure 5.6A). This band can be clearly seen in the WT sample. In the patient sample, a 
delete linear band can be seen along with a very faint higher WT band, attributable to the 
small amount of WT mtDNA this patient has (Figure 5.6B). 
The uncut samples will have super coiled mtDNA which will run much higher than the 
linearised samples. This can be seen in the WT uncut lane, and also a delete molecule 
super coiled band in the patient 2 uncut lane. Both the WT and the patient lane also 
contain a smaller band corresponding to some naturally occurring linear mtDNA in the 
sample. 
SnaBI cuts once at position nt.10735, which is within the break points of the “common 
deletion” (Figure 5.6A). The gel would appear to show that this enzyme has not cut very 
efficiently. In addition to a 16.5Kb linear band in the WT sample, there would appear to 
be some closed super coiled DNA that has not been linearised. Furthermore, there is a 
third band below this one that cannot be explained. Because the restriction site for this 
enzyme is within the breakpoints for the common deletion, the delete mtDNA from the 
patient will not have been cut and consequently there is a band corresponding to delete 
super coiled mtDNA. 
If this sample harboured any mtDNA duplications then bands above the WT super coiled 
fragment would be observed for the uncut samples. 
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Figure 5.6 Southern blot. A. Myoblast mtDNA from patient 2 was digested using restriction 
endonucleases that cut at nt.14257 and nt.10735. B. From the WT sample a super coiled mtDNA band 
and a WT linear band can be identified. The SnaBI enzyme appears to not have fully digested the mtDNA 
as there is still a super coiled fragment visible. Using BamHI a linear fragment of delete mtDNA can be 
observed that sits below the linear WT mtDNA band. 
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5.5 Discussion 
The aims of this chapter were to culture myoblasts from patients who had previously 
been shown to harbour single mtDNA deletions in their satellite cells. This was to 
determine what happens to any mutations present as the cells progress towards and 
differentiate into, myotubes. It was hoped this would identify the step of muscle 
regeneration where selection is acting on these cells enabling mutations to be lost. 
5.5.1 MtDNA Deletions in Myoblasts 
When these experiments were started it was expected that no mtDNA deletions would be 
present in the myoblasts from patients harbouring sporadically occurring mutations. 
Finding single mtDNA deletions in myoblasts from some of the patients is therefore 
surprising. In addition, the fact that in some patients the mutation is maintained and in 
others it is lost, adds to the intrigue. Patient 3 is particularly interesting. In his second 
biopsy he lost the mutation after the second passaging of his cells, but in his third biopsy 
he maintained the mutation. 
When the mutation was lost from his myoblasts the starting level in his satellite cells was 
higher than it was for his third biopsy which is when it was maintained. This pattern is 
somewhat repeated in patient 2. Patient 2 maintained the deletion in both his first and 
second biopsy; however, it was much higher in his second biopsy which is when the level 
of mtDNA deletion in his satellite cells was the lowest.  
This would suggest that whether a patient loses the mutation in their myoblasts is not 
mutation or patient specific and not dependent on the starting level of deletion in their 
satellite cells. In addition, patients 2 and 3, who maintained the mutation in at least one 
of their biopsies, had further samples examined. Blood samples from both patients had 
no mtDNA deletions and a urine sample from patient 2 had no mutation. These findings 
were not surprising, given suggestions that sporadically occurring mutations are lost from 
mitotic cells, for example blood, urinary and buccal cells (Brockington et al., 1995, 
Marzuki et al., 1997, Aure et al., 2007). This demonstrates that the mutation can be lost 
from dividing cells in these two patients, but was not always lost from their dividing 
myoblasts. 
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5.5.2 An MtDNA Duplication? 
It was initially thought that a more complex mtDNA rearrangement may be responsible 
for the maintenance of the single mtDNA deletion in the dividing myoblasts. MtDNA 
rearrangements include partial deletions or duplications of the genome. While patients 2 
and 3 have been diagnosed as having large scale single mtDNA deletions, it was possible 
that they also harboured an mtDNA duplication. 
Duplications can consist of a WT genome with a delete genome inserted into it, or as 
deletion dimers (two delete molecules joined together) (Poulton et al., 1993, Grossman 
and Shoubridge, 1996). The mixture of recombinations observed, and the fact that the 
proportion of duplicated molecules varies with both time and tissues, has led to 
suggestions that duplications are in fact an intermediate species. Observed reductions in 
duplications coinciding with increases in deletion dimers over time, may be caused by the 
delete molecule being ejected from the enlarged duplicated one (Poulton et al., 1993, 
Poulton et al., 1995). 
MtDNA duplications have been reported in KSS (Poulton et al., 1994b), and in Pearson’s 
syndrome (Rotig et al., 1995). It has been suggested that the balance of duplicated and 
delete species is partly responsible for the differing phenotypes of these diseases 
(Poulton and Holt, 1994). 
The presence within a duplicated molecule of all the necessary genes that are required 
for OXPHOS could result in an absence of selection acting on the myoblasts of patients 2 
and 3. Indeed, this is part of the reason duplications can be inherited. 
However, the results of the Southern blot show that the maintenance of a single mtDNA 
deletion in the myoblasts of patient 2 is not because the patient harbours an mtDNA 
duplication. In addition mtDNA duplications are often detectable in blood (Poulton et al., 
1994b, Poulton et al., 1993) and analysis of both blood and urine samples from patient 2 
and a blood sample from patient 3 found no mtDNA deletion present (Table 5.3). 
Additional support for an mtDNA duplication not being involved in the maintenance of 
mtDNA deletions in the myoblasts of these patients comes from findings by Poulton et al. 
(1994). This paper examined eighteen patients with KSS or CPEO and found duplications 
associated with 10 out of 10 KSS patients but not in any of the patients presenting with 
CPEO. This suggests that this particular type of mtDNA rearrangement may be primarily 
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associated with KSS and not CPEO (Poulton et al., 1994b). All the patients examined in the 
present study have CPEO, including patients 2 and 3 who maintain the mtDNA deletion in 
their myoblasts (Table 3.1). 
5.5.3 Losing the Mutation 
There were marked differences both between patients and in one case between biopsies 
in the loss and maintenance of mutations. There would appear to be two periods of 
potential loss. The first occurs at the point of satellite cell activation and is extremely fast 
and almost absolute; the second is a more gradual decline in mtDNA deletion levels in the 
myoblasts. 
As previously stated the rapid loss at the point of satellite cell activation could be 
attributable to cells with mutation not being able to activate, although findings in this 
chapter suggest they can activate. In addition even cells with a high level of mtDNA 
deletion (patient 2 second biopsy, patient 3 third biopsy) are able to do so. In addition, 
there is a considerable time period between the investigation of the satellite cells and the 
myoblasts. This is when the myoblast cultures are being established, and can take up to 
two weeks. It is possible that mutations are lost during this time frame. However, the 
maintenance of deletions in three out of ten of the myoblast cell lines suggests this may 
not be the case. 
Alternatively there could be a bottleneck occurring. A bottleneck occurs when there is a 
reduced amount of DNA followed by replication from a smaller set of genomes. In 
mitochondrial genetics the bottleneck accounts for the rapid shifts in heteroplasmy that 
can occur between generations. 
There are a few potential ways this could happen during satellite cell activation. If, after 
activation, satellite cells are dividing asymmetrically to both form myoblasts, and 
repopulate the stem cell pool, the myoblasts may either maintain or lose the mutation 
depending on the way the cell divides. Alternatively, if muscle contains satellite cells that 
have varying amounts of single mtDNA deletions, depending on the exact cells activated, 
the resultant myoblasts could experience a rapid shift in heteroplasmy levels. These 
theories are discussed more in the next chapter. 
The second phase of selection occurs in the myoblasts. On two out of the three occasions 
the mutation was maintained, there was a slight drop in levels as the cells progressed 
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towards differentiation into myotubes (Figure 5.3). Previous reports have suggested that 
there is an increase in mitochondrial biogenesis as myoblasts proceed towards 
differentiation as well as a switch from primarily glycolytic energy generation to OXPHOS 
(Leary et al., 1998, Brunk and Yaffe, 1976, Herzberg et al., 1993, Duguez et al., 2001). This 
increased reliance on OXPHOS and/or an up regulation of mitochondrial biogenesis could 
mark a point at which negative selection occurs on the cells. Any cells that have a 
respiratory chain deficiency may die when these processes begin. 
Alternatively, after myoblast division, there may be uneven segregation of WT and delete 
mtDNA, with cells harbouring large amounts of delete mtDNA dying, or being unable to 
proliferate as quickly as WT myoblasts. Again, these possibilities are discussed and 
examined further in the next chapter. 
The differences observed between proliferating myoblasts and dividing blood and urinary 
epithelial cells in patients 2 and 3, may be attributable to the nature of these tissues. 
Blood stem cells and urinary epithelia are constantly dividing and thus there is a longer 
period of time over which negative selection could occur. In contrast, selection can only 
happen in myoblast after injury to the muscle. 
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5.5.4 Pyruvate and Uridine Supplementation 
When cells from patients who had originally lost the mutation in their myoblasts (patients 
5 and 6) were grown a second time, but with the addition of pyruvate and uridine, the 
MTND1/MTND4 qPCR results suggested the levels were still below 30%. While it is 
possible to make the assumption that the mutation had been lost again, only the relevant 
SYBR Green assay would confirm this. In addition it was only possible to perform this 
experiment on myoblasts from passage four onwards, this would allow for a possible 
period of selection on the myoblasts when they were originally being grown without 
supplementation up to passage four. 
The mutation was maintained in myoblasts from patients 2 and 3 when the cells were 
grown both with and without supplementation. Patient 2 maintained the mtDNA deletion 
in his myoblasts at a similar level to the growth without supplementation. Patient 3 
harboured the deletion at a lower level when his myoblasts were grown with 
supplementation. However, this decrease was observable at the first passage, which 
suggests that when the cells were thawed there may have been an initial cull of cells with 
high levels of mtDNA deletion. It was intriguing that these cells actually increased their 
heteroplasmy levels slightly. This did not happen when the cells were grown without 
supplementation. This suggests that the medium was acting somewhat selectively for 
these cells when they were grown without supplementation, and that the addition of 
these factors may have allowed myoblasts with mutations to persist for a short while 
longer. However, this is based on a single observation in patient 3, and did not occur in 
patient 2. 
It is interesting to note that it was possible to grow the cells for an extra passage for both 
patients 2 and 3 when the medium was supplemented. It is possible that when the cell 
cultures were originally set up in the MRC Centre for Neuromuscular Diseases Biobank 
that the lack of supplementation caused selection to act on some of the myoblasts. 
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5.5.5 Previous Findings 
While the presence of sporadically occurring mtDNA deletions in the myoblasts of these 
patients was unexpected given previous reports (Fu et al., 1996, Weber et al., 1997), they 
still do not contradict them. In the current study two patients had no detectable mutation 
in their myoblasts, and a further patient harboured amounts below the sensitivity of the 
assays used in the original papers. In addition there have been previous reports of mtDNA 
deletions in myoblasts, just at lower levels than in muscle homogenate (Moraes et al., 
1989a, Moraes et al., 1989b, Bonod-Bidaud et al., 1999). 
The papers using cell culture to examine mutations (Fu et al., 1996, Weber et al., 1997) 
supplemented the media with pyruvate and uridine, at the start of culture. It is probable 
then that the selection point for these cells occurred at the satellite cell activation stage. 
The methods used to induce regeneration when testing the theory of “gene shifting” 
were bupivicaine (Clark et al., 1997) and biopsying (Shoubridge et al., 1997). These were 
very severe techniques and muscle necrosis will have been severe. In order to regenerate 
the muscle a large amount of cell division will have occurred thus allowing for selection. 
The change from glycolysis to OXPHOS has been reported to occur around day twelve 
(Leary et al., 1998) and while this was an in vitro experiment, a similar switch could have 
occurred in the three weeks these papers allowed for muscle regeneration. In addition, 
the mutations could also have been lost at the satellite cell activation stage. 
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5.6 Conclusions 
Sporadically occurring single mtDNA deletions can be maintained in proliferating 
myoblasts. However, there would appear to be considerable variation both between 
patients and even between biopsies. Whether the mutation is lost or maintained, is not 
dependent on the mutation type, heteroplasmy level, or size. It would appear to be a 
more stochastic process. 
There are probably two periods of selection acting on the cells responsible for muscle 
regeneration. In some cases the mutation is lost at the point of satellite cell activation; 
and in others it is lost as the myoblasts progress towards differentiation. 
While the maintenance or loss of mutation from myoblasts would appear to be a random 
process, analysis of the myoblasts from patients 7 and 8 using a SYBR Green assay may 
give a better indication as to the likelihood of maintenance or loss in future patients. 
The findings of mtDNA mutations in myoblasts may be initially worrying for the 
possibilities of “gene shifting” in patients undergoing the exercise trial. However, the fact 
that in the majority of biopsies performed the mutation was lost and in the others there 
was a downward trend in deletion levels suggests that “gene shifting” is still a viable 
option for these patients. 
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Chapter 6 MtDNA Deletions and Selection Points 
6.1 Introduction 
The previous two chapters have demonstrated the presence of large scale single mtDNA 
deletions in the satellite cells of all patients examined. The myoblasts of two of these 
patients (patients 2 and 3) also contained mtDNA deletions. In patient 2’s first biopsy 
there was a gradual decline as the cells headed towards differentiation, while in his 
second biopsy there was no such decline. Patient 3 maintained the mtDNA deletion in his 
third biopsy but by the time the cells had differentiated into myotubes the mutation had 
been lost. 
It has been hypothesised in chapter 5, that the loss of mutation in many of the patients at 
the point of satellite cell activation is attributable to a bottleneck effect, or possibly 
selection. Whether the bottleneck occurs through an actual reduction in mtDNA copy 
number caused by cellular division immediately after activation, or via activation of 
certain satellite cells and thus replication of subgroups of mitochondrial genomes is 
unclear. 
A second period of selection occurs in the myoblasts that maintain the mtDNA deletion as 
they head towards differentiation. This suggests that myoblasts with impaired respiratory 
chain deficiency are dying. This may be attributable to an increase in mitochondrial 
biogenesis and a switch from a primarily glycolytic nature to one in which OXPHOS is the 
main supplier of energy (Leary et al., 1998). Although the fact this gradual decline only 
occurred in two out of three myoblast cell lines that maintained the mutation, opens up 
the possibility that a different mechanism could be responsible for the cells dying. After 
myoblast division, if there is uneven segregation of the mtDNA on the basis of deletions, 
then the cells that have inherited high levels of mtDNA deletions may die. 
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6.1.1 Bottlenecks and Satellite Cells 
Ever since investigations into Holstein cows suggested that “amplification of one or a few 
mtDNA molecules will yield one predominant genotype”(Hauswirth and Laipis, 1982), 
research into mtDNA bottlenecks has focused on the shift in genotype that is sometimes 
observed in embryogenesis. This shift involves a stage in primordial germ cell (PGC) 
development where a reduction in reproducible mtDNA occurs, amplification of mtDNA 
then proceeds from this small population (Figure 1.15). However, there is still ongoing 
debate about the exact mechanism of this particular mtDNA bottleneck (Khrapko, 2008). 
The differing opinions about the mechanism of the bottleneck fall into three main groups. 
Cao et al. (2007) proposed the bottleneck occurs via the aggregation of mtDNA into 
(homoplasmic) segregating units (or nucleoids). They isolated PGCs by staining with 
alkaline phosphatase and then used qPCR to measure mtDNA copy number. No decrease 
in copy number was observed and they concluded that the bottleneck was created 
without an actual reduction in mtDNA. The amplification of a small number of the 
segregated units could account for the rapid shifts in heteroplasmy (Cao et al., 2007). 
However, Cree et al. (2008) argued that staining the PGCs with alkaline phosphatase 
disrupts the extremely sensitive qPCR reaction that is used to determine mtDNA copy 
number. They used stella-GFP transgenic mice and isolated PGCs via FACS sorting. Using a 
qPCR method they demonstrated an actual reduction in mtDNA copy number in PGCs and 
hypothesised that the segregation of these much reduced genomes could account for the 
bottleneck (Cree et al., 2008). 
Having found a similar reduction in mtDNA copy number Wai et al. (2008) came to a 
different conclusion. They failed to show a wide variation in heteroplasmy immediately 
after the initial reduction, leading them to suggest that the variation does not occur until 
a later stage. Again, contrasting results were attributed to different isolation techniques. 
Rather than using FACS sorting, this group opted for manual isolation of PGCs, as they 
found FACS sorting resulted in an unacceptable amount of “debris and doublets”. Their 
proposed mechanism involves the selective replication of a subpopulation of mtDNA 
copies at a later stage of development, but without a reduction in copy number (Wai et 
al., 2008). 
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Given that satellite cells are known to be mitotically quiescent, and that even the very 
first EM images suggested these cells consisted mostly of nucleus with a “paucity” of 
cytoplasm (Mauro, 1961), it is reasonable to assume they have a low mtDNA copy 
number. Replication of a sub-population of these molecules could result in dramatic shifts 
in the heteroplasmy level. However, like the bottleneck that occurs during 
embryogenesis, there may be a few possible mechanisms accounting for the effect that 
occurs here. 
While results in chapter 4 suggest that satellite cells are heteroplasmic on the basis of 
mtDNA deletions, this may not be the case for individual cells. A homogenate sample of 
satellite cells with a heteroplasmy level of 50% may be the result of all cells harbouring 
50% delete mtDNA, the cells being homoplasmic with either 0% or 100% delete mtDNA. 
Alternatively cells may contain a mixture of different heteroplasmy levels which all 
average out to 50%. 
6.1.2 Replication of a Subgroup of Mitochondrial Genomes 
After injury satellite cells are activated, the size of their response is proportional to the 
extent of the injury. If the basal lamina has been damaged then satellite cells may migrate 
to adjacent fibres. A smaller injury which has left the basal lamina intact, will allow for 
satellite cells to migrate underneath it to the site of injury (Hawke and Garry, 2001). 
However, it is very difficult to give a precise number on how many satellite cells are 
activated in order to repair an injury. One experiment suggested that a single bout of 
eccentric training was enough to activate between 5% to 11% of satellite cells in three 
month old mice (Darr and Schultz, 1987). While in humans, a single bout of exercise 
resulted in an increase in satellite cells at day two of over 100% (Crameri et al., 2004). But 
the numbers of these cells that will go on to form myoblasts is unknown, and it is difficult 
to say how many satellite cells are activated in response to resistance training in our 
patients. 
Nevertheless, there is a possibility that the dramatic shifts in heteroplasmy observed in 
our patients is caused by an activation of a random subgroup of satellite cells which have 
either very high or very low amounts of single mtDNA deletion (Figure 6.1B). 
Alternatively, the satellite cell population may consist of homoplasmic WT and delete 
cells (Figure 6.1C). Through the activation of primarily WT or delete mtDNA satellite cells, 
the mutation may be either lost or maintained. 
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6.1.3 Reduction in MtDNA Copies via Asymmetric Division 
Satellite cells are able to proliferate and commit to a myoblast fate, and in addition, are 
able to self-renew to repopulate the stem cell pool. This divergent fate of satellite cells 
involves an asymmetric division after activation, which has been demonstrated on the 
basis of many factors. 
The cytoplasmic protein Numb is involved in determining the fate of muscle precursor 
cells and is thought to exert its influence through attenuating the effects of Notch-1, an 
inhibitor of these cells. Asymmetric localization of Numb, to one pole of dividing cells, 
perpendicular to the plane of mitosis, precedes a heterogeneous expression of Numb in 
daughter cells. Numb positive cells are more committed to a muscle phenotype, as 
demonstrated by their high levels of Myf5 expression (Conboy and Rando, 2002). 
The asymmetric division of satellite cells has also been shown to occur on the basis of 
template DNA strands, which co-segregate to one daughter cell (Shinin et al., 2006). This 
provides support for the Cairn’s hypothesis, that stem cells retain immortal template DNA 
during divisions, thus protecting them from replication induced errors (Cairns, 1975). 
More recently Kuang and colleagues demonstrated both symmetric and asymmetric 
satellite cell divisions. Symmetric divisions occur in a planar orientation generating 
identical daughter cells that either renew the stem cell pool or become muscle progenitor 
cells. Asymmetric divisions occur in an apical-basal orientation and result in a stem cell at 
the basal side and a committed muscle precursor cell on the apical surface. This 
asymmetric division has segregated localisation of Myf5, with the negative cells being 
self-renewing, and the positive cells becoming committed to a muscle cell fate. In support 
of Shinin and colleagues (2006) they demonstrated that 41% of Myf5 positive cells 
labelled for BrdU, while only 14% of negative cells did, suggesting these cells were 
synthesising DNA and proceeding through the cell cycle (Kuang et al., 2007). 
While the above examples of asymmetric satellite cell division suggests the localisation of 
various signalling molecules and DNA is very targeted, in the case of mtDNA, the 
localisation would appear to be more stochastic. If the mtDNA copy number is low in 
satellite cells then a single division would reduce this number further. In addition it would 
segregate the mtDNA copies into two daughter cells. Depending on the cell that 
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proceeded to form muscle precursor cells, the resultant myoblasts may either lose or 
maintain the mutation (Figure 6.1A). 
It should be noted that the above mechanisms for a bottleneck are not mutually 
exclusive. Activation of a subgroup of satellite cells followed by asymmetric division 
would provide an even stronger bottleneck and given the drastic reduction observed 
when some of the patients lose their mutation; this may be the causative factor. 
 
Figure 6.1 Satellite cell activation selection point. At the point of satellite cell activation a large 
number of patients lose their mtDNA deletion from their satellite cells. This has been 
hypothesised to occur via a bottleneck. There are a few possible mechanisms by which this could 
have occurred. A. Asymmetric division of the activated satellite cell results in two daughter cells, 
one which has a mutation and one which does not. Depending on which daughter cell proceeds to 
form myoblasts, the patient will either lose or maintain the mutation. This mechanism involves an 
actual reduction in the mtDNA copy number. B & C Alternatively it could involve replication of a 
sub group of mtDNA copies through the activation of satellite cells that have either very large or 
very small amounts of delete mtDNA (B), or cells that are homoplasmic for the presence or 
absence of the mutation (C). Red mitochondria indicate high levels of mtDNA deletions, green 
mitochondria are WT. 
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6.2 Aims 
Results so far suggest that selection is acting on regenerating muscle cells at two points; 
satellite cell activation, and the proliferation or differentiation of myoblasts into 
myotubes. The aims of this chapter are to investigate possible mechanisms of selection at 
these two time points. 
It aims to show that a bottleneck is occurring at the first stage, mediated by activation of 
a sub-population of satellite cells and/or asymmetric division of activated cells. 
In addition it is hypothesised that the switch from a glycolytic nature to OXPHOS and an 
increase in mitochondrial biogenesis is involved in the second selection point 
If “gene shifting” is to occur, then muscle fibres with high levels of mutation will need to 
be able to regenerate in order for the mutation to be lost. This chapter also aims to 
present some preliminary work showing that respiratory deficient cells are able to 
regenerate. 
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6.3 Methods 
6.3.1 MtDNA Copy Number 
An mtDNA bottleneck involves amplification of DNA from a small population of genomes. 
In order to determine if that is the case here, a TaqMan® based qPCR method was used to 
establish the amount of mtDNA present in the satellite cells, proliferating myoblasts and 
differentiated myotubes of patients. The 18S/MTND1 qPCR compares the ratio of the 
mitochondrial ND1 gene to a nuclear marker, 18S. ND1 is not in the major arc region and 
therefore tends to be preserved in patients with large scale single mtDNA deletions. All of 
the patients in this study harboured mtDNA deletions in their major arc (Table 3.3) and 
their ND1 region was consequently preserved. The nuclear gene, 18S, is an rRNA gene 
present in multiple copies in the cell. This assay produces a number that is a ratio 
between nDNA and mtDNA. 
Samples of the patient’s CD56+ cells, myoblasts, myotubes, and muscle homogenate 
were analysed together on a single qPCR assay. A blood sample and a muscle 
homogenate sample were analysed as controls. The blood sample would always be 
expected to have a copy number value less than 1, while the muscle sample should 
always be above 10. Samples were analysed in triplicate and the mtDNA copy number 
calculated using the equation r=2-ΔCt (He et al., 2002), with ΔCT being the difference in Ct 
values generated by the ND1 and the 18S probes. 
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6.3.2 Creating a Bottleneck 
To investigate if large shifts in heteroplasmy in muscle cells can result from amplification 
of a small population of mtDNA, it was decided to create a bottleneck by reducing the 
amount of mtDNA in myoblasts and allowing it to recover. If a corresponding shift in 
heteroplasmy occurred, it would suggest that amplification of a small number of genomes 
could account for the differences observed between patients with regards to their 
maintenance or loss of mtDNA deletions. 
Myoblasts from patient 2’s second biopsy (passage five) and from patient 3’s third biopsy 
(passage four), along with control myoblasts, were seeded with SKCM containing 
pyruvate, uridine and glucose. After five days, half of the plates had their medium 
changed for that containing 50ng/ml ethidium bromide (EtBr). Due to fears that 
myoblasts grown with EtBr would not reattach to the flasks after harvesting, cells were 
seeded in six well plates (~8300 cells per well) and a different well harvested for each 
time point. 
The cells were grown with or without EtBr for fifteen days, after which all cells were 
grown in medium without EtBr for a further thirty five days to allow the mtDNA copy 
number to recover. Cells were harvested at days 0, 6, 11, 15, 20, 25, 30, 37, 44, and 50 so 
that a sample of myoblasts grown both with and without EtBr was available for each time 
point. The cell harvesting days were chosen to enable many data points early on in the 
experiment close to the addition and removal of EtBr, as it was assumed most changes 
would occur around this switch. 
Myoblasts had their mtDNA extracted using the Qiagen DNeasy Blood & Tissue Kit. All 
cells were then analysed for heteroplasmy levels using the MTND1/MTND4 qPCR and 
copy number using the MTND1/18S qPCR. 
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6.3.3 Single Cell QPCR 
If there is a bottleneck occurring in the satellite cells it could be via a few mechanisms 
(Figure 6.1). The satellite cells may contain a mixture of WT and delete mtDNA or they 
could be homoplasmic, containing either WT or delete copies. 
In order to determine which of these two situations is correct, single CD56+ cells from 
patient 6 were FACS sorted with one cell going into each well of a ninety six well plate. 
The plate was then sealed, centrifuged and stored at -20oC until required. 
Thirty two cells from this plate were lysed with single cell lysis reagents (see section 
2.2.8.1.2) and then run on the MTND1/MTND4 qPCR in order to determine heteroplasmy 
levels. It was anticipated that many Ct values would be very high due to the lack of DNA 
present in the sample, so to ensure that results generated were attributable to mtDNA 
deletions, only samples that resulted in ND1 Ct values more than three cycles away from 
the ND1 no template controls were used. 
6.3.4 Inducing Differentiation 
While the stage of satellite cell activation served as one selection point, a second 
selection occurred as the myoblasts were proliferating and differentiating. In order to 
determine if it was during myoblast proliferation or differentiation that the mutation was 
lost, it was decided to differentiate an early passage of myoblasts into myotubes. 
Myoblasts at passage five from patient 2’s first and second biopsy and patient 3’s second 
and third biopsy were all differentiated into myotubes (as per section 2.2.7.4). 
The myotubes were then harvested and run on the MTND1/MTND4 qPCR assay to 
determine heteroplasmy levels. 
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6.3.5 Muscle Staining 
In order for “gene shifting” to occur muscle fibres containing mtDNA deletions will need 
to regenerate in order to incorporate developing myoblasts with little or no mtDNA 
mutation. 
To determine the regeneration status of respiratory chain deficient muscle cells, two sets 
of serial biopsy sections from a female patient harbouring a large scale single mtDNA 
deletion were stained for complex I subunit 20kDa (complex 1:20), and NCam (see section 
2.2.6). Complex I:20 staining was performed to provide an indication of the respiratory 
chain function, while NCam was used as a marker of muscle regeneration. Images were 
taken of the sections and fibre status was recorded on the basis of complex I:20 and 
NCam. The counts for the two sets of serial sections were combined. 
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6.4 Results 
6.4.1 MtDNA Copy Number 
In order for a bottleneck to occur there must be amplification of mtDNA from a small 
population of molecules. To determine if satellite cells have a small population of mtDNA, 
a qPCR copy number assay was performed. 
The MTND1/18S qPCR was used to give a relative indicator of mtDNA copy number of 
CD56+ cells, myoblasts, and myotubes. Each patient’s samples were all analysed on a 
single qPCR assay in triplicate. This was done to avoid any variation between runs. 
In all patients the mtDNA copy number of CD56+ cells was below six. In the first set of 
myoblasts examined, the copy number had risen to above that of the satellite cells in six 
out of ten cell lines and by the second set of myoblasts it was eight out of ten. While 
there was some fluctuation, the general trend was for an increase in mtDNA copy number 
after satellite cell activation and during myoblast proliferation (Table 6.1). In order to 
determine how copy number changed with passage number a Pearson correlation 
analysis was performed on the results. The R values demonstrated the relationships were 
positive, so as the passage number increased so did the mtDNA copy number (Table 6.1). 
Two cell lines did not give a significant result, patient 4’s second biopsy and patient 2’s 
first biopsy. 
 
 
 
 
 
 
 
 
 
  
  
 
Table 6.1 Copy number of cells. CD56+ cells, myoblasts, myotubes, and muscle homogenate samples were run on the MTND1/18S qPCR in order to determine 
relative copy number. All CD56+ cells had lower levels of mtDNA than the corresponding muscle homogenate sample, apart from patient 4. A gradual increase 
in mtDNA copy number was observed as the cells were proliferating and heading towards differentiation. The values given are relative to an nDNA marker, so 
increases in copy numbers also suggest mtDNA is being replicated faster than nDNA. Myob = myoblasts, MyoT = myotubes, SKM = skeletal muscle homogenate. 
C
h
ap
te
r 6
 
 
 
 
 
 
 
M
tD
N
A
 D
eletio
n
s an
d
 Selectio
n
 P
o
in
ts 
2
04
 
Chapter 7                                             Satellite Cell Numbers in Mitochondrial Myopathy Patients 
205 
  
6.4.2 Creating a Bottleneck 
To determine if an mtDNA bottleneck could account for the rapid change in heteroplasmy 
between satellite cells and myoblasts the effect was recreated. This was performed on 
myoblasts from patients 2 and 3, which maintained the mutation, and on a control cell 
line. Myoblasts were grown with and without EtBr for fifteen days before all cells had 
medium changed for that without EtBr and were grown for a further thirty five days. 
The results from the control cell line showed that myoblasts with and without EtBr had a 
reduction in mtDNA copy number that never recovered (Figure 6.2E). 
The myoblasts from patient 2 that contained EtBr had a reduction in copy number, but 
apart from a high copy number at day twenty, this never recovered. The heteroplasmy 
level remained between 70-80%, apart from day thirty seven which was 91% (Figure 
6.2A). When myoblasts from this patient were grown without EtBr, again the 
heteroplasmy levels remained steady. While the copy number increased initially, this was 
followed by a dramatic reduction which never recovered (Figure 6.2B). 
The cells from patient 3 that had EtBr added saw an initial reduction in copy number, 
followed by a slight recovery after the medium was changed to that without EtBr. There 
was an initial increase in heteroplasmy levels followed by a decrease to around 25% 
(Figure 6.2C). The cells from this patient that did not contain EtBr saw an initial increase in 
copy number, but this preceded a general trend downwards, apart from the cells 
harvested at day thirty seven. In line with this downward trend was a reduction in 
heteroplasmy level. It was not possible to harvest a set of cells from day fifty for this 
patient (Figure 6.2D). 
When myoblasts were grown without EtBr there was an initial increase in copy number, 
but this was followed by a decrease around days fifteen to twenty. While the addition of 
EtBr did cause an initial reduction in mtDNA copies, there was never any recovery and 
thus no amplification of mtDNA from a small population of genomes. Cell counts were 
performed on the myoblasts, but were not deemed accurate. While cells were still visible 
in the wells, low numbers resulted in a value of zero using the haemocytometer. While 
these counts were disappointing, it suggests the myoblasts were dying, which could be 
the reason for the reduction in copy number. Therefore no conclusions may be drawn 
from this experiment about the hypothesised bottleneck mechanism. 
  
  
Figure 6.2 Effects of ethidium bromide on myoblasts. Myoblasts from patients 2 and 3 were grown with and without EtBr in order to induce an mtDNA bottleneck. E. 
The control cell line declined in copy number when grown both with and without EtBr. B & D. The two patient cells lines both saw an initial increase in copy number 
when grown without EtBr, but this reduced around day twenty. A & C. When grown with EtBr both patient cell lines had a decrease in mtDNA, that never recovered to 
levels observed before the addition of EtBr. While there were variations in heteroplasmy levels for patients, this did not appear to be related to mtDNA copy number. 
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6.4.3 Single Cell QPCR 
Having hypothesised that the first selection point was attributable to a bottleneck, it was 
decided to perform single cell qPCR on some of the satellite cells in order to determine if 
they were heteroplasmic or homoplasmic on the basis of mtDNA deletions. Single CD56+ 
cells were FACS sorted into wells of a ninety six well plate, lysed and run on a 
MTND1/MTND4 qPCR to determine deletion levels. 
Out of the thirty two cells that were originally lysed and run on this assay, ten resulted in 
ND1 Ct values that were far enough away from the no template controls to be analysed. 
Five of these samples were run a second time to confirm the findings. 
The cells were heteroplasmic on the basis of mtDNA deletions. Two of the cells had quite 
high levels of deletions, two had levels around 50% and the rest had levels below the 
detection sensitivity of this assay, 30%. The level set for sensitivity of this assay (30%) is 
justified by the results of the repeats. While the cell with a high heteroplasmy level (88%) 
was consistent in the second run (90%), the cells that had levels below 30% were not 
consistent between the two runs (Table 6.2). 
This patient has a muscle heteroplasmy level of 48% and a satellite cell heteroplasmy 
level of 44%. The heteroplasmy level for his homogenate sample of satellite cells has been 
obtained through a mixture of different heteroplasmy values for individual cells. 
 
 
Table 6.2 Single cell qPCR. Single CD56+ cells from patient 6 were FACS sorted into wells of a ninety six 
well plate. An MTND1/MTND4 qPCR assay was performed on the lysed cells. The cells were 
heteroplasmic, with variable levels of mtDNA deletions. Five of the samples were run a second time and 
confirmed the presence of heteroplasmy. 
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6.4.4 Inducing Differentiation 
In order to determine if myoblast proliferation or the process of differentiation causes the 
mtDNA deletion to be lost, a number of the myoblast cell lines were differentiated at 
passage five. This was earlier than they had previously been differentiated. Their 
heteroplasmy levels were then determined using the MTND1/MTND4 qPCR. 
After differentiation all the myotubes still harboured mtDNA deletions and when 
compared to myoblasts of the same passage there appeared to be no difference. Deletion 
levels in patient 2’s first biopsy passage five myotubes appeared to be a little higher than 
myoblasts of similar passage number and were much higher than the myotubes 
differentiated at a later passage. His second biopsy passage five myotubes, were again a 
little higher than similar passage myoblasts, but generally were no different to cells 
around the same passage (Table 6.3). 
Patient 3 had originally lost the mtDNA deletion after his myoblasts were differentiated 
into myotubes at passage six, however, that did not occur on this occasion. His passage 
five myotubes were of a similar level to passage five myoblasts (Table 6.3). 
These data would suggest that differentiating myoblasts into myotubes did not induce the 
mutation to be lost. On the two out of three cases the mutations were lost, it occurred 
during the process of myoblast proliferation. 
 
 
Table 6.3 Heteroplasmy levels in myotubes. Differentiating myoblasts did not appear to change their 
heteroplasmy levels. Levels of mtDNA deletions were maintained as if the cells had carried on to 
their next passage. Myob = myoblasts, MyoT P5 = myotubes differentiated at passage 5. 
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6.4.5 Muscle Staining 
If “gene shifting” is to succeed, then muscle fibres with a respiratory chain deficiency will 
need to be capable of regeneration. Then through the incorporation of cells with lower or 
absent levels of mtDNA mutation, the phenotype of the fibre may be changed. 
Complex I:20 reacts against the NDUFB8 subunit of complex I. If a cell is lacking the ND4 
gene because it has been removed by a deletion in the major arc, the assembly pathway 
of complex I will be inhibited, resulting in a loss of NDUFB8 incorporation into the 
complex. NCam was used to determine if the fibres were regenerating. Through staining 
serial muscle sections with these antibodies it was possible to determine the NCam and 
complex I:20 status for muscle fibres visible on both sections (Figure 6.3A). 
In total 206 muscle fibres were counted, of which the majority, 62%, were NCam 
negative. The complex I:20 staining showed that most of the fibres were complex I:20 
positive, 61% (Figure 6.3B). In total there were 80 fibres that were complex I:20 negative. 
Out of these 80 complex I:20 negative fibres 58% were NCam positive, compared to 25% 
of complex I:20 positive fibres. This suggests that respiratory deficient muscle fibres were 
trying to regenerate. 
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Figure 6.3 Muscle regeneration and respiratory chain function. A. Serial sections were stained for 
complex I:20 and NCam. Fibres were then identified on both sections and staining for both antibodies 
recorded. In the above image, fibres 1 and 2 both have a normal respiratory chain and are not 
regenerating. Fibre 3 however, is complex I:20 deficient and NCam positive suggesting it is trying to 
regenerate. While fibre 4 is also trying to regenerate, it is complex I:20 positive. B. In total 206 fibres 
were counted and recorded. 
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6.5 Discussion 
The aims of this chapter were to identify selection points and mechanisms of selection 
acting on the cells responsible for muscle regeneration. It had been hypothesised that 
selection was acting after satellite cell activation via a bottleneck effect. Then as the 
myoblasts proliferated and headed for differentiation a second selection point occurred, 
possibly mediated by a switch in energy generation from mainly glycolytic to primarily 
oxidative. In addition this chapter sought to determine if respiratory deficient cells could 
regenerate. 
6.5.1 Bottleneck Theory 
It was hypothesised that one of the selection points was caused by a bottleneck taking 
place at the point of satellite cell activation. One of the possible mechanisms by which 
this could occur is through homoplasmic satellite cells being selectively activated. 
While only a few single satellite cells resulted in Ct values that could be used; the qPCR 
studies revealed that satellite cells are heteroplasmic on the basis of mtDNA deletions. 
The levels of heteroplasmy were spread out (range of 0-88%), consisting of a couple of 
cells harbouring high levels of mtDNA deletions, two with intermediate levels and the rest 
contained low levels. When the homogenate sample of CD56+ cells from this patient was 
examined, it contained a heteroplasmy level of 44% (Table 4.5). This is a result of 
individual cells having different levels rather than all cells harbouring 44%. This suggests 
that the bottleneck is acting on satellite cells that are heteroplasmic for mtDNA deletions. 
This experiment was performed after many of the patients had undergone all of their 
biopsies, so it has only been possible to perform it in one subject. It will be necessary to 
repeat this experiment in future patients to confirm the findings. In addition, to 
determine the exact levels of mtDNA deletions in the CD56+ cells with less than 30% 
heteroplasmy, it will be necessary to use the relevant mtDNA deletion specific SYBR 
Green assay. 
The segregation of mutant mtDNA within the CD56+ cells is intriguing. The mutation is 
present in the satellite cells but not in all of them. This would be in agreement with the 
status quo in muscle fibres, where a mosaic pattern of COX staining is observed between 
muscle fibres, which corresponds to a variable mtDNA deletion level (He et al., 2002). 
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This raises the question of how the CD56+ cells have such a wide variety of heteroplasmy 
levels. It is possible, given the low mtDNA copy number they contain, that clonal 
expansion has occurred in some cells, but not in others. This selective clonal expansion 
could be dependent on which satellite cells have been activated in the past and therefore 
have undergone mtDNA replication. 
Alternatively, the mtDNA deletions are present in all the satellite cells and after the first 
division there will be a random distribution of delete molecules between the two 
daughter cells. This could result in very different heteroplasmy levels in these two cells. 
One of the daughter cells will return to the satellite cell pool until further activation and 
division. Over time and multiple activations, the levels of mtDNA deletions in the stem 
cell will head towards one of two possible fates, homoplasmic WT or homoplasmic 
mutant. Given the low mtDNA copy number in satellite cells, this could occur very rapidly. 
Computer simulations have suggested this could happen in around 70 divisions in a stem 
cell with 250 copies of the mtDNA (Coller et al., 2002). 
In order for a bottleneck to occur there needs to be amplification from a small population 
of mtDNA copies. To demonstrate that satellite cells contain relatively few copies of 
mtDNA when compared to their descendents, a qPCR assay was performed that 
compared the ratio of mtDNA with nDNA. These data demonstrate that there are very 
low levels of mtDNA relative to the amounts seen in myoblasts, in some cases in very 
early stage myoblasts. 
As well as providing support for the bottleneck theory of selection, the copy number data 
also shows the large increase in mitochondrial biogenesis that occurs as the myoblasts 
proliferate and differentiate. 
While the satellite cells and myoblasts come from the same biopsies, the myoblasts were 
cultured from different satellite cells in the biobank; this could account for the slight 
delay in myoblast mtDNA copy number exceeding that of the satellite cells. 
One of the aims of this chapter was to demonstrate that a bottleneck could create large 
shifts in heteroplasmy in muscle cells. In order to create a bottleneck effect, the mtDNA 
content was reduced in myoblasts containing a single mtDNA deletion, through the use of 
EtBr for fifteen days. 
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While EtBr succeeded in reducing mtDNA copy number there was never any recovery in 
levels. In addition, after fifteen days, even the myoblasts that did not contain EtBr started 
to lose mtDNA. This was probably attributable to myoblasts dying. Similar depletion 
experiments using EtBr have shown that cell lines containing heteroplasmic mtDNA 
deletions are repopulated with delete mtDNA two to three times faster than that with WT 
mtDNA (Diaz et al., 2002). It would have been intriguing to examine such an effect in 
myoblasts. 
However, myoblasts are difficult to culture after a number of passages and length of time. 
It may be that starting this experiment with cells at passages three and four was too late, 
especially considering that the whole experiment lasted fifty days. Performing this 
experiment at an earlier passage, reducing the EtBr concentration, or applying it for less 
time may help. In addition there are other methods of reducing mtDNA. While drugs such 
as chloramphenicol and doxycycline have been used to simulate an mtDNA depletion 
phenotype, they affect mtDNA translation and would not have reduced mtDNA copy 
number (Olgun and Akman, 2007). An actual reduction in mtDNA copy number can be 
obtained with nucleoside reverse transcriptase inhibitors (NRTIs), which inhibit the 
mitochondrial polymerase POLG (Koczor and Lewis, 2010). Treatment of myoblasts with 
one of these drugs may have resulted in a less harsh response. 
While a bottleneck could explain the rapid shift in heteroplasmy observed in some of our 
patients at the stage of satellite cell activation, it does not result in complete separation 
of WT and delete mtDNA. Most of the patients who lost the mutation from their cells, lost 
it completely, for example patients 4 and 6. However, with patient 3’s second biopsy and 
patient 5’s first biopsy there was some evidence of a small amount of delete mtDNA 
persisting in the myoblasts. In addition, the myoblasts that maintained the mtDNA 
deletion also contained WT mtDNA; this suggests that the segregation is not absolute. 
This is probably because of small amounts of delete mtDNA present in mitochondria that 
are otherwise WT, or WT mtDNA in mitochondria which primarily consist of delete 
mtDNA. 
However, taken together the above experiments suggest a bottleneck is responsible for 
the rapid loss of mtDNA deletions in some patients and its maintenance in others at the 
point of satellite cell activation. However, it does not distinguish between the two 
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remaining hypotheses for how it occurs (Figure 6.1A&B). It could be attributable to a 
physical reduction in mtDNA copy number caused by a cellular division followed by 
segregation of the genomes. Alternatively it could be caused by random activation of 
satellite cells that consist primarily of WT or delete mtDNA. A third possibility is that both 
mechanisms are occurring. 
6.5.2 MtDNA Deletion Loss from Myoblasts 
A second selection point was hypothesised to occur during myoblast differentiation to 
myotubes, coinciding with an increase in OXPHOS. In order to test this, cells from patients 
who maintained the mutation in their myoblasts were differentiated at passage five, this 
would hopefully push the cells into using OXPHOS for energy. If the switch from glycolysis 
to OXPHOS was causing selection against cells with impaired respiratory chain activity, 
then a parallel decrease in heteroplasmy levels as the cells were differentiated should 
have been observed. 
The results show that the process of myoblast differentiation into myotubes did not cause 
the loss of mtDNA deletions from the cells. This would suggest some other mechanism is 
responsible for the reduction in heteroplasmy as the cells are proliferating. 
Given that mtDNA deletions were lost in two out of three sets of myoblasts, it is possible 
that a more random mechanism is acting on the cells. As the myoblasts are dividing there 
could be asymmetric segregation of mtDNA on the basis of mtDNA deletions. Any 
myoblasts that inherit a large amount of mtDNA with a deletion may be unable to survive 
or proliferate as rapidly as myoblasts that have inherited very little or no delete mtDNA. 
6.5.3 Muscle Regeneration 
If gene shifting is to be successful then muscle fibres with a respiratory chain defect will 
need to be able to regenerate. In order to test their capability to do so, serial sections 
were stained for complex I:20 and NCam. NCam is expressed in regenerating myofibres 
and has previously been used in studies examining muscle regeneration (Walsh and 
Moore, 1985, Shoubridge et al., 1997). 
The finding that 58% of complex I:20 negative cells were NCam positive, suggests these 
fibres were attempting to regenerate. Although it is not possible to determine how 
advanced this regeneration is, or if it will ultimately be successful. It was interesting to 
note that 25% of complex I:20 positive cells were also NCam positive. The source of this 
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biopsy was a female patient with a large scale single mtDNA deletion. While she is not 
involved in the current exercise trial taking place in Newcastle, she had been undertaking 
an exercise trial at a centre in Texas. It is possible that there was some degree of 
regeneration occurring in her muscle caused by this trial. 
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6.6 Conclusions and Future Work 
Muscle regeneration in these patients potentially involves two selection points; the first 
at the time of satellite cell activation, and a second during myoblast proliferation (Figure 
6.4). 
While it is very difficult to determine exactly what happens at the point of satellite cell 
activation, the results of these experiments suggest that a bottleneck is occurring. 
Satellite cells are heteroplasmic for mtDNA deletions. The mutations are being 
dramatically lost or maintained through either, asymmetric division and a reduction in 
mtDNA copy number, or activation of satellite cells that consist primarily of WT or delete 
mtDNA. 
If single fibre culture could be performed with samples from these patients it would be 
possible to examine copy number and heteroplasmy levels in cells as they were leaving 
the fibre. This would give a much better indication of what was going on at the point of 
satellite cell activation and possibly help determine if the bottleneck is occurring via 
selected satellite cell activation or asymmetric division. In addition, obtaining more single 
satellite cells from future patients and analysing them with the relevant SYBR Green qPCR 
would provide a much more accurate picture of what is occurring in these cells. 
It would be interesting to attempt to examine absolute copy number in satellite cells. This 
may be difficult to perform on homogenate samples, as cells will have been lost during 
the process of centrifugation to remove supernatants, and also DNA extraction. However, 
if a small number of cells, for example less than fifty, were FACS sorted into a ninety six 
well plate, they could be lysed in the plate and would hopefully contain enough DNA to 
run on a qPCR assay. This could be performed using a probe for MTND1 and a standard 
curve of mtDNA concentrations. 
The second selection point did not coincide with differentiation from myoblasts to 
myotubes, but probably with myoblast proliferation. While it is possible that the cells 
with mtDNA deletions were dying, this did not happen in all cases, which suggests it may 
be a more stochastic mechanism. This could be the asymmetric localisation of 
predominantly WT and delete mitochondria, with myoblasts inheriting large amounts of 
delete mtDNA dying. 
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While both selection points seem somewhat random, out of the nine biopsies that 
myoblasts were available for and where the mutation levels could be mapped, eight 
resulted in myotubes with no mutation. This continues to suggest that gene shifting is 
theoretically possible; especially considering respiratory chain deficient cells are capable 
of regenerating. 
 
  
  
Figure 6.4 Selection points. It has been hypothesised in this chapter that selection acts at two points during the process of muscle regeneration. The first selection 
point is after satellite cell activation, and occurs through a bottleneck mechanism. This could occur via an asymmetric division with one daughter cell going back to 
repopulate the satellite cell pool and the other proceeding to form myoblasts, and/or through activation of satellite cells with either a high or low amount of mtDNA 
mutation. If the mutation is maintained then a second period of selection occurs when the cells divide and any resultant myoblasts with high levels of deletions die.  
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Chapter 7 Satellite Cell Numbers in Mitochondrial Myopathy 
Patients 
7.1 Introduction 
The previous chapters have concluded that the stimulation of muscle satellite cells and 
loss of mtDNA mutation as the resultant myoblasts head towards differentiation could 
benefit mitochondrial myopathy patients through the process of “gene shifting”. To 
stimulate satellite cell activation, our lab is using resistance training to induce damage 
within the muscle. However, for this approach to be successful satellite cells must be 
present in sufficient quantities to repeatedly activate and repair muscle. 
Mutations of mtDNA have often been described as causing an ageing phenotype 
(Trifunovic et al., 2004). This coupled with the myopathic nature of the conditions the 
patients in the current study have, give cause for concern regarding the ability of their 
muscles to regenerate. As well as any muscle wasting caused by their condition, there 
is the added issue of inactivity in these patients. This will lead to a further decline in 
the health of their muscles. If these patients are performing resistance training in 
order to “gene shift” it will be necessary to ensure they have adequate numbers of 
satellite cells to repair their muscles, and do not experience an exhaustion of the stem 
cell pool. 
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7.2 Aims 
The aims of this chapter are to examine satellite cell numbers in patients with 
mitochondrial myopathies caused by sporadically occurring single mtDNA deletions. 
This is to ensure that efforts to stimulate satellite cells will not be detrimental to 
patients in terms of stem cell numbers. 
To investigate this, satellite cell numbers will be determined in mitochondrial 
myopathy patients harbouring sporadically occurring single mtDNA deletions under 
three conditions. The first will be examining satellite cell numbers in patients 
compared to control samples to determine if the disease itself causes any significant 
increase or decrease in numbers. Secondly it will investigate how satellite cell numbers 
change in a patient over eleven years, in order to ascertain if there is likely to be any 
detrimental increase or decrease as patients’ age. Finally, it will examine the effects of 
six months of resistance training in patients that has been designed to stimulate 
satellite cells and encourage their incorporation into muscle. 
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7.2.1 Satellite Cell Numbers in Mitochondrial Myopathy Patients Compared to 
Control Subjects 
7.2.1.1 Satellite Cells in Myopathies 
Patients with muscle degenerative conditions will naturally undergo repeated bouts of 
degeneration and regeneration, with each cycle requiring satellite cells in order to 
repair the muscle. There is some concern as to if this damages or exhausts the satellite 
cells. 
An early study using electron microscopy (EM) examined satellite cell numbers in 
patients suffering from a range of neuromuscular disorders. It was found that they 
contained higher percentages of satellite cells per nuclei (satellite cell frequency) 
when compared to control subjects. Patients with Duchenne’s Muscular Dystrophy 
(DMD) had a satellite cell frequency of 28.10 ±7.3%, polymyositis (PM) patients had 
14.88 ±6.31%, and myotonic dystrophy (MD) patients had 11.6±4.4%. The control 
subjects had a much lower frequency of 4.32±1.29%. While this data suggests that 
patients with a neuromuscular disorder have a higher satellite cell frequency, there 
were marked differences in the age of patients, which was a reflection of typical age of 
onset. The mean age of the control subjects was thirty years. The DMD patients were 
around seven years, the PM patients fifty two years, and the MD patients were an 
average of thirty six years (Ishimoto et al., 1983). 
The later age of onset of PM may mean that despite the increase in satellite cell 
numbers their stem cell pool never becomes exhausted, however this may not be the 
case in DMD patients. Their greatly increased satellite cell numbers at such a young 
age may result in an exhausted stem cell pool later on. This could be a problem with 
the increasing survival age of DMD patients, in no small part helped by the use of non-
invasive ventilation (Simonds, 2006). This increased life span results in their muscles 
undergoing many more rounds of degeneration and regeneration. 
The possibility that patients with dystrophic muscle may reduce the regenerative 
ability of, or exhaust their satellite cells has been partly suggested because of findings 
in the mdx mouse, an animal model of DMD. These mice have been shown to lack a 
population of highly proliferative radiation resistant cells, when injected with the 
strong myotoxin notexin (Heslop et al., 2000). This has been attributed to the 
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exhaustion of this particular cell lineage through repeated bouts of degeneration and 
regeneration (Luz et al., 2002). 
The repeated bouts of regeneration may not only exhaust the satellite cell pool. 
Muscle biopsies from dystrophic muscle, caused by DMD and Limb Girdle Muscular 
Dystrophy 2C (LGMD 2C), have shown significant reductions in telomere length when 
compared to controls. This signals an increased senescence of the satellite cells 
(Decary et al., 2000). The shortness of telomeres indicates that the satellite cell have 
undergone repeated divisions in order to repair the muscle. The participation of 
satellite cells in this regeneration has been shown to reduce their proliferation 
potential (Schultz and Jaryszak, 1985). 
While the cycles of degeneration and regeneration may not be as numerous in 
patients with mitochondrial disease compared to those with DMD, it is still necessary 
to examine the situation in mitochondrial patients, especially if they will be partaking 
in activities to cause muscle damage. 
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7.2.1.2 Methods 
In order to compare the satellite cell frequencies of patients and controls, Pax 7 
staining was performed (see section 2.2.6.1). Muscle biopsies from the vastus lateralis 
of ten patients with a mitochondrial myopathy caused by a sporadically occurring 
single mtDNA deletion were cut at 12µm by Dr. J. Murphy. These patients included the 
eight described in chapter 3, from whom sections were obtained from their baseline 
biopsy. This single mtDNA deletion group consisted of ten subjects, six male and four 
female, with an average age of forty two. Except for patients 8 and 9, two muscle 
sections were cut and stained for Pax7. Patients 8 and 9 only had small biopsy samples 
and tissue was required for other experiments, as a result counts were performed on 
one muscle section. 
Control muscle samples were received from the Freeman Hospital, Newcastle, from 
patients undergoing operations to repair their anterior cruciate ligament (ACL). When 
patients undergo this operation part of their hamstring is removed to repair the 
ligament. When the operation is performed, part of the muscle attached to the 
ligament is removed along with it, and usually discarded. This is the muscle sample 
that was received to be used as control tissue. 
Eleven muscle samples were obtained from these control subjects, eight male and 
three female with an average age of thirty six. They were cut at 12µm, and stained for 
Pax7. Counts were only performed on one muscle section from each subject. Given the 
large size of the muscle sections and therefore the large number of fibres counted this 
was deemed sufficient to give an accurate impression of the muscle biopsy. 
Counts of muscle fibres, satellite cells, and myonuclei were performed on an Olympus 
BX51, using Stereo Investigator software (MBF Biosciences, USA). To perform the 
counts, an outline was drawn around the section at a low magnification, ensuring the 
marked area encompassed a minimum of one hundred fibres. Occasionally staining 
resulted in a darker band around the outside of the muscle section, so to prevent any 
ambiguity regarding counting, the boundary was drawn a couple of fibres into the 
section. 
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The magnification was then increased, and the computer software scanned the section 
within the outlined image. On each new image, counts of fibres, myonuclei and 
satellite cells that lay within the boundary of the area were performed (Figure 7.1). 
Any fibres that lay across the line were only counted if both the left hand and bottom 
edge was within the boundary. The numbers of fibres, myonuclei, and satellite cells 
were recorded every fifty fibres. 
The numbers of satellite cells were assessed by determining the satellite cell frequency 
in each biopsy. This was performed using the equation: 
Satellite cell frequency = 
                     
                           
 X 100 
 
Figure 7.1 Counting cells on Stereo Investigator. On each muscle section a line was drawn 
around the outside of the muscle section, seen here in green, with fibres to the right of this 
line being included in the count, and those to the left of the line not being counted. Satellite 
cells were stained for Pax7 and visualised with DAB. They are therefore visible as brown 
nuclei. In each area the fibres (red dots), myonuclei (blue dots), and satellite cells (pink stars) 
were counted. 
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7.2.1.3 Results 
Counts were performed on ten patients (six males: mean age 42.5±9.9, and four 
females: mean age 42.5±12). There were considerable differences between patients in 
terms of how many fibres (148 to 1380), myonuclei (3113 to 9694), and satellite cells 
(51 to 214) that were counted (Table 7.1). This was attributable to the differing sizes of 
the biopsies. 
Control muscle sections were available from the hamstring group of muscles from 
eleven subjects. While this sample is from a different muscle, its common 
embryological origin and similar fibre type ratio to the vastus lateralis, which was 
biopsied in the patients, suggested it would provide an appropriate comparison 
(Garrett et al., 1984). The control muscle samples consisted of eight males (mean age 
38 ±10 years) and three females (mean age 32 ±10 years). As previously, there were 
marked differences between the numbers of fibres (220 to 1792), myonuclei (1348-
12030), and satellite cells (57 to 267) counted, which again was attributable to 
variation in section sizes (Table 7.2). Interestingly this group demonstrated much more 
variation in numbers of fibres, myonuclei, and satellite cells, as evidenced by their 
standard deviations. Satellite cell frequencies were determined for both groups using 
the equation stated previously. 
The average satellite cell frequency for the patients was 2.37±0.725, while for the 
controls it was 2.39± 1.03. As can be seen from the graph and the standard deviations, 
there was slightly more variation in the satellite cell frequencies of the control subjects 
(Figure 7.2). An Anderson Darling test showed satellite cell frequencies were not 
significantly different from a normal distribution. A two sample t-test showed there 
was no significant difference between the satellite cell frequencies of patients when 
compared to controls (P=0.958). 
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Table 7.1 Satellite cell numbers in patients. Ten mitochondrial myopathy patients 
had counts of muscle fibres, myonuclei, and satellite cells performed to determine 
satellite cell frequency. 
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Table 7.2. Satellite cell numbers in control subjects. Eleven control subjects had 
counts of muscle fibres, myonuclei, and satellite cells performed. The control 
subjects appeared to have a wider distribution of fibres, myonuclei, and satellite 
cells. 
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Figure 7.2 Satellite cell frequencies in mitochondrial myopathy patients and 
control subjects. Satellite cell frequencies were determined for ten patients with 
a mitochondrial myopathy, and eleven subjects who had undergone an operation 
to repair their anterior cruciate ligament. The control subjects appeared to have a 
wider spread of data. The line indicates the average satellite cell frequency for 
each group. 
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7.2.2 Effects of Ageing on Satellite Cell Numbers in Mitochondrial Myopathy 
Patients 
7.2.2.1 Satellite Cells in Ageing 
As muscle ages its ability to regenerate diminishes. When this results in a large amount 
of muscle loss it is termed sarcopenia. Sarcopenia contributes to falls and general 
weakness, which in turn leads to a greater morbidity in ageing people. While the exact 
cause is still being debated, many things are thought to contribute to this loss of 
regeneration potential in aged muscle. Possible influences include malnutrition, injury, 
hormonal changes, denervation, lack of exercise and general disuse. These factors 
cause decreased protein synthesis, the accumulation of deleterious effects of reactive 
oxygen species, altered enzyme activities and impaired glucose metabolism (Carmerli 
et al., 2002, Fulle et al., 2004). 
In addition, a role for mitochondria in sarcopenia has been suggested. Aged muscle 
fibres from rats were found to contain high levels of mtDNA deletions. When levels of 
mutation exceeded 90% the fibres displayed impaired COX activity and were prone to 
splitting (Herbst et al., 2007), a phenomenon often observed in neuromuscular 
disorders (Swash and Schwartz, 1977). While mtDNA mutations have been found in 
ageing human tissue, they are at a very low level, less than 1%. However, this 
heteroplasmy level has been generated through many fibres with no mutation and 
some containing segments of very high levels. These segments of high mutation load 
may then be prone to splitting, resulting in muscle loss (Khrapko and Vijg, 2009, Bua et 
al., 2006). 
Satellite cells are also thought to contribute to sarcopenia, although their exact role is 
still under discussion. A satellite cell’s decreased potential to regenerate could be 
attributable to a systemic factor, problems relating to the muscle itself, changes in the 
stem cell niche, or something intrinsic to the satellite cell. 
The importance of systemic factors in satellite cell mediated muscle regeneration was 
nicely highlighted by experiments creating parabiotic pairings between old and young 
mice (Conboy et al., 2005). Exposure of old mice to a young circulatory system 
restored the proliferation and regenerative capacity of “old” satellite cells. Partly 
mediated by a restoration of Notch signalling, that had previously been shown to be 
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impaired in aged muscle (Conboy et al., 2003). Notch is an important regulator of the 
pathway that leads from activated satellite cells to differentiated myotubes. 
Extrinsic factors caused by the stem cell niche could also play a role. As muscle ages it 
suffers from a reduced blood flow and a consequent decline in factors needed for 
satellite cell activation. The basal laminar also thickens with age, again making it 
harder for activation and for other factors to diffuse through to the satellite cells 
(Brack and Rando, 2007). 
Factors intrinsic to the stem cell will also contribute to reduced muscle regeneration. 
Aging in haemopoetic stem cells has been linked to genetic damage, but whether this 
holds true for satellite cells that have a lower cellular turnover is somewhat unknown 
(Brunet and Rando, 2007). 
One study found that both intrinsic and extrinsic factors contributed to the decline in 
satellite cell potential. Experiments isolating aged myofibres and culturing the satellite 
cell progeny demonstrated that while there was a reduction in myogenic cells, a 
minority were capable of proliferating, differentiating, and self-renewing. When these 
aged myofibres were engrafted into young mice, this preserved minority of satellite 
cells were able to regenerate muscle just as efficiently as “young” satellite cells (Collins 
et al., 2007). 
Other studies examining the contribution of satellite cells to the aging phenotype of 
muscle, have examined the numbers of these cells available for regeneration as people 
age. Evidence for a depletion of satellite cells in ageing came from early studies 
marking a decline in satellite cell frequency in mice from 4.6% to 2.4% as they aged 
over a period of twenty two months, starting at month eight (Snow, 1977). More 
recently it was noted that satellite cell numbers as determined by Pax7 staining, in 
extensor digitorum longus (EDL) and soleus muscle fibres, significantly decreased 
towards the end of the life span in mice. It was interesting to note that the decrease in 
the EDL muscle occurred much quicker than in the soleus muscle (Shefer et al., 2006). 
In rodents the EDL is primarily composed of type II fibres, while the soleus is primarily 
composed of type I fibres (Soukup et al., 2002, Barclay and Weber, 2004), suggesting a 
susceptibility of type II fibres to satellite cell exhaustion. 
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However, in humans the debate is somewhat less clear. Roth et al. (2000) examined 
men and women classed as young (20-30 years) and old (65-75 years) and found no 
difference between any of the groups. Biopsies from the vastus lateralis were 
collected and analysed using EM. Satellite cell frequency as a percentage of total 
myonuclei was determined. While the older groups had more central nuclei than the 
younger groups, suggesting more regeneration was occurring in their muscles, it was 
concluded that there was no reduction in the stem cell pool as people age (Roth et al., 
2000). 
In contrast to this, Verdijk et al. (2007), observed a reduction in satellite cell numbers 
in old (average 76 years) verses young (average 20 years) males, in the vastus lateralis. 
This reduction was only observed in type II fibres and not in type I fibres and coincided 
with the atrophy patterns observed in the older subjects, with specific degeneration of 
the type II fibres (Verdijk et al., 2007). This supported findings of a specific fibre type 
related atrophy in aging mammals (Shefer et al., 2006). 
Other studies have found no age associated differences in the vastus lateralis (Dreyer 
et al., 2006). But declines noted with age when the tibialis anterior (Kadi et al., 2004) 
and the biceps brachii and masseter (Renault et al., 2002) muscles were studied. 
Findings that older people did not have significantly shorter telomeres in their satellite 
cells suggests that any exhaustion of the satellite cell pool may not be attributable to 
excessive turnover of cells (Renault et al., 2002). 
While the previous section suggests that an exhaustion of the satellite cell pool may 
not initially be an issue in these patients, the combined effects of multiple cycles of 
regeneration over time, in addition to any changes that occur due to aging, may create 
a deficiency. This situation may be compounded by the fact mitochondrial disease has 
often been compared to an aging phenotype. Although it would appear that the 
reduced ability of satellite cells to repair muscle as people age is multi-dimensional, 
the opportunity to examine one of these potential factors, satellite cell numbers, must 
be taken. 
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7.2.2.2 Methods 
In order to determine how the numbers of satellite cells change as a patient ages, a 
series of biopsies from a patient with a sporadically occurring large scale single mtDNA 
deletion were examined. This patient had previously been shown to contain COX 
negative fibres in her muscle. Patient 9 (Table 7.1) has undergone ten muscle biopsies 
over a period of eleven years (130 months), with her first biopsy being performed at 
the age of thirty two. 
Muscle sections were cut at 12µm, stained for Pax7, and counted as previously 
described (section 7.2.1.2). Due to the small amount of tissue available from some of 
the biopsies, it was only possible to obtain two sections from seven out of the ten 
biopsies performed. The remaining three biopsies only had one section counted. 
Where two sections were counted the results were averaged. 
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7.2.2.3 Results 
A total of ten biopsies from the vastus lateralis of a single patient over eleven years 
were analysed to determine satellite cell frequencies. The sizes of the biopsies varied, 
as evidenced by the wide ranging numbers of muscle fibres (332 to 1737), myonuclei 
(3067 to 9736), and satellite cells (80 to 240). The average number of muscle fibres 
counted was 886±536; myonuclei 7448±2808, and satellite cells were 190±60. Over 
the ten biopsies average satellite cell frequency was 2.53±0.45. There appeared to be 
a slight increase over time (Figure 7.3), which was shown to be significant using a 
Pearson’s Correlation (P<0.05).The Pearson’s number was 0.644, demonstrating the 
correlation was positive. In this patient, satellite cell frequency increased with age. 
When the satellite cell frequencies for mitochondrial myopathy patients from the 
previous experiment (section 7.2.1.3) were plotted against age at biopsy, a regression 
line showed a slight increase had occurred (Figure 7.4A). However, Pearson’s 
Correlation showed there was no relationship between age at biopsy and satellite cell 
number (P=0.491), Pearson’s value 0.247. When the same analysis was performed on 
the control subjects a regression line showed a gradual decrease over time (Figure 
7.4B), but again a Pearson’s Correlation showed this was not significant. (P=0.432), 
Pearson’s number -0.264. 
This suggests while an individual patient undergoes some changes in satellite cell 
numbers, the differences observed between patients are greater. Alternatively, this 
pattern may be unique to this particular patient. The reason this patient has 
undergone numerous biopsies over this period of time is due to her participation in a 
number of different exercise trials. This may have resulted in a gradual accumulation 
of satellite cells. Importantly however, this patient has not undergone an exhaustion 
of her satellite cell pool with age. 
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Figure 7.3 Changes in satellite cell frequency over time. A single patient with a 
mitochondrial myopathy caused by a sporadically occurring single mtDNA deletion 
underwent ten biopsies over a period of eleven years. There was a gradual increase in 
her satellite cell frequency over time, although the R
2
 value of the line of best fit 
suggests wide variation in this relationship. This may be attributable to various exercise 
interventions. 
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Figure 7.4 Satellite cell frequency with age. A. The satellite cell frequency was 
plotted against age at biopsy of mitochondrial myopathy patients. A slight increase 
occurred with age, but this was not significant. B. When the satellite cell frequency 
was plotted against age for the control subjects a decrease with age was observed, 
again this was not significant. 
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7.2.3 Satellite Cells in Response to Resistance Training 
Eight of the patients being examined for satellite cell numbers are undergoing an 
exercise trial at Newcastle University (see section 3.3.1). One of the aims of this trial is 
to attempt “gene shifting” in patients by inducing muscle damage and thus satellite 
cell activation and eventual incorporation. 
While the trial is still ongoing, biopsies are available both before and after the 
resistance arm of the exercise program for these eight patients. This presented the 
opportunity of examining the effects of six months of high intensity resistance training 
on the satellite cell numbers in patients with mitochondrial myopathies. 
7.2.3.1 Effects of Resistance Training on Muscle 
Many studies have examined the effects of resistance training on muscle. The wide 
variety of exercise programs undertaken, the muscles examined, and the methods of 
data collection, makes direct comparisons and obtaining an overall consensus 
somewhat difficult. An added problem when examining the long term effects of 
resistance training in healthy people has been that many of the subjects are long term 
weight lifters, and have often used steroids. In addition it is important to note that 
increases in strength are only observed when measured using the same type of 
contraction that the exercise training involved (Higbie et al., 1996). In general, studies 
examining resistance training have consisted of a five to sixteen week program, two to 
four sessions a week, with each session exercising a range of muscles with three sets 
of between eight to fifteen repetitions. 
Resistance training is widely known to increase muscle strength and the mechanism of 
the adaptation has been the focus of many studies. It is thought that some of the 
increases in strength are attributable to neural adaptations, including increased motor 
unit recruitment, increased motor unit firing rates, increased activation of synergistic 
muscles and decreased activation of antagonistic muscles (Higbie et al., 1996, 
Hakkinen et al., 2003, Duchateau et al., 2006). In addition architectural changes are 
thought to be responsible for some of this improvement, although there have been 
conflicting reports regarding this (Blazevich et al., 2007, Aagaard et al., 2001). 
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Resistance training affects males and females differently, with men tending to gain 
more muscle size and women gaining more in strength. Initially there were 
suggestions that both hyperplaesia and hypertrophy could account for the increases in 
muscle strength and size in response to exercise (Grounds, 1998). It is now thought 
however, that hyperplaesia only occurs in response to exercise in certain animals, and 
previous reports in humans were probably attributable to muscle fibre splitting (Toigo 
and Boutellier, 2006). 
Fibre hypertrophy in muscle has been reported in both athletes who perform 
resistance exercise as part of their training (Tesch et al., 1984, Kadi et al., 1999), and in 
none athletes undergoing a program of strength training (McCall et al., 1996, Higbie et 
al., 1996, Aagaard et al., 2001). This increase is particularly strong in the type II fibres, 
demonstrating their greater adaptive response to exercise (Tesch et al., 1984, McCall 
et al., 1996, Kadi et al., 1999, Aagaard et al., 2001). 
Concurrent with this increase in fibre hypertrophy, an increase in capillarisation also 
occurs. Although this effect is not visible when determined per fibre, only when 
determined by area, and has thus occurred relative to hypertrophy (Tesch et al., 1984, 
McCall et al., 1996). 
The increase in fibre hypertrophy is mediated by increases in gene transcription and 
thus protein synthesis. These have been shown to occur after only a single bout of 
exercise (Bickel et al., 2005). The early stages of muscle hypertrophy are mediated by 
an increase in the myonuclei domain of a muscle nucleus. However, there are limits to 
the area for which a single myonuclei can initiate protein synthesis. Further increases 
in hypertrophy require the activation and incorporation of satellite cells (Petrella et al., 
2008). 
 
 
 
 
Chapter 7                                             Satellite Cell Numbers in Mitochondrial Myopathy Patients 
238 
  
7.2.3.2 Effects of Resistance Training on Satellite Cell Numbers 
Mechanical stretch is thought to activate satellite cells through the release of 
hepatocyte growth factor (HGF) from the extracellular matrix in a nitric oxide 
dependent manner. The HGF binds to the c-met receptor on the satellite cells and 
initiates a cascade reaction that results in DNA synthesis and eventual satellite cell 
activation (Toigo and Boutellier, 2006, Tatsumi et al., 1998, Anderson et al., 2002, 
Tatsumi et al., 2006). 
Increases in satellite cell numbers have been reported in weight lifters (Kadi et al., 
1999), and in subjects given resistance training programs (Petrella et al., 2006, Roth et 
al., 2001). This increase in satellite cell number has even been reported to occur after 
a single bout of exercise (Crameri et al., 2004). The effects of age and sex on the size of 
the satellite cell response to exercise are still being debated (Petrella et al., 2006, Roth 
et al., 2001). One report suggested the size of response was dependent on initial 
starting numbers of satellite cells (Petrella et al., 2008). 
In 2000 Kadi and colleagues demonstrated an increase in strength, fibre size, satellite 
cell numbers and myonuclei per fibre in females undergoing ten weeks of resistance 
training. This study demonstrated nicely the “myonuclei domain” hypothesis, where 
satellite cell activation and eventual incorporation leads to an increase in the numbers 
of myonuclei in muscle fibres and allows continued hypertrophy of the fibre (Kadi and 
Thornell, 2000). 
In a study examining the effects of twelve weeks of resistance training in patients with 
a mitochondrial myopathy caused by sporadically occurring single mtDNA deletions, 
Murphy et al. (2008) also reported increases in strength and satellite cell frequencies. 
Although it was not reported if there was an eventual increase in overall myonuclei 
content of the fibre and there were no significant changes in fibre area, suggesting 
that hypertrophy may not have occurred (Murphy et al., 2008). 
This current study has examined the effects of six months of resistance training in a 
similar group to Murphy et al. It is hoped that the extended duration of the training 
program will initiate a stronger response. 
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7.2.3.3 Methods 
To determine the effects of six months resistance exercise on patients with a 
mitochondrial myopathy caused by a sporadically occurring single mtDNA deletion, 
eight patients underwent a muscle biopsy of the vastus lateralis before and after 
training. 
These patients were participating in an exercise trial at Newcastle University. They 
were biopsied at baseline and then underwent six months of resistance training, which 
consisted of three sessions per week, with each session comprising three sets of eight 
repetitions of their 80-85% one repetition maximal. After six months a second biopsy 
was performed. When performing the experiments in chapters 4 and 5 it was not 
always possible to get muscle samples from both these biopsies for FACS sorting and 
myoblast culture. However, the samples for this study were taken from the muscle 
sample supplied to the Newcastle Mitochondrial Diagnostic Service, which had 
obtained tissue from all of the biopsies performed. 
Muscle biopsies of the eight patients both before and after resistance training were 
cut at 12µm by Dr. J. Murphy, stained for Pax7, and counted as previously described. 
In addition, the myonuclei per fibre was determined both before and after training, to 
see if there had been any satellite cell incorporation into the fibres. 
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7.2.3.4 Results 
Eight patients have completed the resistance arm of the trial and moved on to the 
endurance section of the program. Biopsy samples are not currently available for 
immunohistological analysis from the endurance section of the trial. Counts were 
performed to determine satellite cell frequency before and after resistance training 
(Table 7.3). There was a slight increase in mean satellite cell frequency after six 
months of resistance training from 2.15±0.29 to 2.41±0.72. The data appeared slightly 
more spread after the training period, suggesting there were maybe individual 
differences in patient’s response to exercise (Figure 7.5A). However, a paired t-test 
(data normally distributed) revealed the increase was not significant (P=0.331). 
Interestingly, when myonuclei number per fibre was determined for the eight patients, 
there was an increase from 7.06±3.66 to 8.37±4.4 (Figure 7.5B), which represented an 
overall increase of 19%. This increase occurred in six of the eight patients, with three 
of the six patients having over 100% increase, and the other three patients having an 
increase of between 8% to 28% (Table 7.3). However, a paired t-test showed this was 
not a significant difference (P=0.609). 
The two patients that did not follow this trend showed a substantial decrease in 
myonuclei per fibre number of around 60%. For patient 1 this was not surprising as she 
left the trial after the resistance arm of the exercise program due to a considerable 
loss of weight. In addition doubts have been raised about the compliance of patient 8 
to the exercise program. These patients had mtDNA deletion heteroplasmy levels of 
53% and 43% respectively, which was very close to the average level of 48.6% for this 
patient group. This suggests their response, or lack of it, was not attributable to the 
amount of delete mtDNA they harboured. When the statistical analysis was performed 
with these two patients removed, the test showed a significant increase in myonuclei 
number (P=<0.05). However, these two subjects are part of the trial, and it may be 
that patients differ in their responses to resistance training. In addition sex may be an 
influencing factor, as these two patients were the only two females partaking in the 
study. 
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An interesting observation was made with patient 2 during this study. His second 
biopsy, after resistance training, demonstrated a large number of satellite cells as well 
as many small fibres (Figure 7.6A). This was hypothesised to be an area undergoing a 
period of strong regeneration, presumably following degeneration. There was a clearly 
defined border to this area of tissue, and it did not appear indicative of the rest of the 
biopsy (Figure 7.6B). The normal appearing area did contain some central nuclei, but 
had fewer satellite cells and no small fibres. 
It is possible that this phenomenon occurred because of an injury sustained by the 
patient in the performance of his previous exercise session, or possibly through the 
second biopsy hitting the site of the first biopsy. The second reason would be 
somewhat worrying given that six months have elapsed since the previous biopsy and 
regeneration would appear not to be complete. 
For the purpose of analysis this section was counted twice. Firstly, including the highly 
regenerative area, resulting in a satellite cell frequency of 7.868, and secondly without 
the unusual area giving a satellite cell frequency of 3.946. It was the latter value that 
was used for the statistical analysis. 
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Table 7.3 Individual responses to resistance training. Eight patients underwent six 
months of resistance training intended to injure muscle and activate satellite cells. While 
five out of eight patients had an increase in satellite cell frequency after training, this was 
not significant. The variation in the satellite cell frequencies was greater after training. 
When the myonuclei and fibre counts were used to determine the myonuclei per fibre 
ratio an increase was observed for six out of the eight patients. 
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Figure 7.5 Effects of six months of resistance training on satellite cell frequency and 
myonuclei number. A. Satellite cell frequency before and after six months of resistance 
training. B. Average myonuclei per fibre increased after six months of resistance 
training; however this increase was not significant. Lines indicate average values for 
the group. 
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Figure 7.6 Patient 2. After six months of resistance training patient 2 showed a 
highly unusual area of degeneration/regeneration in his biopsy. A. Magnification 
x20. Many small fibres were visible, with numerous satellite cells. In the “normal” 
part of the biopsy central nuclei could be observed (arrow heads), suggesting 
regeneration had also occurred here. B. x10 magnification. This unusual response 
was limited to a defined area in the biopsy. 
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7.3 Discussion 
The aims of this chapter were to investigate the numbers of satellite cells in patients in 
three scenarios. Firstly this research wanted to determine if patients suffering from a 
mitochondrial myopathy had fewer or more satellite cells than controls. Secondly it 
sought to see if there was any decrease in numbers as patients’ age. Finally, the effects 
of six months of resistance training were examined. It was hoped that by investigating 
satellite cell frequencies under these three conditions it could be determined if efforts 
to activate satellite cells and “gene shift” would result in detrimental changes in terms 
of stem cells available for muscle regeneration. 
Previous investigations have generally resulted in a satellite cell frequency of between 
1.6 ±1.2 to 6.4 ±1.3 in the vastus lateralis (Kadi et al., 2005). The values obtained for 
this research are generally within this range for both mitochondrial myopathy patients 
and control subjects, suggesting appropriate staining and counting methods have been 
employed. While this study used Pax7 to stain and count satellite cells, other groups 
have used NCam (Crameri et al., 2004, Kadi et al., 1999). It would be interesting to use 
other markers for satellite cells to perform counts. 
When assessing the effects of age and exercise on muscle, studies have performed 
analysis on a wide number of fibres, ranging from 43 fibres per subject (Roth et al., 
2000) to 1850 per subject (Crameri et al., 2004). One study suggested a minimum of 
twenty five type I fibres and twenty five type II fibres should be counted in order to 
observe any differences (Mackey et al., 2009). The investigations performed here have 
involved an average of 781 fibres being counted, with a minimum of 148 fibres. This is 
well within the range previous studies have examined and higher than the 
recommendation given by Mackey and colleagues. 
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7.3.1 Satellite Cell Frequencies in Mitochondrial Myopathy Patients 
While a very small number of satellite cells are obviously a problem for regenerating 
muscle, the same may be said for myopathy patients who have very large amounts. 
For example, findings of large satellite cell frequencies in myopathy patients (Ishimoto 
et al., 1983), are probably an indicator of large amounts of degeneration and 
regeneration occurring in the muscle. The danger being, that as the patients age they 
may experience an exhaustion of the satellite cell pool, as is seen in the mdx mouse 
(Luz et al., 2002). 
Findings in our patients of similar levels of satellite cells when compared to controls is 
therefore encouraging, especially considering the control subjects were on average 
younger than the patients. It suggests that the patients have neither exhausted their 
stem cell reserve, nor are they currently on their way to exhausting it. 
Consideration must however be given to the control tissue used in this study. While 
the fibre types between the hamstring muscle group and vastus lateralis are similar, 
and the embryological origins of the muscle are the same, there may still be 
differences between these muscles. In addition, these patients were undergoing 
operations to repair their ACL ligaments, and while the exact cause of the injury is 
unknown, it is often associated with football. The quick changes of direction required, 
its stop/starting nature, and the tendency for players to be “side tackled” when their 
feet are planted, means this injury is quite common in this particular sport. While our 
control group included both men and women and an age range of 21-52 years, they 
were still generally younger and more male orientated than our patients. In addition, 
there may have been a slight tendency for more athletic subjects to be a part of this 
group. Although finding that our patients had similar satellite cell frequencies to a 
group of healthy, younger, and possibly fitter subjects is reassuring. 
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7.3.2 Effects of Ageing 
While a “snap shot” of our patients has suggested there is no significant difference 
between their satellite cell numbers and that of healthy controls, it was still interesting 
to examine how age and time affected them. Studies examining the effects of age on 
healthy subjects have reported differing findings. Experiments examining mice have 
suggested a decrease in satellite cell frequencies with age (Shefer et al., 2006, Snow, 
1977), while studies in humans have reported both decreases (Verdijk et al., 2007) and 
no difference (Roth et al., 2000) in the vastus lateralis with age. Although there were 
slight differences in the ages studies, Roth et al. had a “young” group of an average 
age of twenty five and a half, and an “old” group with an average age of sixty eight. 
While Verdijk’s “young” group were an average of twenty years, and the “old” group 
were an average of seventy six years. While this may not appear a great difference, the 
thirteen and a half year gap between the age ranges could have contributed to the 
conflicting findings. 
Our patients will undergo more degeneration and regeneration over their life time due 
to their myopathy, and the comparisons made between mitochondrial disease and 
ageing phenotypes does mean the effects of age on our patients should be 
investigated. 
One of our patients has been biopsied repeatedly over eleven years from the age of 
thirty two to forty three. A correlation analysis showed she had experienced an 
increase in her satellite cell frequency over time. While this may be an indicator of her 
progressive myopathy, her satellite cell frequencies were still within the range 
observed for healthy controls (Table 7.1B). Although, as already highlighted the reason 
this patient has undergone so many biopsies is her participation in a number of 
exercise trials. It is possible that this increase is a result of the long term effects of 
exercise. 
It should also be noted that when all satellite cell frequencies for the patients 
examined in the initial part of this chapter were plotted against age there was no 
relationship between age and satellite cell frequencies, this was a similar pattern to 
the control subjects. This suggests that there may be more variation between patients 
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in terms of satellite cell frequency, than is seen in a single patient over time. Again this 
is encouraging as it suggests that even with a mitochondrial myopathy this patient 
group does not experience a detrimental increase or decrease in satellite cell 
frequency as they age. 
Studies examining satellite cell number in aging people have often contained an older 
group of over sixty years. It may be possible that any differences are only observed 
when people cross a threshold of around this level. Given that none of the patients 
examined here are past this age, it may be expected that no differences are observed. 
It would be interesting to examine our patients as they get older to see if there is any 
change. In addition it may be intriguing to investigate satellite cell numbers in relation 
to fibre type and see if these patients suffer from the same type II fibre susceptibility 
to satellite cell loss that healthy subjects do (Verdijk et al., 2007). While performing 
multiple biopsies over a period of years is somewhat difficult, it would be interesting 
to examine other patients or even control subjects longitudinally to investigate any 
changes. 
While this research has suggested that these patients do not experience an exhaustion 
of their stem cell pool as they age, this does not rule out the possibility that other 
factors associated with aging may impair the ability of their satellite cells to regenerate 
their muscle. Other factors that should be examined in these patients include 
telomere lengths, and the proliferative capabilities of satellite cell progeny in aged 
muscle. 
7.3.3 The Effects of Resistance Training on Patients 
The final part of this chapter aimed to examine the effects of six months of resistance 
training on patients with a mitochondrial myopathy caused by a large scale single 
mtDNA deletion. A previous exercise trial in a similar group of patients found a 
significant (P=0.003) increase in satellite cell number after three months of resistance 
training (Murphy et al., 2008). However, that finding was not repeated here. There 
was a slight increase in the satellite cell frequency after the resistance training, but this 
was not significant. While the patients on the previous resistance trial performed a 
similar exercise protocol, the duration was only twelve weeks, compared to twenty 
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four weeks on this trial. In addition the methods for staining and counting satellite 
cells varied between the trials. 
Findings of an average 19% increase in myonuclei number per fibre may be important. 
However, an increase was only observed in six out of the eight patients studied, and 
was not significant. This may be attributable to differing individual responses to 
training. When Petrella et al. (2008) examined the effects of sixteen weeks of 
resistance training they found vastly differing responses in subjects. They were able to 
group their participants into “non-responder”, “moderate responders”, and “extreme 
responder” on the basis of changes in fibre area. Only the moderate and extreme 
responders demonstrated an increase in myonuclei number per fibre. 
This study did not examine fibre area, but on the basis of myonuclei number per fibre, 
it is possible to group our patients into similar groups using the percentage change. 
High responders, patients 2, 3, and 6 (range of 126%-237% increase), moderate 
responders were patients 4, 5, and 7 (range of 8%-28% increase), and negative 
responders who were patients 1 and 8 (-66% to -68%). The removal of one of the 
negative responders from the trial and the questionable compliance of the other may 
raise doubts about these groupings. Alternatively there could be a sex based 
difference in the response. 
These results may suggest that in at least some of our patients there has been 
incorporation of satellite cells into muscle fibres. It would be interesting to examine 
changes in fibre area in these patients, especially the high responders, it would be 
expected that they would demonstrate greater fibre hypertrophy. If they respond the 
same way as healthy controls, this may occur in the type II fibres (Tesch et al., 1984) 
(McCall et al., 1996, Kadi et al., 1999, Aagaard et al., 2001). They may also have 
responded with greater strength increases. 
These results are interesting given that no significant change was observed in satellite 
cell frequency. Interestingly, all three of the high responders demonstrated a slight 
increase in satellite cell frequency. Previous research in this patient group 
demonstrated a significant increase in satellite cell frequency after twelve weeks of 
resistance training (Murphy et al., 2008), half of what was performed here. In addition, 
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previous exercise trials in healthy subjects have examined satellite cell frequencies 
after a maximum of sixteen weeks. It may be that the adaptive response changes in 
subjects after this length of training program. 
The current trial is one of the longest resistance trials in both this particular patient 
group, and in healthy subjects. It may be that adaptations over the first few months 
require large increases in satellite cell numbers, but after this a smaller or muted 
satellite cell response is occurring. This is still enough to result in a steady increase in 
myonuclei number but small enough not to be significant when analysed. Examination 
of the response of healthy subjects or high responders from our patient group, to 
resistance training over a similar or even longer time frame would be interesting. 
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7.4 Conclusions 
These results are very promising for attempts to “gene shift” in patients with a 
mitochondrial myopathy. This research suggests they will not exhaust their satellite 
cell pool either due to their myopathy or as they age. 
While patients may experience a slight increase in satellite cell number as their 
myopathy progresses, this increase is still within ranges observed in healthy subjects. 
It may be necessary to further assess satellite cell numbers in this group of patients as 
they age further. 
Performing resistance training can lead to satellite cell incorporation into the muscle 
fibres in selected patients. This finding is therefore very important in terms of efforts 
to “gene shift” in these patients. 
However, there may be individual or sex linked differences in the responses to 
resistance training in these patients, which should be investigated further using 
greater numbers of participants. 
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Chapter 8 Final Discussion 
8.1 Introduction 
Ever since the discovery of mtDNA deletions and point mutations in humans in 1988 
(Wallace et al., 1988, Holt et al., 1988) mitochondrial mutations have increasingly been 
recognised as a major cause of genetic disease. In 2000, the prevalence of people 
either with or at risk of developing a mitochondrial disease was determined to be 
12.48 in 100,000 (Chinnery et al., 2000), while a more recent study put the number at 
25.7 in 100,000 (Schaefer et al., 2008). This number may continue to increase through 
further advances in diagnostic techniques and a greater public awareness of 
mitochondrial disease. 
Patients with mitochondrial disease often require long term health care support, 
furthermore, the multi-systemic nature of the conditions requires input from many 
specialities. Developing therapies and treatments for mitochondrial disease is 
therefore paramount. Pharmacological interventions can help manage some of the 
neurological symptoms, for example with seizures, and surgery has helped patients 
suffering from ptosis, and cataracts (Horvath et al., 2008a). In addition, strides are 
being taken to prevent the transmission of certain mitochondrial diseases (Craven et 
al., 2010, Poulton et al., 2009). 
One avenue being explored is exercise, both endurance and resistance training 
(Taivassalo et al., 2001, Cejudo et al., 2005, Jeppesen et al., 2009, Murphy et al., 2008). 
Exercise interventions may be particularly helpful for patients who suffer from a 
mitochondrial myopathy. In addition to improvements in strength, it may help stall or 
even reverse the downward spiral that occurs in patients due to a lack of general 
physical activity. 
The rationales behind the two types of exercise are somewhat different. Endurance 
exercise is thought to increase mitochondrial biogenesis and hopefully increase the 
amount of mtDNA in the muscle (Taivassalo and Haller, 2004, Taivassalo et al., 2006). 
In contrast, resistance training aims to activate satellite cells and promote their 
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incorporation into the muscle. This will serve to increase muscle strength in patients 
and in the presence of heteroplasmy change the amounts of WT and delete mtDNA. 
The aims of this project were to investigate the rationale behind the use of resistance 
training in patients with mitochondrial myopathies caused by a sporadically occurring 
single mtDNA deletion. This was to ensure there would be no adverse effects from 
stimulating satellite cells in terms of variations in the muscle mutation load, and 
changes in stem cell numbers. It was originally hypothesised that no sporadically 
occurring mtDNA mutations would be found in the satellite cells of these patients. 
Accordingly, the original intention of this research was to investigate why there was an 
absence of mutation in these stem cells. However, early findings during this project in 
chapter 4 contradicted this hypothesis and, consequently, the research was taken in a 
different direction. 
8.1.1 Rationale for Research 
The rationale for using resistance training in mitochondrial myopathy patients with a 
sporadically occurring mtDNA mutation arose from reports in the 1990s (Weber et al., 
1997, Fu et al., 1996). These papers reported finding no mutation in the cultured 
myoblasts of patients with sporadically occurring conditions. Previous reports in the 
1980s had found much reduced levels of single mtDNA deletion in the cultured 
myoblasts of patients with KSS (Moraes et al., 1989a, Moraes et al., 1989b). It was 
suggested that the reason for lower or no mutation in cultured myoblasts was that the 
muscle satellite cells harboured little or no mutation. 
These studies then led to successful attempts to change the phenotype of muscle 
fibres in patients with sporadically occurring mtDNA point mutations by the induction 
of muscle necrosis and the incorporation of WT cells into the regenerating fibres (Clark 
et al., 1997, Shoubridge et al., 1997). However, the methods used to induce muscle 
necrosis by the above groups, bupivicaine (Clark et al., 1997), and biopsying 
(Shoubridge et al., 1997), were deemed too invasive for clinical application. As a result, 
resistance training has been suggested as a viable alternative. High intensity resistance 
training induces sarcomere disruption and the activation of satellite cells to repair the 
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damage. If the satellite cells harbour no mutation, then the heteroplasmy level of the 
repaired fibre should change favourably. 
However, the above studies were based on molecular findings in either myoblasts or 
regenerated muscle fibres. This would have allowed for a period of selection to act on 
the developing cells and it may be that the mutation was lost during the process of cell 
culture or muscle regeneration. With exercise being increasingly seen as a possible 
therapeutic intervention in patients with sporadically occurring mitochondrial 
myopathies, it became increasingly necessary to examine the exact processes that 
were occurring during muscle regeneration. 
The current exercise trial at Newcastle University investigating the effects of both 
resistance and endurance training on patients with sporadically occurring single 
mtDNA deletions provided the opportunity to investigate this in a homogeneous 
group. 
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8.2 Major Findings 
8.2.1 Muscle Satellite Cells 
When this research was started it was hypothesised that examination of the satellite 
cells of these patients would show they were devoid of any mtDNA deletion, or at the 
very least there were very low levels. 
Having isolated satellite cells by FACS sorting on the basis of CD56, it was possible to 
perform molecular investigations to examine their mutation status. It was shown in 
chapter 4, using two types of real time PCR and a long range PCR, that single mtDNA 
deletions were present in the satellite cells of all patients investigated. In addition they 
were found at similar levels to that found in the patient’s muscle samples. 
When individual satellite cells were collected and analysed they were shown to be 
heteroplasmic on the basis of single mtDNA deletions, with some cells containing high 
levels of mutation and some cells harbouring no mutation or very low levels. This is a 
very similar pattern to that observed in mature muscle. 
This research led to the hypothesis that the mutation was present in the satellite cells 
during embryogenesis. The variations in heteroplasmy levels could be attributable to 
one of two processes or indeed a combination of the two. When the satellite cells are 
activated mtDNA replication will be initiated; given the low copy number in the stem 
cells, clonal expansion could be rapidly occurring. The other possibility is that the 
asymmetric division of satellite cells after activation and subsequent return to the 
stem cell pool of one of the daughter cells could cause a drifting of the genotype 
within the satellite cell to either homoplasmic WT or delete. 
However, in order to get a clearer picture of what is occurring in the satellite cells it 
will be necessary to perform single cell studies on many more samples and use the 
relevant SYBR Green assay to determine levels below 30%. 
8.2.2 Myoblasts 
Myoblast cultures were set up from many of the biopsies performed and grown for a 
number of passages. When these cell lines were examined for single mtDNA deletions, 
the results were again surprising and demonstrated marked differences between 
patients. 
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It was shown in chapter 5 that while many of the cell lines had lost the disease causing 
mutation by the first passage, three of them had maintained it. In addition one patient 
both lost and maintained the mutation in consecutive biopsies. In two out of the three 
cell lines that maintained the mutation there was a gradual reduction in the 
heteroplasmy levels as the cells headed towards differentiation. 
Using these data it was possible to define two selection points for the loss of the 
mtDNA mutation. One occurred at the point of satellite cell activation, and the second 
occurred as the myoblasts proliferated, and not as originally thought, as the myoblasts 
differentiated. 
It has been hypothesised that the two selection points occur through different 
mechanisms. The loss of mutation at satellite cell activation is hypothesised to occur 
via a bottleneck mechanism. Two proposals for this bottleneck have been made, 
although they are not mutually exclusive. Firstly, when muscle damage is initiated 
satellite cells are activated to repair the damage. If satellite cells that have a primarily 
WT or delete genotype are activated, the resultant myoblasts could have astoundingly 
different heteroplasmy levels. Secondly the initial division of the activated satellite cell 
results in two daughter cells, only one of which will proceed to form myoblasts. If 
there is uneven segregation of mtDNA in these two cells then the resulting myoblasts 
may either primarily maintain or lose the mutation. Over time the stem cell that is 
maintaining the satellite cell pool may tend towards a homoplasmic fate, either WT or 
mutant. 
The second selection point is hypothesised to occur because of the dividing nature of 
myoblasts. After each cell division there will be segregation of mtDNA. If a myoblast 
obtains a slightly higher amount of delete mtDNA it may suffer from a respiratory 
chain defect large enough to result in it dying. The process of myoblast proliferation is 
very reliant on mitochondrial biogenesis, as evidenced by increasing mtDNA copy 
number. An increased reliance on OXPHOS will result in any cells with high levels of 
mtDNA deletions being unable to survive. 
These findings still concur with earlier reports examining sporadically occurring mtDNA 
mutations in proliferating myoblasts and regenerating muscle. Previous experiments 
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examining the cultured myoblasts from patients with sporadically occurring mutations 
found no mutation in these cells (Fu et al., 1996, Weber et al., 1997); this research 
found similar results in seven of the ten cell lines examined. It may be hypothesised 
that in both these papers and subsequent ones investigating the effect in vitro 
(Shoubridge et al., 1997, Clark et al., 1997) the mutation was lost at the point of 
satellite cell activation through a bottleneck effect or through negative selection on 
the dividing myoblasts. 
While findings in some patients of mtDNA mutations in their myoblasts were again 
worrying for attempts to “gene shift”, the results presented here suggest it will still be 
possible. The activation of satellite cells and subsequent loss of the mutation through 
either a bottleneck or negative selection will result in healthy myotubes being 
incorporated into the damaged muscle fibre. In addition, it is possible that the exercise 
being performed by patients will place added stress on the regenerating muscle cells 
and give a stronger selection pressure on myoblasts with high levels of mtDNA 
deletions. This should change the amounts of WT and delete mtDNA present in the 
muscle and will hopefully improve the muscle symptoms of patients. 
However, a number of groups have now performed exercise interventions in patients 
with mitochondrial myopathy and a favourable change in mutation load has not been 
reported (Taivassalo et al., 2001, Jeppesen et al., 2006b, Murphy et al., 2008, Jeppesen 
et al., 2009). It may be that any changes will be too subtle to detect or the exercise 
programs are not sufficient or appropriate for “gene shifting”. This highlights the need 
for further research in this area. 
8.2.3 Satellite Cell Numbers 
Attempts to “gene shift” involve the activation of satellite cells through inducing 
muscle damage via high intensity resistance training. Previous suggestions of 
significantly increased numbers of satellite cells followed by an exhaustion of the 
satellite cell pool in dystrophic muscle are worrying (Ishimoto et al., 1983, Heslop et 
al., 2000, Luz et al., 2002). Given that patients with a sporadically occurring single 
mtDNA deletion often present with myopathic symptoms, including muscle wasting, it 
was necessary to investigate the possibility the same may occur. 
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When compared to control subjects our patients had neither an increase nor decrease 
in satellite cell numbers, which was very encouraging. In addition, we demonstrated a 
slight increase in satellite cell numbers in a single patient over a period of eleven 
years. While this may have been caused by an increase in her myopathy, her satellite 
cell frequencies were still within the ranges observed for all other patients and control 
subjects.  
This research also investigated the effects of six months of resistance training in 
patients with a mitochondrial myopathy and found no significant increase or decrease 
in satellite cell numbers. An interesting observation was made regarding the numbers 
of myonuclei per fibre. While a decrease was observed in two out of the eight 
patients, the other six showed increases in myonuclei per fibre. The patients were 
grouped into high, moderate and negative responders on this basis, which coincided 
with another report of grouped responses to resistance training (Petrella et al., 2008). 
It suggests that similar to healthy subjects, there may be individual differences in the 
direction and strength of response to resistance training. However, many more 
subjects should be examined before any firm conclusions may be drawn. 
The increase in myonuclei number in six of our patients was encouraging as it suggests 
that there has been some satellite cell incorporation into the muscle fibres. This is one 
of the main requirements for “gene shifting”. In addition, the results suggest 
hypertrophy maybe occurring in these patients, which should provide strength 
increases. However, if there are inherent differences between patients in the way they 
respond to resistance training, it will be necessary to determine how a particular 
patient will respond before starting any training program. 
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8.3 Further Work 
This research has revealed sporadically occurring mtDNA deletions in satellite cells of 
all of the patients studied. While the mutation is lost early on in the majority of 
patients, this is not always the case. In the cell lines that maintain the mutation there 
is generally a reduction as the myoblasts proliferate. These selection points are caused 
initially by a bottleneck followed by negative selection, although the exact mechanism 
of these phenomena is still somewhat ambiguous. 
While this research was able to examine satellite cells, and early passage myoblasts, 
there was still around a two week time gap between these cell types while the cultures 
were being established in the biobank. In order to determine exactly what is occurring 
at the point of satellite cell activation, very early stage myoblasts should be examined. 
If a large piece of muscle could be obtained from these patients, a single muscle fibre 
culture could be set up. This would allow for the collection of muscle precursor cells 
just after activation, and as they move away from the fibre in the first couple of days. 
Individual cells could be picked out for both heteroplasmy and mtDNA copy number 
analysis, providing a much tighter time frame for the changes observed. 
While it is difficult to perform this experiment in human subjects, part of it could be 
carried out in mice. Single fibre culture and collection of early cells seen migrating 
away from the fibre could provide information on mtDNA copy number in the early 
stages of muscle regeneration. Unfortunately, the absence of an appropriate mouse 
model of single mtDNA deletions precludes the examination of heteroplasmy levels. 
Mice models have been produced that harbour deletions, but these have been 
through nuclear mutations, for example the TWINKLE mouse (Tyynismaa et al., 2005), 
or have modelled an early onset multisystem disease (Inoue et al., 2000). 
While the heteroplasmy levels were examined in individual satellite cells, a similar 
analysis should be performed in individual myoblasts. It can be hypothesised they also 
contain variable heteroplasmy levels but this should be verified. This could be 
performed with FACS sorting of individual cells on the basis of desmin or through laser 
dissection of individual myoblasts from a membrane cell culture plate. 
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This research has demonstrated that patients will probably not run out of satellite cells 
as they age. However, it will be important to re-examine satellite cell numbers in 
patients who are much older than this cohort, probably into their seventies. 
While results in this small group of patients suggests that there may be individual 
differences in the way mitochondrial myopathy patients respond to resistance 
exercise, this effect should be examined further. The changes observed in myonuclei 
per fibre need to be considered in relation to any other muscle adaptations the 
patients undergo. Therefore the extent of hypertrophy of both muscle fibres and 
overall muscle should be determined. It would be especially interesting to see if 
patients undergo selected hypertrophy of the type II muscle fibres, as experienced by 
healthy subjects. 
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8.4 Strengths, Limitations, and Difficulties 
The main strength of this research was also the source of many of its limitations and 
difficulties. The availability of human tissue has been invaluable during this project. 
The lack of appropriate mouse models of mitochondrial disease and suggestions that 
satellite cells are somewhat different between rodents and humans would have meant 
this research would otherwise have been impossible to perform. The use of human 
tissue has resulted in findings that are highly relevant to our patients and will enable 
future exercise studies to proceed with a much greater understanding of the 
mechanisms involved. 
The enrolment of these patients on a particular clinical trial has allowed the 
examination of a very homogeneous subject group. These patients all have a similar 
phenotype and harbour a large scale single mtDNA deletion. Consequently, more 
confidence may be placed in the reported findings, as it is known that differences 
between patients are not attributable to a difference in genotype or phenotype. 
However, the reliance on human samples has also led to gaps in the research. Tissue 
samples were not always available from all the biopsies performed for FACS sorting 
and myoblast culture. These patients were primarily being investigated for their 
response to exercise so it was paramount that sufficient tissue was always acquired for 
these studies. This particular study required participants to undergo a muscle biopsy 
every six months and consequently samples from patients were often analysed quite 
far apart from each other and occasionally on different machines. In addition, as the 
project developed different experiments were performed on the cells, so in some 
cases very few samples have been available for the more recent investigations. 
There are always issues regarding compliance to exercise studies in humans. When 
examining the effects of resistance training on muscle adaptations, it is difficult to be 
confident that a reduced or absent response is a true result or partially attributable to 
questionable compliance. 
Another limitation of this study was its reliance on cell culture as a model of muscle 
regeneration. Whether the cell culture environment is more or less hostile, when 
compared to a regenerating muscle, is somewhat unknown. However, the differing 
Chapter 8  Final Discussion     
262 
  
environments will have caused different selection pressures on the myoblasts, which 
could have influenced heteroplasmy levels. 
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8.5 Final Conclusions 
Attempts to “gene shift” in patients with a sporadically occurring large scale single 
mtDNA deletion could change the balance of WT to delete mtDNA in their muscles, 
although via a different mechanism to what was originally envisioned. 
Selection acts on developing muscle cells at two points; satellite cell activation through 
a bottleneck mediated mechanism initially, followed by negative selection during 
myoblast proliferation. 
It is likely that patients will not exhaust their satellite cell pool as a result of their 
myopathy or as they age. Resistance training will therefore not be detrimental in 
terms of exhausting their stem cell pool. On the contrary, it should help these patients 
via the incorporation of WT developing muscle cells and through the increases in 
strength that are attained through training. 
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